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Sommario 
 
Le cellule pluripotenti umane stanno velocemente emergendo come strumenti 
fondamentali nella ricerca in vitro. In particolare, l’avvento delle cellule 
pluripotenti indotte ha aperto nuovi orizzonti sullo studio e la modellazione delle 
malattie umane e lo screening di approcci terapeutici. La possibilità di avere in 
coltura cellule di origine umana provenienti da tessuti da cui è difficile ottenere 
campioni bioptici, ha permesso di delineare nuove prospettive di studi in vitro 
per tessuti come il cervello, il pancreas o il cuore. Specialmente in quest’ultimo 
caso, il bisogno di nuovi modelli di studio è esaltato dall’impatto che le malattie 
cardiache hanno sulla sanità e sull’economia mondiali, a cui i modelli di studio 
tradizionali non riescono a far fronte in modo efficace.  
L’oggetto di studio di questa tesi di dottorato sono i cardiomiociti umani 
derivati per differenziamento da cellule staminali pluripotenti e la loro 
applicazione come modello di studio del tessuto cardiaco. In particolar modo, ci 
si è focalizzati sul loro fenotipo, ritenuto precoce ed immaturo rispetto al 
cardiomiocita adulto, che limita enormemente il loro impiego in campo medico e 
scientifico, impedendo il pieno sviluppo del loro potenziale.   
Dopo aver introdotto i modelli sperimentali attualmente impiegati nello studio 
di patologie cardiache, verranno descritte le principali caratteristiche delle cellule 
pluripotenti umane (hPSC) e dei loro derivati cardiaci (hPSC-CM). 
Successivamente, l’attenzione verrà focalizzata su due caratteristiche 
fondamentali che descrivono la fisiologia di un cardiomiocita: l’organizzazione 
strutturale della cellula legata alla sua funzionalità ed il suo profilo metabolico. In 
entrambe queste categorie, i hPSC-CM vengono spesso paragonati a cellule 
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cardiache fetali, lontane in termini di sviluppo dal fenotipo del cardiomiocita 
adulto. 
L’organizzazione ultrastrutturale di una cellula cardiaca è strettamente correlata 
con la sua capacità funzionale: nei cardiomiociti adulti si assiste ad una perfetta 
concertazione spazio-temporale di diverse componenti molecolari la cui azione 
coordinata permette alle cellule del cuore di svolgere l’attività contrattile. Nel 
Capitolo 2 di questa tesi, vengono impiegati biomateriali e substrati micro- 
ingegnerizzati per studiare i meccanismi molecolari che promuovono la 
maturazione strutturale e funzionale dei cardiomiociti umani in vitro, rendendoli 
così più vicini fenotipicamente ad una cellula adulta su cui svolgere studi 
farmacologici e di modellazione di patologie. 
Il metabolismo cardiaco è una caratteristica altrettanto unica e caratterizzante 
per un cardiomiocita, essendosi adattato ad sostenere un’attività costante ed 
energicamente dispendiosa com’è la generazione di forza meccanica. Nel 
Capitolo 3 viene descritto il metabolismo di un cardiomiocita e viene proposta 
una nuova piattaforma microfluidica da utilizzare per la validazione di protocolli 
di maturazione metabolica in vitro. Con il saggio funzionale messo a punto viene 
inoltre dimostrato come l’induzione di un metabolismo maturo è possibile 
attraverso la variazione dei substrati energetici presenti nel mezzo di coltura. 
Infine, in prospettiva dell’applicazione dei protocolli di maturazione descritti nei 
capitoli precedenti a colture cardiache umane, nel Capitolo 4 viene presentato 
l’allestimento di due modelli cellulari di patologie genetiche: la distrofia 
muscolare di Duchenne e la cardiomiopatia aritmogena del ventricolo destro. 
Vengono presentati e caratterizzati cardiomiociti umani derivati per 
differenziamento da cellule hiPS di pazienti affetti, mostrando come i 
cardiomiociti in coltura presentino il fenotipo molecolare aberrante 
caratterizzante le malattie prese in esame. Si fornisce, così, un modello cellulare 
cardiaco umano che può trovare impiego nella modellazione in vitro delle due 
patologie.          
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Summary 
 
Human pluripotent stem cells are quickly emerging as a fundamental tool for in 
vitro studies. In particular, the advent of “induced pluripotency” opened 
completely new horizons for in vitro disease modeling and patient-specific 
disease-on-a-dish therapeutic approach screening. The easy access to cell types 
of human origin hardly available otherwise, with virtually infinite amounts in a 
donor-unrestricted manner, unlocked in vitro studies for human tissues such as 
brain, pancreas and the heart. In the latter case, the need for new models of 
human cardiac physiology and physiopathology is highlighted by the severe 
fallouts of heart conditions on worldwide health and economy. 
The main focus of this thesis are human cardiomyocytes derived through 
differentiation of pluripotent stem cells, and their application as an in vitro 
model of the human cardiac tissue. In particular, the stress point of the work is 
their early and immature phenotype, that often limits their application and 
frustrates the potential of a human heart model in a Petri dish. 
After introducing the current scenario of study models for heart diseases and 
describing the main features of human pluripotent stem cells (hPSCs) and their 
cardiac derivatives (hPSC-CMs), this thesis will separately focus on the two main 
aspects of the cardiomyocyte physiology: structural and functional features and 
metabolic profile. From these perspectives, human cardiomyocytes derived from 
hPSCs display in vitro an early and immature phenotype, closely resembling 
cardiomyocytes at early stage of the development, such as fetal cardiomyocytes. 
Cell ultrastructural organization and functional performance are two strictly 
related features that find in adult cardiomyocytes perfect synthesis, with a very 
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specialized function performed through a finely orchestrated sequence of events 
hugely relying on the right spatial distribution of key molecular components. In 
Chapter 2, biomaterials and microengineered substrates are employed to 
address the molecular mechanisms triggering cardiac maturation in vitro, in 
order to provide insight in the process and drive hPSC-CMs towards more adult-
like phenotypes, better suiting disease modeling and drug screening. 
Cardiac metabolism is likewise a characterizing feature of the tissue supporting 
in a unique fashion the impressive workload of the heart. In Chapter 3, hPSC-CM 
metabolism is described and a novel microfluidic technology is developed for 
metabolic maturation screening of cardiac cultures. With this approach, hPSC-
CMs are shown to positively respond to an optimized metabolic maturation 
protocol, similar to the very rapid fetal-to-adult metabolism switch in hCMs after 
birth in response to changing metabolite availability. 
Finally, in perspective of the maturation approaches previously described and 
their feasible application to human cardiac cultures, in Chapter 4 are discussed 
two human genetic diseases affecting the heart muscle. For both Duchenne’s 
muscular dystrophy and arrhythmogenic right ventricular cardiomyopathy/ 
dysplasia, cardiac cellular models are set up and proven to display in vitro the 
molecular hallmarks of the disease, thus providing the biological substrate for 
further studies on human cardiomyocyte cultures.   
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Chapter 1 
 
Human Pluripotent Stem Cells and 
Cardiac Disease Modeling 
 
This chapter introduces the state of the art in the development of models for 
studying cardiac diseases. It also discusses the new perspectives introduced in 
the field with the derivation of human cardiac cells by differentiation of human 
pluripotent stem cells. An overview of the differentiation of human pluripotent 
stem cells into cardiomyocytes is presented, highlighting the current limitations 
of the hPS-derived cells for in vitro studies and disease modeling. Finally, the aim 
of this thesis is presented. 
1.1 Study models for heart disease 
The development of reliable and effective models for studying cardiac diseases 
is one of the most urgent needs in basic and translational research. The toll of 
pathological conditions associated with the heart muscle is extremely high from 
both human lives and economic expense perspectives. Cardiac ischemia alone is 
still at the top of the list among the death causes worldwide (Go et al., 2014) and 
congenital cardiomyopathies affect a relevant portion of the population 
(Bruneau, 2008; Go et al.,2014) (Fig. 1.1A). The economic burden for the 
treatment of these conditions, both immediate and chronic, and the associated 
loss of productivity are counted by the billions in any currency taken into account 
(Go et al., 2014) and they are at the top of the list when confronted with other 
diagnostic groups (NIH Fact Book, 2012; Go et al.,2014) (Fig. 1.1B). Moreover, the 
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expense for drug research has always been high and cardiac pre-clinical study 
models closely resembling the human physiology could help in reducing the costs 
of compound screenings and the losses due to failed trials or market 
withdrawals, being the drug-induced cardiotoxicity the leading cause for the 
latter (Gwathmey et al., 2009) (Fig. 1.1C). 
Fig. 1.1 Statistical data describing the impact of heart diseases on worldwide health and 
economy. (A) Worldwide mortality by diagnostic group (WHO, 2012). (B) Economic cost by 
diagnostic group (NIH Fact Book, 2012). (C) Causes of drug market withdrawal by organ-specific 
toxicity (adapted from Wilke et al., 2007).  
Animal models are the best tool for advancing the understanding of the 
mechanisms of human pathologies, but differences such as heart architecture, 
heart rate, protein expression and even resident stem cell populations can 
deeply impact the experimental outcome of therapeutic approaches (Zaragoza et 
al., 2011). Small animals such as mice, rats, guinea pigs and rabbits are 
commonly employed because of the relatively low economic costs of housing 
and handling in respect to the high numbers of specimen. However, the intrinsic 
differences in anatomical structure and physiology, often produce in results 
untranslatable to other species (Terrar et al., 2007) and are not cost effective, 
especially in pharmacological studies, in which they often fail to predict 
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cardiotoxicity (Mandenius et al., 2011). In the past years bigger animals such as 
dogs, pigs and primates started being employed, in order to guarantee a closer 
resemblance to the human anatomical and physiological background (Netzer et 
al., 2001; De Ponti et al., 2002; Zaragoza et al., 2011). As the size (and 
resemblance to humans) of the animal model increases, the costs of specialized 
equipment, facilities and personnel grow accordingly to proportions in which 
their availability is limited to big companies or very well funded research groups 
(Zaragoza et al., 2011). Nevertheless, these in vivo studies are still a mandatory 
and unavoidable step in the drug development pipeline, regardless many 
spectacular examples of misleading results sentencing the following phases on 
human patients to fail (Wilke et al., 2007). As a specific example, studies on KATP 
channels involved in arrhythmogenic activity in the ischemic heart displayed 
extreme variability in drug function and sensitivity across rodents, rabbits and 
dogs, the latter two displaying more similarities to the human samples (Fedorov 
et al., 2011).     
Reliable in vitro models can cut down the number of approaches flowing into 
this expensive pre-clinical step, by providing the opportunity for cost-effective 
high-throughput screening campaigns (Carlson et al., 2013). Current in vitro 
models, however, are either over-simplistic or affected by similar species-related 
downfalls as their in vivo counterparts. The simplest in vitro cell culture model is 
represented by heterologous or human cell lines over-expressing specific cardiac 
ion channels, most notably the potassium hERG channel (De Ponti et al., 2002). 
This is a perfect approach for studies on single-target drug studies, but only 
recorded signals of the complex multichannel phenotype of cardiac ion channels 
in their native environment can ensure reliable data on the compound effect and 
safety (Meyer et al., 2004; Dick et al., 2010). The most notable and widely 
reported example (De Ponti et al., 2002) of such difference is verapamil, which 
strongly blocks hERG K+ channel (thus, failing the “cell line assay”) but has not 
adverse effect at all in assays employing primary animal cardiomyocyte cultures, 
and it is considered a “safe” drug (Meyer et al., 2004; Dick et al., 2010). Although 
offering an already fully assembled “cardiomyocyte system”, primary animal 
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cardiac cultures are still labor intensive, lack consistency and insufficient for large 
high-throughput approaches (Carlson et al., 2013).  
The only human in vitro model available today that surpasses the simplicity of 
cell cultures is represented by ex vivo experiments on isolated intact organs. 
Human explanted hearts could arguably be the “gold standard” for pre-clinical 
cardiac drug safety screenings, and represents to date a unique tool to explore 
direct and clinical effects of chemical compounds. The two main limitations to 
this approach comprise the extremely limited number of biological substrate 
available and the intrinsic shortcomings of an ex vivo procedure on a denervated 
and not physiologically normal, perfused organ which cannot be considered a 
healthy human heart, even from non-failing infarct-free donors (Fedorov et al., 
2011). 
In this scenario, the constantly developing field of human pluripotent stem cell 
cultures will have a great impact in creating new approaches in compound 
screening and design of drug-safety assays. In particular for the cardiac research, 
since the first report of the derivation of cardiomyocytes from human embryonic 
stem cells in 2001 (Kehat et al., 2001), great hopes are placed on this cells to fill 
the long-standing void in available preclinical models as surrogate for human 
myocardium (Turnbull et al., 2014). 
 
1.2 Human embryonic and induced pluripotent stem cells 
Stem cells are defined by their ability to proliferate maintaining their original 
features in the daughter cells in a mechanism called self-renewal, which for most 
stem cells can go on indefinitely while the proper environmental conditions are 
preserved. The second defining characteristic of a stem cell is the ability to 
differentiate into other cell types when triggered by the right stimuli, and the 
number and type of these differentiation derivatives classifies stem cells in 
“potency” classes (Fig. 1.2). 
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 Fig. 1.2 Schematic 
representation of the 
defining features of 
stem cells (adapted 
from National 
Academies of Science 
Booklet, 2005) 
 
 
Pluripotent stem cells (PSCs) can give rise to all the cells of an organism’s body 
(exception made for the trophoblast) and are defined by the ability to generate 
all three embryonic germ layers. The pioneering works on mouse embryos in the 
early 1980s (Evans and Kaufman, 1981; Martin, 1981) paved the way to the 
derivation of the first pluripotent human embryonic stem cell (hES)-line in 1998 
(Thomson et al., 1998). hPSCs carry the promise of becoming an important 
source of models for a wide range of adult cell types (Pouton and Haynes, 2005), 
and since the first derivation huge improvements have been made in methods 
for their expansion and differentiation. From conditions entirely dependent on 
co-cultures with feeder cells and untargeted spontaneous differentiation now 
are available chemically-defined xeno-free culture protocols (ISCIC, 2010) 
producing large numbers of clinically relevant cells with constantly increasing 
subpopulation-specificity of post-mitotic cells (examples being neuronal 
populations (Compagnucci et al., 2014), hepatic and pancreatic cells (Cheng et 
al., 2013) and cardiac subtypes (David and Franz, 2012)).  
A great breakthrough in the field was achieved in 2007, when human induced 
pluripotent stem cells (hiPS) were first reported (Takahashi et al., 2007), one year 
after their first generation from murine somatic cells (Takahashi and Yamanaka, 
2006). Sharing most hESC features (for hPSC characterization see Table 1.1) hiPS 
technology is groundbreaking for two main reasons: i) it overcomes some ethical 
issues of using fertilized human embryos and ii) it allows the generation of 
patient-specific cell lines, with the associated huge outcomes for autologous 
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therapeutic approaches and specific disease modeling (Passier et al., 2008; Bellin 
et al., 2012). Currently, the original reprogramming factors Oct4, Sox2, Klf4, c-
Myc (Takahashi et al., 2007), Lin28 and Nanog (Yu et al., 2007) are employed in 
different combinations, delivered by xeno-free non-integrating vectors such as 
episomes (Okita et al., 2008) and modified mRNA molecules (Warren et al., 
2010), that surpassed the original viral and genome integrating retro- and lenti-
viral protocols in both efficiency and manipulation safety. 
Table 1.1 List of assays and readouts describing the features describing hPSCs. 
Feature Description 
Morphological 
assessment 
Translucent colonies, densely packed with smooth and 
defined borders, round cell-shape with high 
nucleus/cytoplasm ratio, prominent nucleoli 
Nuclear markers OCT4, SOX2, NANOG, REX1 
Surface markers TRA1-60, TRA1-81, SSEA-3, SSEA-4 
Enzymatic activity Alkaline phosphatase, telomerase 
Differentiation in vitro 
Spontaneous (embryoid bodies) or directed differentiation 
with detection of protein markers from all three germ-layers 
Differentiation in vivo 
Teratoma formation with structures from all three germ-
layers 
Karyotype Normal 
The applications of hPSC, and in particular hiPSCs, are vastly dependent on our 
ability to drive and control their differentiation. Being the source material of 
virtually unlimited numbers of cells with the same characteristics, their 
derivatives can be employed in both cell-based therapeutic approaches (with an 
autologous transplantation strategy for hiPSCs) and for in vitro studies of drug 
screening and disease modeling (Fig. 1.3) (Bellin et al., 2012). 
Although very compelling, the application of hPSCs in clinic for most diseases is 
still years ahead (for a summary of ongoing hPSC trials, see Table 1.2) and the 
more immediate and straightforward field of application for these cells are in 
vitro studies. With restricted availability of tissues such as cardiac, hepatic or 
neuronal ones, patient-specific hiPSC-derivatives for those tissues are an 
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incredible source for studying pathological phenotypes in cell models of human 
origin (Benam et al., 2015). 
Fig. 1.3 Schematic representation of the hiPSC applications (adapted from Bellin et al., 2012). 
Moreover, the employment of these differentiated cells in pharmaceutical 
industry can provide an invaluable human platform in drug discovery and 
screening. In the right conditions, hPSC-derivatives could easily replace 
immortalized cell lines and animal primary cultures in preclinical studies and 
offer a “cheaper” alternative to ex vivo human tissue testing, being unrestrained 
by donor heart availability (Pouton and Haynes, 2005). 
Table 1.2 Summary of clinical trials employing human pluripotent stem cell-derivatives 
Disease 
treated 
Accession # 
ClinicalTrials.gov 
Cell 
type 
Year Notes Reference 
Spinal cord injury --- hES 2010 
Withdrawn 
in 2011 
Ratcliffe et 
al., 2013 
Dry age-related 
macular 
degeneration 
NCT01344993 hES 2011 
First reports 
published 
2014 
Schwartz et 
al., 2014 
Stargardt's 
macular 
dystrophy 
NCT01345006 hES 2011 
First reports 
published 
2014 
Schwartz et 
al., 2014 
Type 1 Diabetes NCT02239354 hES 2014 
Began late 
2014 
Viacyte 
website, 
2014 
Wet age-related 
macular 
degeneration 
Japanese Health 
Ministry, unknown 
hiPS 2014 
First hiPS 
trial, began 
late 2014 
Cyranoski, 
2014 
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For both clinical and in vitro applications of the human pluripotent stem cells, 
the main limiting step is our ability to tightly control their differentiation towards 
the desired cell type, this including both cell type specification and maturation 
degree. Of particular interest is the cardiac derivatives, as human heart samples 
are relatively rare and difficult to handle. 
 
1.3 Human cardiomyocytes derived from hPSCs 
Differentiation towards the cardiac lineage of pluripotent stem cells was first 
reported in 2001, when hESC cultured in suspension formed organoids called 
embryoid bodies (EBs) and displayed spontaneous contractions after 2 weeks in 
culture (Kehat et al., 2001). Since then, the studies on murine embryonic 
development (Murry and Keller, 2008) propelled the optimization of in vitro 
differentiation conditions and resulting in three classical directed differentiation 
protocols: 
  evidence of paracrine signaling of the endoderm germ-layer priming 
the mesodermal specification inspired the first cardiac differentiation 
protocol that improved the ∼1% efficiency of the spontaneous 
differentiation to a ∼12%-25% by co-culturing  hPSC with the END-2 
endodermal cell line (Mummery et al., 2003; Graichen et al., 2007); 
 implementation of Activin/Nodal and BMP signaling in the in vitro 
differentiation process in monolayer cultures  produced ∼30% efficient 
protocols (Laflamme et al., 2007); 
 final optimization of the EB-based protocol to a >50% efficiency was 
achieved by integrating a chronologically defined cytokine stimulation 
regulating the Action/Nodal, BMP, Wnt, VEGF and FGF pathways (Yang 
et al., 2008; Kattman et al., 2011). 
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Fig. 1.4 Cardiac differentiation protocols recapitulate embryonic cardiac development by 
addition of growth factors and small molecules in a time- and dose-dependent manner 
(adapted from Später et al., 2014). 
Cardiomyocyte-enrichment steps following the cardiac differentiation protocols 
(Fig 1.4) are often required when the selection of pure cardiomyocyte cultures is 
necessary (>98% cardiac troponin T positive cells, cTnT+). The most notable 
selection strategies, not involving  genomic integration of selection markers such 
as Puror or GFP+ under cardiac-specific promoters (Anderson et al., 2007), 
include: 
 surface-antigen sorting for SIRPα (Dubois et al., 2011) and/or VCAM 
(Elliott et al., 2011; Uosaki et al., 2011); 
 metabolic selection through glucose-to-lactate substitution in the 
culture medium (Tohyama et al., 2013); 
 sorting for cells with high mitochondrial content with fluorescent 
mitochondria-specific dyes (Hattori et al., 2010).  
More recently, new chemically defined and highly efficient cardiac 
differentiation protocol were published, based on the biphasic role of the Wnt 
signaling in murine embryonic cardiogenesis (Naito et al., 2006; Ueno et al., 
2007). These protocols employ small-molecules to tune the Wnt signaling 
pathway, greatly reducing cell line- and passage number-dependent variability 
(Jiang et al., 2012) and achieving differentiation efficiencies >90% (Lian et al., 
2012). A recent improvement to this protocol reduced drastically the number of 
components in the differentiation media employed, reporting the first 
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completely xeno-free and chemically defined differentiation protocol (Burridge 
et al., 2014). 
Finally, it is a matter of particular interest the opportunity to drive the cardiac 
differentiation selectively towards a restricted subtype of cardiomyocyte. 
Although some studies report subtype classification based on expression of 
molecular markers (such as MLC2a, MLC2v or HCN4), the main criterion of 
classification is the action potential phenotype, even if this method’s reliability 
has been recently challenged (Du et al., 2015). The differentiation protocols 
currently employed generate mainly atrial and ventricular myocytes, which 
proportions can be greatly altered by retinoic acid signaling tuning (Zhang et al., 
2011). Nodal and conduction system cells are present in various proportions 
(Blazeski et al., 2012), with the first ones enriched upon NRG-1β/ErbB signaling 
pathway inhibition (Zhu et al., 2010), while Notch signaling is involved in the 
generation of Purkinje-like cells (Rentschler et al., 2012). Moreover, 
overexpression of specific proteins can promote subtype-specific phenotypes, as 
observed for sinoatrial-like cells by the force expression of Tbx18 and Tbx3 
(Bakker et al., 2012; Kapoor et al., 2013). A better understanding of the in vitro 
sub-specification processes will provide explanation to experimental evidences 
such as nodal-like inhibition by culture substrate modification (Melkoumian et 
al., 2010) or the ventricular-like phenotype enrichment as function of extended 
time in culture (Fu et al., 2009; Lian et al., 2012). 
This exciting field of stem cell research evolves very rapidly integrating promptly 
findings from basic development science in the differentiation protocols 
employed. The derivatives of these protocols will provide in the near future a 
precious source for both clinical and in vitro applications, but before the full 
potential of the hPSC-CMs can be unlocked there are critical points that need to 
be faced.   
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1.4 Challenges and limitations of human pluripotent stem 
cell-derived cardiomyocytes   
From a clinical perspective, the major concerns regarding human pluripotent 
stem cell-derived cardiomyocytes (hPSC-CMs) are summarized by three possible 
pathological outcomes of a cell therapy: teratoma formation, arrhythmogenesis 
and rejection (Prowse et al., 2014). As the latter is a common concern in any 
transplantation/implantation medical procedure and it has a good chance of 
being surpassed by autologous transplantation of hCM derived from hiPS cells, 
the first two have to be addressed at the early stages of hCM production as rely 
on culture purity. Remaining undifferentiated Oct4+ cells can generate teratomas 
or ectopic tissues resulting in dysfunction (Blin et al., 2010), while hCM-subclass 
electrophysiological heterogeneity can generate pro-arrhythmic substrates in the 
reformed tissue (Chen et al., 2009). Although purification might in the end 
become unnecessary with optimization of the cardiac differentiation and 
specification protocols, the enrichment approaches cited in Paragraph 1.3 are 
difficult to scale-up to the cell numbers needed for human therapeutic 
applications (an estimated 109 hCM per treatment (Mummery et al., 2012)) in a 
cost effective manner (Prowse et al., 2014). 
A relevant concern raised since the first derivation of hPSC-CMs in regard of 
their functional outputs is the early and immature phenotype displayed (Snir et 
al., 2003). Although it could not be problematic for clinical purposes, as 
cardiomyocytes at earlier developmental stages display greater proliferative 
potential and are more malleable and adaptable (Reinecke et al.,1999), it is a 
highly desirable feature for in vitro studies. The best fitting comparison for hPSC-
CMs are human fetal cardiomyocytes (Mummery et al., 2003), with whom they 
share most of their phenotypic characteristics, thus defining them as similar to 
the early stages of cardiac development and “immature” in respect to adult 
cardiomyocytes. The most striking difference from the large rod-shaped adult 
cardiomyocytes (aCMs) is their multi-angular irregular morphology with mono-
nuclear appearance typical of a proliferating and mitotically active cell (Cui et al., 
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2007). Gene expression profiles are closely resembling those of fetal cardiac 
tissues more than the adult ones, nevertheless clearly indicating a full-on cardiac 
expression pattern (Cao et al., 2008; Xu et al., 2009). From the functional point of 
view, the gap between the hPSC-CM and the aCM phenotypes has been 
characterized with a plethora of different assays in terms of electrophysiology, 
calcium handling and force generation, with specific numerical values often very 
different from one another (Robertson et al., 2013). All these differences (Table 
1.3) are best condensed in the two main features cited above: morphology, 
which deeply reflects the internal ultrastructural organization of the 
cardiomyocyte, and gene expression patterns, determining the presence of the 
right components of the cardiac molecular machineries.  
Table 1.3 Main reported differences between immature hPSC-CMs and adult hCM. 
Cardiac feature hPSC-CM Adult hCM Reference 
Morphology 
Multi-angular, occasionally 
oblong 
Large, rod-
shaped 
Snir  et al., 
2003 
Number of nuclei Mono-nuclear 
Bi-nuclear, 
multi-nuclear 
Kehat et al., 
2001 
Proliferation Some to low None 
McDevitt  et 
al., 2005 
Chronotropic and 
inotropic response 
Chronotropic Both 
Brito-Martins 
et al., 2008 
Contraction Spontaneous Only induced 
Kehat et al., 
2001 
Action potential 
features 
Low diastolic potential 
(-30 mV to -75 mV) 
Slow depolarization rate 
(2 V/sec to 40 V/sec) 
Diastolic 
potential 
(-85 mV) 
Depolarization 
rate (300 
V/sec) 
Kim et al., 
2010 
 
Ma et al., 
2011 
Ca2+ handling 
machinery 
Absent to low: 
CSQ2, TRDN, Junctin, PLN 
Abnormal levels: 
others 
All present at 
correct 
expression 
levels 
Satin et al., 
2008 
Itzhaki et al., 
2011 
Force/frequency 
relationship 
Negative Positive 
Dolnikov et 
al., 2006 
Metabolism Glycolytic Oxidative 
Rana et al., 
2012 
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The three main functional features of a cardiac cells (action potential 
propagation, calcium-induced calcium release and contraction) require a finely 
orchestrated sequence of events, which in the aCMs is secured by tight structural 
organization and the correct genetic program. The functional performance of 
hPSC-CMs, missing either key molecular components or their right spatial 
distribution, results in unclear and conflicting experimental observations, and 
determines their immaturity.  
With the differentiation protocols constantly improving the purity and the 
yields of human cardiomyocytes from hPS cells, the final challenge for the field is 
the maturation of the cardiomyocytes in vitro. Especially, understanding the 
triggering mechanisms of cardiac development is important in order to integrate 
the appropriate stimuli to cardiomyocyte cultures and promote their maturation, 
thus, providing the best in vitro model for human cardiac physiology available.  
 
1.5 Aim of the thesis   
This thesis aims at the in vitro maturation of human cardiomyocytes derived 
from pluripotent stem cells. We addressed the cardiac maturation from two 
perspectives: the structural and functional phenotype and the cardiomyocyte 
and its metabolic performance. The employment of microengineered surfaces 
for mechanical and topological control of the culture substrate provided insight 
in the molecular signaling involved in cardiac structural development and the 
associated improved functional performance. Moreover, the topological 
confinement of human cardiac cultures allowed to recreate in vitro multicellular 
complexes increasingly resembling the cellular organization in vivo. From the 
metabolic perspective, we show how development of novel technologies 
provides tool for hCM screening and testing during the optimization of culture 
methods aimed at modeling an adult-like metabolism in vitro.  
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Overall, the process of in vitro cardiac development is poorly understood and 
most of the maturation reported in literature (introduced in Paragraph 2.1 and 
Paragraph 3.1) is based on experimental observations, without proposed 
mechanisms. Insight in the mechanisms driving cardiac maturation in vitro will 
provide a better understanding of the process and the development of enhanced 
culture methods aimed at the generation of adult-like hCMs. 
In Chapter 2 is presented the work on the influence of culture substrate on 
human cardiomyocytes, with particular focus on the structural maturation and 
functional performance improvement of the cardiac cell, providing insight in the 
physical cues necessary for the process and the important components of the 
cell signaling network. 
In Chapter 3 the focus is put on the metabolic maturation of the 
cardiomyocytes, with special regard to cell sensitivity to oxygen concentrations. 
We present a novel approach to control oxygen concentrations inside cell culture 
describing the design and validation of a new microfluidic device. This device 
serves as an assay for testing cardiomyocyte metabolic phenotype and 
performance in hypoxia/reperfusion conditions after the application of a 
metabolite-driven metabolic switch in human cardiomyocyte cell cultures. 
Finally, in Chapter 4 are presented two cardiac disease models set up by 
differentiation of patient-specific hiPS cells in cardiomyocytes. The cell models 
described in this chapter can be easily subjected to the maturation protocols 
defined in Chapters 2 and 3, thus providing the biological substrate for disease 
modeling in vitro.                                       
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Chapter 2 
 
Structural and Functional Maturation 
of Human Cardiomyocytes Derived 
from Pluripotent Stem Cells  
 
This chapter focuses on structural and functional maturation of the human 
pluripotent stem cell-derived cardiomyocytes. The state of the art of the 
approaches employed to increase in vitro maturation is presented, and the main 
differences between the resulting cardiac phenotype and the hPSC-CM features 
presented summarized in Paragraph 1.4 are pointed out. It is then introduced 
the experimental approach we will follow address the improvement in structural 
organization and functional performance of the differentiated hCM, presented 
with the literature-derived motivations for such approach. Moreover, the 
technological bases for the experimental approach are laid out with the 
description of the biomaterial employment to modify cell physical environment. 
We then proceed with the presentation of the data on the improved structural 
and functional cardiac features in hCM cultured on compliant microengineered 
substrates and the molecular signaling mechanism behind the process. 
Detailed cell cultures protocols, substrate fabrication are described in Appendix 
A, while molecular biology assays are presented in  Appendix C. All experimental 
data presented in Paragraph 2.4 are contained in manuscripts attached in Annex 
1, with detailed material information. 
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2.1 In vitro maturation of human cardiomyocytes 
The early and immature phenotype displayed by hPSC-CMs presented in 
Paragraph 1.4 is a big concern for in vitro applications such as disease modeling 
and drug testing (Davis et al., 201). Although some degree of structural 
maturation and improved functional performance have been published 
(Robertson et al., 2013), most reports are experimental observations and the 
mechanisms of the hCMs development towards the adult phenotype remain 
elusive. 
The main determinant in most studies showing in vitro maturation is the 
extension of the time of culture (Lundy et al., 2013; Kamakura et al., 2013; Otsuji 
et al., 2010; Sartiani et al., 2007). The results of these studies can be summarized 
by dividing the hPSC-CMs in two major categories according to the length of the 
time in culture after differentiation: early-stage and late-stage, in which 60-90 
days in culture is roughly the discriminating time frame (Fig. 2.1). Despite 
different differentiation approaches and culture maintenance techniques, there 
is a consensus of the cardiac features difference between the two classes: 
i) sarcomeric organization improves over time, with progressive 
appearance of Z-, A-, H-, I- (Lundy et al., 2013) and finally M-
bands (Kamakura et al., 2013) and time-dependent myofibril 
thickening in aligned bundles is observed; 
ii) electrophysiological properties lean towards an adult-like 
phenotype in terms of action potential (AP) parameters: 
increasing maximal upstroke velocity, lower maximum 
diastolic potential, and amplitude (Lundy et al., 2013); 
moreover, the performance of single ion channels and ion 
currents drug-response improves (Otsuji et al., 2010; Sartiani 
et al., 2007); 
iii) calcium handling improves in terms of Ca2+ transient increased 
upstroke and decay velocities (Lundy et al., 2013); 
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iv) time-dependent cardiac population subtype shift is observed, 
with increasing percentages of ventricular-like cardiomyocytes 
over time (Lian et al., 2012; Kamakura et al., 2013). 
Further extension of time in culture (up to 1 years) did not promote relevant 
changes in cardiac phenotype, still far from adult-like. 
 
Fig. 2.1 Schematic representation of the in vitro maturation process of hPSC-CMs in comparison 
with adult myocytes. Cardiomyocyte fundamental structural features usually taken into account 
are represented (adapted from Robertson et al., 2013) 
In order to achieve more adult-like phenotypes for single cardiac functional 
features, such as calcium handling or action potential performances, approaches 
of ectopic delivery of missing molecular components has been proposed (Liu et 
al., 2009; Lieu et al., 2013). To enhance Ca2+ handling ability of hESC-CMs it was 
sufficient to forcefully overexpress the usually absent calsequestrin (Liu et al., 
2009), and similar results for were obtained for action potential profiles with 
Kir2.1 overexpression (Lieu et al., 2013). Both the approaches, however, did not 
promote any other kind of maturation. Somehow similar results were reported 
with miRNA-based approaches (Fu et al., 2011). In this case, overexpression of 
two miRNAs associated in vivo with cardiac developmental processes (miR-1 and 
miR-499) were shown to improve either ion handling performance (miR-1) or 
contraction machinery maturation (miR-499), but in this case as well neither 
promoted a coordinated cardiac maturation. 
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All the reports presented in this paragraph clearly show that the hPSC-CM in 
vitro cultures we study lack fundamental cues (or contain inhibiting cues) that 
regulate developmental progression towards more mature cardiac phenotypes. 
Moreover, it is clear how inserting (in a targeted or shotgun fashion) missing 
components of the immature functional cardiac machineries is unfeasible. 
Thus, further understanding of the mechanisms that trigger cardiac 
development is necessary in order to make available an in vitro models 
representative of human adult cardiac physiology. 
 
2.2 Motivations and experimental design 
The work presented in this chapter aims at the investigation of the mechanical 
triggers of cardiomyocyte maturation in vitro. We here propose a molecular 
explanation of some of the experimental observations reported in literature of 
improved hPSC-CM cardiac phenotype, by linking the interaction between the 
cell and the culture substrate to structural and functional features. We show 
how the modification of cellular physical environment affects the cardiac 
maturation in vitro, thus providing proof of the benefits of integrating 
mechanical cues in the differentiation protocol to generate human 
cardiomyocytes with more mature phenotype. In our perspective, it is important 
to how the heart, from its early beginning, is a highly dynamic tissue, exposed to 
a combination of physical stimuli of different nature at all time-and size-scales 
(Cimetta et al., 2013). It is the first organ generated during embryogenesis and 
forces such as shear, stretch, hydrostatic pressure (“mechanical loads”) and 
electrical activity shape its development and function. 
The importance of these purely physical stimuli, acting in concert with the 
soluble environment to which the cells are always exposed, is supported by 
experimental evidences of high degree hPSC-CM maturation after engraftment in 
a working myocardium (van Laake et al., 2007; Chong et al., 2014). These 
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observations prove that hPSC-CMs retain the potential to achieve adult-like 
phenotypes in the right environmental conditions (Dick et al., 2010). Some 
reports provide proof that the integration of such electro-mechanical stimuli 
present in vivo drive functional hPSC-CM cardiac maturation (Hirt et al., 2014; 
Chan et al., 2013; Mihic et al., 2014) . In most cases, though, these experiments 
are performed on engineered 3D cardiac tissues, culture condition already per se 
shown to provide remarkable structural and functional improvements in respect 
to 2D monolayer hPSC-CM cultures (Stevens et al., 2009; Zhang et al., 2013; 
Turnbull et al., 2013). Thus, the uncoupling of the physical cues that drive the 
maturation is difficult, and the contribution of single mechanical triggers and the 
activation of molecular mechanisms is lost in the process. Reasoning on the 3D 
culture system and its differences from standard monolayer cultures, we decided 
to address the question whether the very proximal physical cell environment of 
the cardiomyocyte and its mechanical features take share in the cardiac 
maturation process. To investigate how the human cardiomyocytes interact with 
the adhesion substrate we cultured the hPSC-CMs on compliant hydrogels, 
tuning their mechanical properties in order to observe the cellular response in 
terms of structural and functional cardiac features. Further on, we investigated 
how the inhibition of cellular physical sensing ability affects its phenotype, thus 
providing a molecular signaling target which activation is necessary to drive in 
vitro cardiac maturation. 
 
2.3 Biomaterials for tuning cell physical environment 
Standard cell culture techniques have relied for decades on glass and plastic 
surfaces to maintain the cell populations employed as experimental models, but 
these adhesion substrates are far from anything the cell could ever experience in 
vivo, from both biochemical and physical perspectives (Wells, 2008). The elastic 
moduli of the human organs are in the range of a few dozen kilopascals (Pa = 
newton/m2), with soft tissues such as brain and adipose centered below 1 kPa 
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and cartilage and bone surpassing 100 kPa (Discher et al., 2009). The prominent 
importance of culture substrate stiffness in determining the cell phenotype came 
to light when evidence of stem cell directed differentiation by sole variation of 
substrate mechanical properties was reported (Engler et al., 2006). In particular 
regard to the cardiac tissue, it has been shown in chick (Engler et al., 2008) and 
murine cardiomyocytes (Jacot et al., 2008) that culture on plastic or other stiff 
substrates is detrimental to cardiac functional features and substrates in the 
“physiological range” of elastic moduli for the human muscle (8 kPa – 25 kPa) can 
improve sarcomeric organization and calcium handling ability. 
Providing cell cultures with defined biochemical and mechanical cues is not an 
easy task and requires the employment of engineered substrates and specific 
biomaterials (Ahearne, 2014). In the first attempts to study the effects of 
substrate on cell cultures natural polymer gels, such as collagen, fibrin and 
Matrigel, were employed (Wells, 2008). The major drawback of these 
approaches was the bioactivity of the biological gels, which determined the 
impossibility of uncoupling mechanical from biochemical cues of the cultures 
substrate (Nemir and West, 2010). Most commonly, synthetic polymeric 
hydrogels such as polyacrylamide- and PEG-based ones are best suited for this 
studies because of their biocompatibility, transparency, high water content and 
controllable physical features (Pelham and Wang, 1997; Ghosh et al., 2007). For 
instance, polyacrylamide hydrogels are not biodegradable nor bioactive, suiting 
perfectly for in vitro studies on the influence of the substrate stiffness on cell 
behavior, as their elastic modulus can be very finely tuned by adjusting the 
acrylamide/bis-acrylamide ratio in the physiologically relevant range (Tse and 
Engler, 2010). 
The mechanical features of the cellular environment are sensed by the cells 
through a process called mechanotransduction, which converts the physical 
forces, both dynamic (such as active stretching or fluid shear) and static 
(substrate elastic modulus), in biochemical signals inside the cell through kinase 
cascades (Jaalouk and Lammerding, 2009). In this pathways, cell-to-cell and cell-
to-ECM adhesion membrane proteins play major a major role, in concert with 
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the structural components of the cytoskeleton on the cytoplasmic side of the 
system. 
In the following paragraphs of this chapter are presented experimental 
observations and data regarding the influence of the cell-substrate interaction on 
in vitro cardiac maturation of human cardiomyocytes derived from pluripotent 
stem cells. We took advantage of the substrate modification techniques 
described in Appendix A to provide different physical stimuli to the cardiac 
cultures, and explored the involvement of a relevant mechanotransduction 
pathway in the determination of the observed phenotype. 
 
2.4 Substrate-driven maturation of hPSC-CMs 
To study the effects of culture substrate on cardiac in vitro culture, we selected 
two pluripotent stem cell lines (one hES and one hiPS, for details about cell line 
origin and culture media refer to Appendix A and Annex 1) and differentiated 
them towards the cardiac lineage with an EB-based protocol (Yang et al., 2008). 
Both cell populations (undifferentiated and at the end-stage of the protocol) 
displayed stage-specific morphologies, with first contracting EBs observed after 
10-12 days for hESC and after 7-9 days for the hiPSC, and were characterized for 
expression of pluripotent and cardiac markers, assessed by immunofluorescence 
(Fig. 2.2A&B). We decided to maintain the differentiated cardiomyocytes in EB 
aggregates cultured in suspension, in order to keep the cell in their native 
environment without addition of external mechanical stimuli. At desired time-
points the EB were harvested and disaggregated to single-cell suspensions and 
replated for further analyses.   
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Fig. 2.2 Molecular markers in pluripotent and differentiated cells. (A) Expression of pluripotency 
markers in hES HES2 cell line and hiPS ADHF#1 cell line. (B) Expression of cardiac markers in 
human cardiomyocytes derived from the same two pluripotent stem cells lines. 
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2.4.1 Cell-substrate interaction promotes cardiac maturation 
Dissociated single-cell cultures displayed both spontaneous and electrically 
elicited contractions and confocal line-scanning imaging with fluorescent probe 
fluo-4 confirmed they were accompanied by cardiac-like calcium transients (Fig. 
2.1A)  
 
 
 
 
 
 
Intriguingly, calcium transients shortened upon extension of the monolayer 
culture time: Ca2+ transients lasting several seconds were recorded in the 
majority of cardiomyocytes early after single cell replating in adhesion, while 
almost disappearing already after few days, with calcium decay values stabilizing 
after 1 week (Fig. 2.3B). Ca2+ release rate increased in the same temporal span, 
as showed by the reduction of the time to peak (TTP) (Fig. 2.3C).  
The increased calcium handling ability was associated with a marked 
improvement in organization of cardiac cell structural features. As opposed to 
cells clustered in embryoid bodies displaying round morphologies with high 
Fig. 2.3 Calcium dynamics in 
hPSC-CMs (A) Representative 
calcium traces of hES-CMs and 
hiPS-CMs and different times 
of adhesion culture. (B)
Evaluation of calcium re-
uptake rate by the half-life of 
calcium decay. (C) Time to 
peak estimates. 
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nucleus-to-cytoplasm ratio and disorganized myofibrils (Fig. 2.4), cardiomyocytes 
cultured in monolayer showed increasing alignment and regular striation 
patterns of the cTnT staining (Fig. 2.4A). In terms of myofibril alignment, both cell 
lines displayed a marked increase in sarcomere organization after 1 week in 
monolayer culture, reaching nearly parallel sarcomeres (Fig. 2.4B). Western Blot 
analysis confirmed an increased expression of cardiac troponin T isoforms on 
cardiomyocytes cultured in adhesion (Fig. 2.4C).  
Fig. 2.2 Sarcomeric organization improves in replated hPSC-CMs. (A) Immunofluorescence 
against cTnT shows progressive generation of striated patterns of the myofibrils and (B) their 
increased alignment with the long axis of the polarized cells. (C) The expression of cTnT increases 
in monolayer culture, in terms of protein amount, tested by Western Blot. 
Calcium cycling is orchestrated by several molecular components and the Ca2+ 
transient profile is the result of sum of their activities (Bers, 2002). The calcium 
re-uptake phase was most striking difference in the Ca2+ transient profiles we 
observed, thus we investigated the expression and distribution of the Sarco-
Endoplasmic Reticulum Ca2+ ATPase 2 (SERCA2), the component of the calcium 
handling machinery mainly responsible for this phase in human cardiomyocytes.   
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Immunofluorescence staining showed a great increase in SERCA2a accumulation 
after 1 week in adhesion, with a striking reorganization of the SR, from a mostly 
perinuclear localization early after single-cell replating, towards a whole-cell 
spreading after 1 week (Fig. 2.5A). We evaluated the spreading area of the 
SERCA2a staining finding a significant increase in spreading area in both hES-CMs 
and in hiPS-CMs (Fig. 2.5B). We assessed by means of RT-PCR that SR calcium 
handling proteins triadin (TRDN), calsequestrin (CSQ2) and phospholamban 
(PLN), which are often found missing in hPSC-CMs and largely impact on the cell 
calcium handling ability (Fig. 2.5C).  
 
Fig. 2.3 Sarcoplasmic reticulum maturation. (A) Staining for calcium pump SERCA2a responsible 
for Ca2+ re-uptake shows SR spreading from a perinuclear localization towards a whole-cell 
volume distribution. (B) Quantification of the spread area of the staining in percentage to cell 
surface. (C) Expression of SR-associated Ca2+ handling proteins.  
Consistently, as expected from a maturing sarcoplasmic reticulum, the 
cardiomyocyte performance in calcium handling improved after stimulation with 
10 mM caffeine shown by representative traces at the two time points 
considered (Fig. 2.6A) and dynamics quantification (Fig. 2.6B); in particular 
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calcium release and re-uptake rates significantly increased and a two-fold 
increase in peak relative amplitude between 2 days and 1 week in adhesion was 
observed. 
Fig. 2.4 Caffeine stimulation response in hESC-CMs. (A) Representative traces of Ca2+ transients 
during 10 mM caffeine stimulation at 2 days and 1 week on monolayer culture. (B) Quantification 
of caffeine-induced Ca2+ transient parameters. 
At this point, we decided to assess whether the functional and structural 
maturation we observe is a result of the time in adhesion or EBs age by 
performing calcium handling analyses on different preparations (n=3) of both 
hES- and hiPS-derived EBs. Calcium cycling in cardiomyocytes results from the 
coordinated action of different molecular components and requiring a correct 
spatial distribution and sub-cellular compartments organization, thus condensing 
in one read-out several key cardiac features. EBs were maintained in suspension 
culture up to 3 months after differentiation protocol start and three time points 
were chosen for Ca2+ analyses: early after cardiac differentiation protocol end, 1 
month and 2-3 months later. All experiments recapitulated the functional 
maturation of the calcium handling machinery in terms of Ca2+ reuptake rate (Fig. 
2.7) for both hES-CMs and hiPS-CM, as function of time in adhesion. A very 
strong correlation (Two-Ways ANOVA, p<.001) was found between the calcium 
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transient shortening and the time in adhesion culture, but not EB age, thus 
highlighting the importance of the cues from the adhesion substrate over the age 
of EB for the improvement in functional performance. 
As previously cited in Paragraph 
2.1, extension of the time of 
culture of differentiated hPSC-
CMs produced cardiomyocytes 
displayed more mature features. 
In those studies,  the maturation 
process spanned several months 
and the cells were maintained in 
beating clumps, thus the 
contribution of cell-substrate 
interactions could not be clearly 
investigated. In this paragraph, it 
is shown how in our cultures 
structural and functional cardiac 
maturation can be observed and 
quantified. Moreover, we prove 
that the condition prevalently 
contributing to this maturation is 
the time in adhesion to a 
substrate, regardless of the age of the embryoid body from which the hCMs are 
derived. We wanted to further investigate the interaction between 
cardiomyocyte and substrate modifying its mechanical properties. 
2.4.2 Cardiac maturation depends on substrate stiffness 
The elastic moduli of cardiac and skeletal muscle tissues are routinely estimated 
in a range between 8 kPa and 25 kPa and it has been proven that hydrogels in 
this range of stiffness provide the best adhesion substrate for muscle cells and 
Fig. 2.5 Substrate interaction drives the Calcium 
handling maturation. Calcium handling ability in hPSC-
CMs described as Ca2+ re-uptake rate. Ca2+ decay 
values drop after monolayer adhesion culture, 
regardless of EB age.  
Structural and functional maturation Chapter 2 
 
 
34 
cardiomyocytes promoting their differentiation and maturation (Engler et al., 
2008; Serena et al., 2010).   
Fig. 2.6 Effect of substrate stiffness on cardiac maturation parameters. Calcium handling in (A) 
representative Ca2+ transient profiles and (B) quantification of Ca2+ transient decay rate. 
Quantification of SERCA2a spread area percentage (C) and sarcomere alignment (D) with 
representative images for all substrates after 5 days in adhesion culture. 
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To assess whether the hPSC-CM were affected in their adhesion culture-driven 
functional maturation by the stiffness of the culture substrate, we cultured hiPS-
CM after EB disaggregation on polyacrylamide hydrogels of 4 kPa (soft 
substrate), 16 kPa (muscle-like substrate) and glass (stiff substrate). Human 
cardiomyocytes cultured on 16 kPa hydrogels and on glass recapitulated the 
previous results, with a positive correlation between time in adhesion culture 
and functional maturation, with calcium transients decreasing in duration (Fig. 
2.8A), and increasing rate in Ca2+ re-uptake (Fig. 2.8B). In these substrate 
conditions, the structural features of the cardiac cells improved in time showing 
SR maturation and SERCA2a spreading (Fig. 2.8C&E) and proper sarcomere 
alignment (Fig. 2.8D&E). Instead, cardiomyocytes cultured on the 4 kPa hydrogel, 
did not show functional maturation in terms of calcium handling (Fig. 2.8A&B); 
consistently, the SERCA2a distribution maintained a perinuclear localization ( Fig. 
2.8C&E). The influence of the soft substrate on cardiomyocyte structural 
organization was evident as well in the lack of myofibril alignment and poor 
organization of sarcomeric structures (Fig. 2.8D&E).  
2.4.3 Mechanotransduction is necessary for hPSC-CMs maturation 
Cell sensing of the surrounding physical environment has its molecular basis in a 
limited number of signaling pathways (Jaalouk and Lammerding, 2009) 
transducing mechanical cues through pathways such as the RhoA-ROCK pathway 
(Wei et al., 2001). The importance of this specific mechanotransduction pathway 
in cardiac development is demonstrated by severe alterations in heart 
morphogenesis of mouse and chick embryos (Zhao and Rivkees, 2003; Sakata et 
al., 2007). Neonatal rat cardiomyocytes subjected to prolonged exposure to 
RhoA/ROCK inhibitors show a reduction in contraction force (Jacot et al., 2008). 
Moreover, ROCK inhibition has been shown to effectively mimic the effect of soft 
substrates in terms of translocation of transcription factors and activating similar 
transcription profiles (Dupont et al., 2011). This evidence identifies Rho-
associated kinase as a suitable target of inhibition in order to convincingly 
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desensitize hPSC-CM from the mechanical environmental cues, thus providing 
insight in the molecular basis of their substrate-driven maturation. 
Fig. 2.7 RhoA/ROCK mechanotransduction pathway inhibition prevents cardiac maturation 
mimicking the phenotype displayed by cardiomyocytes culture on a soft substrate. (A) Calcium 
transient decay rate. (B) SERCA2a spread area and (C) myofibril alignment with representative 
images (D).   
We cultured hPSC-CM on a stiff substrate with or without 2 µM of ROCK 
inhibitor Y-27632 for 1 week and analyzed the cultures for calcium handling and 
structural features. As expected, the untreated cardiomyocytes recapitulated the 
results reported above (Ca2+ shortening and increased calcium reuptake rate) 
(Fig. 2.9A). This effect of adhesion culture was completely abrogated by the 
ROCK inhibition, with Ca2+ transients lasting several seconds even after 1 week 
and calcium reuptake rates fairly unchanged within this time in culture (Fig. 
2.9A). In line with the previous results, in which calcium handling maturation was 
accompanied by pronounced SR maturation and SERCA2a enhanced expression 
and relocalization, SERCA2a staining revealed how the treated hPSC-CM 
maintains a perinuclear localization of the pump after 1 week without significant 
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spreading throughout the cell volume observed in the controls (Fig. 2.9B&D). 
Interestingly, human cardiomyocytes did not display significant alterations in 
myofibrils alignment, which organized in a parallel fashion with the long cell axis, 
although presenting less degree of sarcomere organization, resulting in thinner 
myofibrils compared to the controls (Fig. 2.9 C&D). 
 
2.5 Conclusions 
In this chapter, we addressed the issue of in vitro cardiac maturation of human 
cardiomyocytes derive from hPSCs. We presented the maturation approaches 
reported in literature, describing the resulting phenotype and highlighting the 
limitations of these experimental observations.  
We provided evidence of phenotypes similar to those reported in our human 
cardiac cultures, but we show how time culture extension in clusters and cell 
aggregates is not the driving force behind the structurally and functionally 
matured phenotype. The cues derived from cell-to-substrate interaction upon 
single cell or monolayer culture are responsible for great structural 
reorganization that results in improved functional performance. This process can 
be observed son after cell replating and is independent on the age of the 
differentiated cells.  
We then show how tuning the interaction between the cardiomyocyte and the 
adhesion substrate affects the maturation, proving that soft substrates do not 
provide enough passive mechanical stress to the cells and do not sustain 
structural reorganization and failing to improve functional performance. 
Biochemical disruption of mechanotransduction signaling “tricks” the 
cardiomyocyte into sensing a lower passive mechanical stress from the substrate, 
thus mimicking a soft-substrate culture and recapitulating the maturation-
inhibited phenotype. With the specificity of the pharmacological target, we 
provide evidence of the involvement of the RhoA/ROCK pathway in the in vitro 
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cardiac maturation and state that the presence of cues positively regulating this 
signaling should be integrated in human cardiac culture to produce structurally 
and functionally more mature human cardiomyocytes for in vitro studies.  
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Chapter 3 
 
Metabolic Maturation of Human 
Cardiomyocytes Derived from 
Pluripotent Stem Cells  
 
This chapter introduces the metabolism as a characterizing feature of a 
cardiomyocyte, highlighting the importance of proper metabolic phenotype for 
in vitro applications of hPSC-CMs. First, the cardiac metabolism and the 
developmental changes are described and compared to the immature phenotype 
displayed by cardiomyocytes derived from hPSCs. Secondly, an assay for 
evaluating the metabolic hPSC-CMs maturation based on a hypoxia-resistance 
analysis is proposed; specifically, microfluidics-based technologies for oxygen 
control in vitro and human cell cultures developed. At last, a metabolite-driven 
metabolic maturation approach is proposed. 
Detailed cell cultures protocols are described in Appendix A, while microfluidic 
device fabrication and validation procedure are reported in Appendix B. All 
experimental data presented in Paragraph 3.3 are contained in manuscripts 
attached in Annex 2 and Annex 3.      
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3.1 Cardiomyocyte metabolism  
The heart is the most energetically demanding organ in the human body. In 
order to face the work load of continuous contraction activity with an average 70 
beats per minute, it is estimated to burn at least 6 kilograms of ATP daily 
(Neubauer, 2007). The metabolic setup necessary to generate this amount of 
ATP characterizes a cardiomyocytes as much as the ability to use it through 
electrophysiological homeostasis, calcium cycling and contraction. Despite the 
high-energy demand, the adult heart does not have energy reserves and must 
continually produce energy, feature that accounts for its high susceptibility to 
nutrient-deprivation stresses during pathological events such as ischemia 
(Lopaschuk et al., 2010). 
The metabolism of adult cardiomyocyte relies for more than 90% on 
mitochondrial oxidation of energetic substrates and, although it can rapidly 
switch from one primary carbon source to another, the preferred substrate for 
oxidation are fatty acids (Fig 3.1A) (Lopaschuk and Jaswal, 2010). This 
preferential substrate usage reflects especially on the mitochondria content and 
structure: in adult cardiomyocytes mitochondria are tightly organized along the 
sarcomeric structures of the contractile machinery (Garcia-Perez et al., 2008) and 
account for at least 30% of the cellular volume (Piquereau et al., 2013); 
moreover, mitochondrial genes related to β-oxidation and respiratory chain are a 
hallmark of an adult phenotype from a transcriptomic and proteomic point of 
view (Fig. 3.1B) (Pohjoismäki et al., 2013). 
During the heart development, the embryonic and fetal cardiomyocytes display 
a strikingly different metabolic phenotype than the adult ones, relying mostly on 
glycolysis for their ATP production (Fig. 3.1C). The switch from a glycolytic 
towards an oxidative metabolism occurs very rapidly after birth, when in a 
matter of days blood levels of oxygen and fatty acids abruptly increase (Knopp et 
al., 1986), while lactate and insulin average concentrations decrease more than 
tenfold (Medina, 1985; Girard et al., 1992). The process is mirrored by 
transcriptome and proteome changes, with vast down-regulation of components 
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of the glycolytic pathway (such as GLUT-1 and HK-1) and up-regulation of those 
of the β-oxidation pathway (for example, ACADVL and CPT1b) (Pohjoismäki et al., 
2013).  
Fig. 3.1 Cardiac metabolism in development. (A) Pathways of energy substrate metabolism in 
ATP production of a cardiomyocyte. (B) Differentially expressed proteins in human adult and fetal 
heart samples. (C) Percent contributions of the different pathways to ATP production in isolated 
rabbit hearts (Lopaschuk and Jaswal, 2010; Pohjoismäki et al., 2013). 
The hiPS-derived cardiomyocytes are reported to closely resemble in culture 
fetal cardiomyocytes and their metabolic phenotype makes no exception 
(Robertson et al., 2013). The bioenergetic profiling of hPSC-CM provided proof of 
primarily glucose-based (Rana et al., 2012) or mixed (Hattori et al., 2010) 
substrate usage, with the associated protein expression patterns heavily shifted 
toward fetal-like glycolytic programs (Chung et al., 2007). The mitochondrial 
mass (Hattori et al., 2010) and distribution (St. John et al., 2005) reflects similarly 
the early phenotype, with a perinuclear distribution of small and poorly 
networked organelles. Nevertheless, even if at lower levels than human fetal 
cardiomyocytes (Cao et al., 2008), expression of β-oxidation associated genes is 
present and the hPSC-CMs display some degree of adaptability in substrate 
usage, being able to metabolize lactate (Tohyama et al., 2010) and switch to 
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galactose and fatty acids when completely deprived of glucose (Rana et al., 
2012).      
 
3.2 Motivations and experimental design 
The work presented in this chapter aims at the development of a fast and 
reliable screening assay to test the metabolic maturation of hPSC-derived 
cardiomyocytes. Moreover, we propose a feasible approach for promoting the 
switch of the hPSC-CMs bioenergetic profile in vitro towards a more mature 
phenotype with a metabolite-driven maturation. 
In vitro maturation of hPSC-CMs is a key feature for this cell type to unlock its 
potential as a robust model for the human cardiac tissue (Cimetta et al., 2013). 
As described in Paragraph 2.1 much of the efforts to drive cardiac maturations 
has been put in structural and functional maturation, as features like 
electrophysiology are highly appealing for most drug screenings and have been 
the target of the first human cardiac in vitro disease models (Paragraph 4.1). 
Nevertheless, in order to provide a fully representative model of the human 
adult myocardium it is unavoidable to pursue metabolic maturation for both 
drug testing, with many drugs resulting in mitochondrial dysfunction (Rana et al., 
2011), and for disease modeling. In the latter case, metabolic diseases or 
pathologies with late onset require a fully mature cardiomyocyte in order to 
provide meaningful data in vitro. Recent reports of required metabolic 
maturation to recreate pathological phenotypes in hiPS-CM based models 
strongly support this concept. Chen and colleagues showed that hiPS-CMs 
derived from an ARVC/D patient, although displaying an aberrant molecular 
phenotype linked to the pathology, would not show aberrant adipogenesis 
typical of the disease unless metabolically activated (Kim et al., 2013). In another 
example, Iacone and colleagues had to promote metabolic maturation and 
glycolytic-to-oxidative switch in order to model type 2 diabetic cardiomyopathy, 
a purely metabolic disease (Drawnel et al., 2014).               
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The adult cardiomyocyte metabolism hugely relies on oxygen supply, as the vast 
majority of its energy comes from fatty acid mitochondrial oxidation (Harris and 
Das, 1991) in which O2 acts as the final electron acceptor (Fig. 3.1A). The entire 
cardiac machinery depends on the impressive work volume of the mitochondrial 
network, and when oxygen levels rapidly drop in the cellular microenvironment, 
the energy shortage triggers stress-adaptive responses while by-products and 
respiration intermediates accumulate (Chouchani et al., 2014). In vivo, such 
conditions are generated by ischemic events when blood supply is severed to 
parts of the myocardium and cardiomyocyte death is caused by extensive 
generation of reactive oxygen species (ROS) accompanying rapid re-oxidation of 
accumulated succinate following O2 reintroduction in the electron transport 
chain (Chouchani et al., 2014). By contrast, fetal cardiomyocytes develop in a low 
oxygen environment and rely on anaerobic glycolysis for their ATP production, 
resulting in a relatively hypoxia-resistant phenotype (Robertson et al., 2013). 
Hence, we reasoned that a good indicator of cardiomyocytes metabolic 
maturation could be the survival rate to acute ischemia-like events, given that 
only cardiomyocytes with developed mitochondria and an oxidative metabolism 
would be affected in these conditions. 
To recreate a spatiotemporally controlled hypoxic environment in vitro, we 
employed microengineering techniques and designed a microfluidic device. The 
use of microscale technologies allows extreme control over cell cultures and the 
miniaturization and ad hoc design of the device permits coupling the system with 
standard labware and analyses instruments.    
In order to activate the metabolic maturation program, we decided to culture 
the hPSC-CMs in media containing different energetic substrates. Although hPSC-
CMs prefer glucose even in presence of other carbon sources, it has been shown 
that they possess the ability to metabolize several other energetic substrates 
when cultured in glucose-free media (Rana et al., 2012). This forced fuel-switch 
resulted in improvement of mitochondrial performance and promoted the 
expression of β-oxidation related genes at the expense of the glycolysis pathway. 
Moreover, a tight link between metabolism and cardiac gene expression 
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programs has been recently proposed, with hypothesis of metabolic signals being 
triggers for fetal/adult switch (Taegtmeyer et al., 2010). Some evidence of such 
effect has been reported, when a metabolite-driven maturation of hiPS-derived 
cardiomyocytes resulted in maturation of structural and functional features 
along with metabolic switch, with sarcomeric alignment and elongation and 
improved electrophysiological properties (Drawnel et al., 2014).      
 
3.3 Microfluidic technologies for hypoxia generation 
Constant exposure to ambient atmosphere during every handling step in a 
laboratory makes controlling gas concentrations in cell cultures very challenging, 
as the chemical gradients are hugely in favor of environmental conditions (i.e. 
0.04% vs. 5% of CO2, or 21% vs. <2% of O2). In the same way as for routine CO2 
control, recreating a hypoxic environment has been conventionally pursued 
maintaining the cell cultures in airtight chambers or incubators with 
macroscopical control over the gas mixtures entering the setup (Fig. 3.2A). These 
systems are characterized by oxygen equilibration periods in the order of hours 
and require burdensome equipment for reagent equilibration, culture handling 
and real-time data acquisition (Allen et al., 2001). The scale-down of the fluid 
volumes involved in the gas exchange processes is the most straightforward 
approach for reducing the physical parameters involved in the oxygen stripping 
process inside a cell culture (Fig. 3.2B) (Russ et al., 2007). The evolution of 
microengineering techniques and the employment of appropriate biomaterials 
allow the fabrication of miniaturized culture systems providing new 
opportunities in controlling the cellular environment (Byrne et al., 2014). 
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Fig. 3.2 Gaseous conditions 
control systems in a laboratory. 
(A) The conventional setup for 
atmosphere control composed 
of an incubator with  airtight 
chamber for cell culturing and 
glove box for cell culture 
handling (Byrne et al., 2014). (B) 
A schematic representation of 
the culture parameters 
influencing gas dynamics in the 
Petri dish  (Russ et al., 2007). 
Microfluidic platforms are usually designed as small devices, reducing the 
operated liquid volumes to the order of microliters. Such dimensions enable 
precise control over the microenvironment of a cell culture lodged inside, 
allowing spatial and temporal regulation of specific chemical and gaseous 
conditions (Oppegard et al., 2009). In particular, the huge increase in the surface-
to-volume ratio and the diffusive-regime for mass transport in microfluidic 
channels benefit gas exchange speeding up enormously the process, thus 
providing a good opportunity to impose fast changes in oxygen concentrations of 
the culture media (Martewicz et al., 2012). The two main microfluidic 
approaches for the design of oxygen controlling device are based on either 
feeding media pre-equilibration or direct control over the cell culture by laminar 
flow of oxygen-stripping fluids (Byrne et al., 2014).  
An example of the first approach is a device of our design: a bi-modular 
microfluidic platform composed by a gas-exchanger for medium pre-
equilibration and a sealed perfusion microscope chamber for real-time confocal 
imaging (see Annex 2 for detailed device description). The low volumes of the 
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glass channel inside the gas-exchanger (Fig 3.3A) allow rapid oxygen stripping of 
the flowing liquid and such preconditioned medium is delivered to the cell 
culture inside the perfusion chamber (Fig 3.3B). In this example of oxygen-
controlling device, we showed that fast transients of hypoxia produce alterations 
of the calcium cycling in contracting cardiomyocytes (Martewicz et al., 2012). 
However, this type of design does not suite long-term cultures due to the 
cumbersome handling of a bi-modular device and the need for constant medium 
flow, which has been proven detrimental to cell cultures by our group (Giulitti et 
al., 2013). 
Fig. 3.3 Schematic representation of the bi-modular hypoxia microfluidic device. (A) The gas-
exchanger unit is composed of a medium channel etched in glass with a gas chamber above and 
separated by a thin gas-permeable membrane. (B) The perfusion chamber is assembled over a 
microscope-slide with the cell culture. (Martewicz et al., 2012)  
The second microfluidic approach feasible for hypoxia generation is pairing a 
cell culture chamber with an oxygen-stripping chamber, filled with either oxygen 
scavenging chemical solutions (Chen et al., 2011; Wang et al., 2013) or gas 
mixtures (Polinkovsky et al., 2009). In these approaches, oxygen gradients are 
generated by direct O2 removal from the culture chamber and the remote 
control of the composition and flow-rate of the stripping fluids allows the control 
of the oxygen levels. Both approaches, though, require the maintenance of cell 
cultures inside the microfluidic device and require  optimization of culture 
conditions, especially with delicate cell types such as hPSC and cardiomyocytes. 
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In order to develop a functional assay for cardiomyocytes metabolism, we first 
addressed the issue of long-term cultures of human pluripotent stem cells and 
human cardiomyocytes inside a microfluidic chip (Luni et al., 2013). We 
employed a microfluidic platform composed of an array of cell culture channels 
capable of sustaining human cell cultures with remote control of the culture 
media  (Fig 3.4A, for detailed device description see Annex 3). We determined 
the optimal culture conditions for expansion and maintenance of human 
pluripotent stem cells inside the microfluidic channels (Fig 3.4B), as well as the 
conditions for cardiac differentiation (Fig 3.4C). Human cardiomyocytes, either 
directly differentiated inside the chip or replated from a standard culture plate, 
maintained their functional features, such as spontaneous contraction and 
calcium cycling, and could be analyzed by live imaging with confocal microscopy 
(Fig 3.4D). The perfusion system allowed biochemical stimulation and cellular 
responses to stimulation with Ca2+ dynamics modifying drugs were recorded. 
Fig. 3.4 hPSC and hPSC-CMs cultures inside microfluidic channels. (A) Schematic representation 
of the microfluidic device. (B) A culture of human embryonic stem cells inside the microfluidic 
channel assayed by immunofluorescence for the expression of SOX2 (green) and nuclei counter-
stained with DAPI (blue) (scale bar = 100µm).. (C) hESC-derived cardiomyocytes inside the 
microfluidic channel stained for cardiac troponin T (red) (scale bar = 25 µm).displaying (D) 
cardiac-like calcium transients acquired by fluo-4 loading (green line scans) and responding to 
drug stimulation.  
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For the generation of stable and highly tunable oxygen conditions, necessary for 
the setup of the hypoxia-resistance assay, we integrated the technology of the 
gas-exchanger with the culture techniques optimized in the abovementioned  
microfluidic platform, achieving a device capable of tight control over the oxygen 
partial pressure inside a human cardiac culture viable for long-term culture in 
such experimental setup.   
3.4 Hypoxia-resistance assay 
In order to provide a tool for evaluating the metabolic differentiation by 
applying an a ischemic-like stress to a human cardiac culture a new microfluidic 
platform had to be designed. Hypoxia-resistance would be determined by the 
survival rate to a hypoxia/reperfusion sequence, quantified by live optical 
imaging of the cell culture labeled with Live&Dead fluorescent assay. Thus, 
optical accessibility, complete isolation from the ambient air during the stimulus 
and fast oxygen dynamics necessary for precise quantification of the stimulus 
length were required features for the device. 
3.4.1 Microfluidic hypoxia device 
We based the design of the cell culture chamber on the microfluidic platform 
employed in the optimization of pluripotent stem cell culture conditions 
(Paragraph 3.3), scaling down the dimensions for better and faster control of the 
pO2 (Fig. 3.5A). To allow the O2 exchange between the liquid and the gas phases, 
a multi-layer structure was produced, with a 50 µm thick PolyDiMethylSiloxane 
(PDMS) gas-permeable membrane as interface between a cell culture chamber 
and the a climatic chamber, where different gas mixtures can be pumped to 
control pO2  (Fig. 3.5C). The overall dimensions for the chip were set in order to 
easily fit the system in a standard 6-well plate for cell cultures and suitable for 
most microscopy holders of 25 mm Ø (Fig. 3.5B). 
Metabolic maturation of hPSC-CMs Chapter 3 
 
51 
Fig. 3.5 Microfluidic chip for O2-control in cardiac cultures. (A) Schematic design of the  culture 
and climatic  chambers with reported sizes of each component. (B) The assemble device with 
colored dyes as counter stain for the culture chambers (red) and the climatic chamber (blue). (C) 
Schematic cross-section of the device. 
 Coupling the device with an external gas mixing system allows to precisely 
control the pO2 inside the climatic chamber. This was achieved by use of air, 
nitrogen and carbon dioxide mass flow meters controlled remotely and varying 
the proportion of N2 and air, with constant 5% CO2 for pH control. To test the 
oxygen equilibration period and the robustness of the system in maintaining the 
set oxygen levels, we performed experiments with the oxygen-sensitive dye 
tris(4,7-diphenyl-1,10-phenanthroline)-ruthenium(II) dichloride (Ru(ddp), already 
employed for the validation of the gas-exchanger (described in Annex 2). The dye 
Ru(ddp) emits green fluorescence when exited at 488 nm and its fluorescence is 
dynamically quenched by molecular O2 in a quantitative manner, with linear 
correlation in the 0-21% pO2 range (Fig. 3.6A). We, therefore, sequentially 
changed the composition of the gas entering the climatic chamber and verified 
fast and stable equilibration to the set pO2 inside the culture chamber (Fig. 
3.6B). 
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Fig. 3.6 Oxygen equilibration dynamics in the microfluidic device. (A) False-colors fluorescence 
photographs of the middle section of a culture chamber filled with Ru(ddp) oxygen-sensitive dye. 
Ru(ddp)fluorescence is proportional to molecular O2 concentrations. (B) Quantification of 
Ru(ddp) fluorescence allows precise determination of the pO2 inside the culture chamber. (C) The 
oxygen-stripping dynamics under sudden total oxygen deprivation are below 60 seconds.   
The time scale of the oxygen dynamics at variations from 21% pO2 to 0% pO2 
was assessed to be in the order of seconds, with plateau reached after 60 
seconds of flow variation (Fig. 3.6C).    
 3.4.1 Assay validation with murine primary cultures 
We then sought to integrate a cardiac cell culture with the microfluidic device 
and test the hypoxia-resistance assay. Primary cardiac cultures were obtained 
from newborn rats (p3) and used as bona fide cardiomyocyte model (Chlopcíková 
et al., 2001). Optimization of the seeding and culturing conditions was necessary, 
as the 300 nl volume and limited height of the microfluidic channel pose 
significant differences relative to standard petri dish cultures. To achieve a 
homogeneous culture composed by 85%±2% of cardiomyocytes a high density 
plating of 8000 cells/µl was necessary, in order to provide immediate contact 
inhibition to proliferating fibroblast, and given the limited nutrient supply fresh 
medium was perfused every 12 hours (Fig. 3.7). Such cardiac cultures were 
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maintained up to 7 days without negative effects on normal cell morphology or 
spontaneous contraction. 
Fig. 3.7 Integration of cardiac culture with the hypoxia-device. Immunofluorescence staining for 
cardiac troponin T (cTnT, red) in rat neonatal cardiomyocytes cultured in the microfluidic chip for 
4 days.  
The neonatal rat cardiomyocytes were subjected to a 3 hours long hypoxia-
stress followed by 3 hours of reperfusion with media equilibrated to ambient 
pO2. Because neonatal cardiomyocytes still retain the ability to switch glycolysis 
when oxygen is not available, we employed a serum-free DMEM without glucose 
during the hypoxic period. The amount of cellular damage during 
hypoxia/reperfusion (H/R) events is deeply dependent on the duration of the 
hypoxic stimulus, thus we aimed at establishing threshold duration of the 
hypoxic phase at which the effect on cell survival would be prominent. In some 
published studies, we found that 150 minutes of hypoxia result in ∼70% survival 
rate (Gorbe et al., 2010), thus we designed our experimental protocol as 
described in Fig. 3.8A: 3 hours of hypoxia in DMEM without glucose, followed by 
3 hours of reperfusion with cardiac culture medium. Exposing the cell to 1 and 2 
hours of hypoxia (Fig. 3.8B&C) did not produced significant mortality, while a 3 
hours exposure produced massive cell death, clearly visible in Fig. 3.8D. The 
quantification of di-ethidium bromide-stained nuclei resulted in a ∼70% mortality 
rate, and this value was consistent through different analyzed samples (Fig. 
3.8E).       
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Fig. 3.8 Hypoxia-resistance validation with murine cardiomyocytes. (A) Experimental design for 
the hypoxia protocol. (B) One hour and (C) two hours of hypoxia followed by reperfusion do not 
affect sensibly the cardiomyocyte survival rate.  (D) Representative images of Live&Dead staining 
inside the microfluidic channels for control samples (same media conditions, 3+3 hrs of 20% O2) 
and hypoxia-subjected samples. (E) Mortality quantification by count of di-ethidium Bromide 
stained nuclei. (scale bars = 100µm) 
Microfluidic devices provide multiple advantages over standard culture 
methods, one of which is the precise spatial control over the cell environment. 
We analyzed the cardiac cultures along the microfluidic channel after the H/R 
stress in order to verify the absence of oxygen gradients that would make the 
mortality unreliable. As expected, the whole culture chamber displayed 
homogeneous mortality rates, but we were positively surprised by the presence 
of >90% viable cultures at the edges of the climatic chamber (Fig. 3.9). PDMS is a 
highly gas permeable polymer and allows oxygen diffusion at nearly the same 
rate as water (Martewicz et al., 2012), thus the portions of the culture channels 
not underneath the climatic channel did not experience any hypoxic stress and 
were constantly maintained at the incubator atmosphere. The precision of the 
hypoxic environment localization is in the range of few tens of microns, and the 
presence of such “protected” areas provides a good internal control over the 
experimental conditions.      
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Fig. 3.9 Spatial control over the hypoxic environment. A schematic representation of the 
microfluidic device with a composite picture of a culture channel after cardiomyocytes were 
subjected to hypoxia/reperfusion (stained with ethidium bromide in red). The hypoxic stress 
affects only the cardiomyocytes inside the culture chamber area in contact with the climatic 
chamber, while protected areas remain viable (scale bar = 100µm).  
 
3.5 Metabolite-driven hiPSC-CMs maturation 
We then proceeded with analyzing the response to hypoxia of human 
cardiomyocytes differentiated from hPSC. We employed for these experiments 
the embryonic stem cell line HES2, already described in Paragraph 2.4.1, and the 
hiPS healthy cell line mRNA-Clone1. Data reported in this chapter refer to the 
latter line, unless otherwise stated, although both of the lines were used to the 
set up of the experimental conditions. In order to obtain large numbers of highly 
pure cardiomyocytes, we employed a monolayer differentiation approach (see 
Appendix A), that is more efficient in terms of cardiomyocyte yield and time of 
the cardiac differentiation process. The expression of pluripotency and cardiac 
markers for mRNA-Clone1 was routinely assessed (Fig. 3.10). 
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Fig. 3.10 Expression of pluripotency and cardiac markers in mRNA-Clone1. (A) Pluripotency-
specific transcription factors and surface markers are expressed. (B) After differentiation mRNA-
Clone1-derived cardiomyocytes spontaneously contract and express cardiac-specific proteins.  
hiPS-CMs were replated in the microfluidic chip and maintained in culture for 4 
days before further testing. Prior to hypoxia induction, the maintenance of wide 
spread spontaneous contractile activity was assessed.  
As hiPS-CMs display fetal-like phenotype and they are known for high glycolytic 
capacity, it was not unexpected finding they were hypoxia-resistant, to the 
extent of the duration of the assay set up with the rat neonatal cardiomyocyte 
(Fig. 3.11A). In order to provide a more harsh stress to the cells, we attempted to 
couple hypoxia with complete nutrient deprivation, subjecting the culture to 3 
hours of hypoxia in DPBS saline solution supplemented only with calcium and 
magnesium. Complete energy substrate deprivation did not produce any 
significant effect over the survival rate of the hCMs  (Fig. 3.11B). Nutrient 
deprivation is a big issue for adult cardiomyocytes in vivo as they do not possess 
intracellular energy stores (Thijssen et al., 2001), but hPSC-CMs are more 
immature and display increased plasticity in response to stressors. This made us 
investigate the possibility of glycogen accumulation in the hiPS-CMs, a feature to 
our knowledge never reported in literature in association to their metabolic 
phenotype.  
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Fig. 3.11 Hypoxia-resistance assay on hiPS-CMs. (A) hCMs differentiate from hiPS cells (mRNA-
Clone1) were replated inside the microfluidic chip and assayed for hypoxia-resistance. The 
human cardiac culture proves to be metabolically immature as the survival rate to the hypoxic 
stress id >90%. (B) Hypoxic stress delivered in pure saline solution (DPBS) proves high resistance 
of the cell type to hypoxia and nutrient deprivation. 
We performed a periodic acid-Schiff (PAS) staining on the differentiated cardiac 
cultures, for both embryonic-derived and induced pluripotent-derived cardio 
myocytes, and observed strong accumulation of glycogen (Fig. 3.12). This feature 
provides a supplementary evidence of the early and immature phenotype of this 
cell type, but additionally provides a possible early readout for our metabolic 
maturation assay. Intracellular energy stores, especially feeding the anaerobic 
glycolytic metabolism, will compensate for any nutrient or oxygen deprivation 
stress we could provide to the cell culture, while being itself a hallmark of a fetal 
metabolic program. 
The “basal medium” employed for the maintenance of hiPS-CMs is RPMI 
supplemented with B27, which was originally designed for culture of primary 
hippocampal neurons (Brewer and Cotman, 1989) and is very rich in proteins, 
hormones and especially energy carbon sources: D-glucose, D-galactose, L-
carnitine and L-glutamine, and three different fatty acids (Burridge et al., 2014). 
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Fig. 3.12 Energy reserve stores in hPSC-CMs. The hCM derived from hPSC display big stores of 
glycogen in PAS staining. The glycogen stores account for the nutrient deprivation resistance and 
provide a readout for hPSC-CMs immaturity. 
We decided to induce a metabolic switch in the human CMs by restraining the 
carbon source availability in the maintenance media in cardiac cultures 1 month 
old, in a similar fashion already reported by Rana and colleagues (Rana et al., 
2012).We designed two different induction media:  
i) DMEM without D-glucose supplemented with 30 µM BSA-Linoleic acid 
and 0.1% insulin-transferrin-selenium solution (170 nM insulin); 
ii) αMEM supplemented with 0.1% insulin-transferrin-selenium solution 
and 0.1% NonEssentialAmminoAcids. 
In the first case, we avoided D-galactose to provide the cardiomyocytes with 
metabolite with solely mitochondrial catabolism (L-glutamine and fatty acids). 
The second “essential cardiac medium” final formulation was derived by 
modifying murine neonatal cardiac culture media and contains as well 3 
mitochondrial energy sources (L-gluamine, pyruvate and lipoic acid), but retains 
low 5.5 mM D-glucose concentration. We observed that the use of animal sera 
even at low concentrations (Martewicz et al., 2012 and Annex 2) in primary 
cardiomyocyte maintenance media results in a high resistance to hypoxia, 
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accordingly to our assay (data not shown). Further literature research provided 
us with evidence of the use of serum-free maintenance media in many 
ischemia-reperfusion studies on cardiac in vitro cultures (Addlerley et al., 1999; 
Akao et al., 2001). 
We treated the differentiated human cardiac cultures with the maturation 
media for 4 days and assayed them for glycogen accumulation. Control cells 
maintained in rich “basal medium” displayed a very strong PAS staining (Fig. 
3.13), recapitulating the results previously obtained on dissociated single hCMs.  
Fig. 3.13 Metabolite-driven metabolic switch. Human cardiomyocytes maintained in the basal 
differentiation medium maintain high stores of glycogen after differentiation. After switching 
from basal medium to media containing different carbon sources, hCMs deplete rapidly the 
glycogen stores  
On the other hand, both maturation media drastically reduced the amount of 
glycogen present in the culture, with a better performance shown by the 
“essential cardiac medium”. In cardiac cultures treated with media containing 
only linoleic acid, displayed a strong reduction in overall PAS staining, but 
cardiomyocytes still retained a significant glycogen stores  (Fig. 3.13). In 
comparison cultures maintained as controls in only DMEM w/o D-glucose 
showed instead almost complete glycogen depletion. This result is in line with 
the effect of free fatty acids on glycogenesis and glycogenolysis, as the latter is 
inhibited in presence of high concentrations of fatty acids, while they are still 
preferred as energetic substrate by the cardiomyocytes. It is a worth noticing 
that cardiac cultures maintained in DMEM w/o D-glucose for 4 days still 
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displayed sustained and regular contractile activity, obviously burning out all the 
glycogen stores and perhaps the amino acids present in the DMEM. 
Unfortunately, extended culture with DMEM w/o D-glucose, either in presence 
of absence of fatty acids, could not support the human cardiac culture for longer 
than 7-10 days. Instead, cardiomyocytes cultured in the “essential cardiac 
medium” sustained contractile activity and long-term viability, up to 2 months. 
We decided to proceed with exploratory experiment to assess the hypoxia-
resistance of these cultures inside the microfluidic chip, noticing an increased 
susceptibility to replating, with fewer numbers of cardiomyocytes adhering to 
the glass slides. In order to avoid cell number variability inside the culture, the 
cardiomyocyte replating inside the chip was performed from the same cardiac 
cultures maintained in “basal medium” and switched to the maturation medium 
after 24hours of adhesion, for at least 4 days before further experimental 
procedure. The first attempts to assay these mature cultures for hypoxia-
sensitivity resulted in high death rates of the human cardiomyocytes resulting in 
unreliable quantification for <10% of surviving cells (Fig. 3.14). This result could 
suggest a inferior resistance to hypoxic stress of the metabolically-induced 
cardiomyocytes, and an new optimization of the stimuli duration is required for 
robust data.   
 
Fig. 3.14 Hypoxia-resistance assay on hCMs underwent metabolic switch. hPSC-CMs replated 
inside the microfluidic device and treated for 4 days with “essential cardiac medium” display high 
sensitivity to hypoxic stress, suggesting possible metabolic maturation. 
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Further investigations are ongoing on the transcriptomic and proteomic 
changes induced by short-term and long-term culture in the “essential cardiac 
medium”, in order to characterize more in detail the metabolic and molecular 
phenotype acquired by these hypoxia-sensitive cardiomyocytes.  
 
3.6 Conclusions 
In this chapter we described the metabolic profile of an adult human 
cardiomyocytes, defining this phenotype as highly desirable in the in vitro human 
cardiac models based on hPSC-derived cardiomyocytes. For all the differentiation 
methods described in literature, almost no metabolic maturation is reported and 
all the cardiac differentiation derivatives display an early and immature mainly 
glycolytic metabolism. While most screening methods for maturation are based 
on evaluation of molecular markers expression, we designed here a functional 
approach, to rapidly screen maturation protocols and select those generating 
cardiomyocytes with hypoxia-sensitive phenotype for further characterization. In 
our perspective, hypoxia-sensitivity is the integration of several structural and 
proteomic changes in the developing cardiomyocyte, thus providing a holistic 
read-out on several maturation features at once.  
We propose, as well, a simple method to drive the metabolic phenotype-switch 
in human cardiomyocyte derived from hPSCs, with variation in the composition 
of supplied metabolites, thus providing a “physiological” induction of the process 
without biochemical or genetic modification of the culture.  
Moreover, the developed microfluidic platform has proven to be robust in 
delivering precisely tuned oxygen stimuli and capable of sustaining a cell culture 
for long-term experiments, thus can be used as a valuable tool for in vitro studies 
of ischemia/reperfusion models or long-term effects of different gaseous phase 
compositions in cell cultures.         
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Chapter 4 
 
hiPS Technology for In Vitro Modeling 
of Human Cardiac Diseases 
 
This chapter introduces the concept of in vitro modeling of human cardiac 
diseases with the hiPSC-technology. In particular, two human genetic diseases of 
interest are presented in detail: Duchenne Muscular Dystrophy and 
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Their cardiac 
fallout is described, as well as the currently employed study models for these 
diseases and the limitations associated each individual approach. The use of 
induced pluripotent stem cells derived from patients affected by DMD and 
ARVC/D allows derivation of cardiomyocytes carrying the patient-associated 
mutations. For each disease, evidence of aberrant phenotype displayed in vitro is 
presented. Finally their future perspectives for in vitro studies are discussed.  
 
4.1 Motivations and experimental design 
The work presented in this chapter aims at the derivation of cell models for two 
human genetic diseases with prominent impact on cardiac function. In order to 
set up an in vitro model, the employed cell type must display the necessary 
features to represent the target of the study, and for the human heart there has 
been a shortage for such biological material for a long time.    
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hiPS cells can be derived from somatic cells of any given individual, thus 
carrying their specific genetic background and individual polymorphism or 
mutations. Since the beginning of the hiPSC era, this opportunity carried the 
great potential for both patient-specific self-therapies and patient-specific 
“disease-in-a-dish” (Savla et al., 2014). In vitro modeling of heart diseases is 
particularly difficult due to the scarce availability of human tissues, as cardiac 
biopsies from patients are a very invasive procedure and we lack viable methods 
of maintaining human adult cardiomyocytes in culture (Sallam et al., 2014). Since 
2010, when the first cellular model of the human LQT1 syndrome was published 
on the New England Journal of Medicine (Moretti et al., 2010) a plethora of 
other human cardiac diseases has been tackled, of which a comprehensive 
summary is reported in Table 4.1. The hiPSC generation and differentiation 
protocols are constantly evolving making the derivation of patient-specific 
cardiomyocytes relatively easy, and many of the proposed models have 
successfully proven that it is possible to recreate the in vivo pathological 
phenotype in vitro to some degree (Karakikes et al., 2014). 
Table 4.1 Summary of published hiPS-based models for cardiac diseases. 
Hereditary cardiac diseases 
 
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia  
 Mutation Reference 
Heterozygous PKP2 (A324fs335X) Caspi et al. 2013 
Homozygous PKP2 c.2484C>T 
Heterozygous PKP2 c.2013DelC 
Kim et al., 2013 
Heterozygous PKP2 (L614P) Ma et al., 2013 
Brugada Syndrome 
 Mutation Reference 
Homozygous PKP2 c.2484C>T Cerrone et al., 2014 
Catecholaminergic Polymorphic Ventricular Tachycardia 
 Mutation Reference 
Heterozygous RYR2 (F2483I) Zhang et al., 2013 
Heterozygous RYR2 (F2483I) Di Pasquale et al., 2013 
Homozygous CSQ2 (D307H) Novak et al., 2012 
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Heterozygous RYR2 (P2328S) Kajula et al., 2012 
Heterozygous RYR2 (M4109R) Itzhaki et al., 2012 
Heterozygous RYR2 (S406L) Jung  et al., 2012 
Heterozygous RYR2 (F2483I) Fatima et al., 2011 
Dilated CardioMyopathy 
 Mutation Reference 
Heterozygous DES (A285V) Tse et al., 2013 
Heterozygous LMNA (R225X) Siu et al., 2012 
Heterozygous TNNT2 (R173W) 
Sun et al., 2012 
Liang et al., 2013 
Heterozygous LMNA (S17fs40X) Ho et al., 2011 
Hypertrophic CardioMyopathy 
 Mutation Reference 
Heterozygous MYH7 (R442G) Han et al., 2014 
Heterozygous MYH7 (R663H) 
Lan et al., 2013  
Liang et al., 2013 
Friedreich’s Ataxia 
 Mutation Reference 
Heterozygous FXN mutation (GAA 
expanded repeats intron1) 
Hick et al., 2013 
LEOPARD syndrome 
 Mutation Reference 
Heterozygous PTPN11 (T468M) Carvajal-Vergara et al., 2010 
Long QT syndrome 
 Mutation Reference 
Heterozygous KCNH2 (A561T)     Matsa et al.,  2013 
Heterozygous SCN5A (V1763M) Ma et al., 2013 
Heterozygous KCNH2 (N996I) Bellin et al., 2013 
Heterozygous KCNQ1 (G269S) Liang et al., 2013 
Heterozygous SCN5A (F1473C) & 
KCNH2 (K897T) 
Terrenoire et al., 2012 
Heterozygous KCNQ1 (P631fs/33) Egashira et al., 2012 
Heterozygous KCNH2 (R176W) Lahti et al., 2012 
Heterozygous KCNH2 (A614V) Itzhaki et al., 2011 
Heterozygous KCNH2 (A561T) Matsa et al., 2011 
Heterozygous CACNA1C (G406R) Yazawa et al., 2011 
Heterozygous KCNQ1 (R190Q) Moretti et al., 2010 
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Pompe Syndrome 
 Mutation Reference 
Homozygous GAA (ex18Del) 
Heterozygous GAA (c.1441DelT & 
W746X) 
Raval et al., 2014 
Heterozygous GAA (ex18Del & 
c.525DelT)  
Heterozygous GAA (ex18Del & ex2Del) 
Higuchi et al., 2014 
Homozygous GAA (D645E) 
Heterozygous GAA (c.1935C>A & 
c.2040+1G>T) 
Huang et al., 2011 
Fabry Disease 
 Mutation Reference 
Hemizygous GLA (W162X) 
Hemizygous GLA (R220X) 
Itier et al., 2014 
Barth Syndrome 
 Mutation Reference 
Hemizygous TAZ c.517delG  
Hemizygous TAZ c.328T>C 
Wang et al., 2014 
Hypoplastic Left Heart Syndrome 
 Mutation Reference 
not published Jiang et al., 2014 
Duchenne Muscular Dystrophy 
 Mutation Reference 
Hemizygous DMD ex50Del Guan et al., 2014 
Hemizygous DMD ex4-43Del Zatti et al., 2014 
Hemizygous DMD ex48-50Del 
Hemizygous DMD ex47-50Del 
Hemizygous DMD c.3217G>T 
Hemizygous DMD ex45-52Del 
Hemizygous DMD c.10171C>T 
Hemizygous DMD c.4918-4919DelTG 
Hemizygous DMD c.7437G>A 
Dick et al., 2013 
Other acquired cardiac diseases 
Type 2 Diabetic Cardiomyopathy 
 high  glucose, h-endothelin, cortisol  Drawnel et al., 2014 
Viral Myocarditis 
 coxackievirus infection Sharma et al., 2014 
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Further development of new models for novel pathologies means creating not 
only a biological substrate for studies on a specific disease and patient-specific 
therapeutic design, but will provide as well a growing panel of functional 
aberrations giving more and more insight in the molecular mechanisms 
regulating cardiac and cardiomyocyte function. 
 
4.2 Duchenne Muscular Dystrophy 
Muscular dystrophies are a heterogeneous group of disorders characterized by 
progressive wasting and weakness of muscle tissues, with cardiac myopathies 
and dysfunctions often contributing to the severity of the clinical phenotype 
(Verhaert et al., 2011). In particular, Duchenne Muscular Dystrophy (DMD) is a 
severe X-linked disease affecting 1/3500 newborn males, in which genetic 
mutations in the dystrophin gene account for the pathological phenotype 
associated with loss-of-function of the muscle-specific dystrophin isoform 
Dp427m. Dystrophin is the largest gene in the human genome, spanning over 2.4 
Mbp and containing 79 exons with at least 7 different internal promoters driving 
the transcription of 5 classes of different molecular-weight isoforms, each with 
several splice variants (Muntoni et al., 2003) (Fig. 4.1). Given these 
characteristics, the tissue-specific transcriptional regulation of these isoforms is 
uber-complex and even decades its genetic characterization the research on the 
molecular pathological  mechanisms is still a hot topic (Hoffman et al., 1987). 
 
Fig. 4.1 Representation of the organization of the DMD gene and all the different isoforms 
indicate. Most of the dystrophin isoforms have splice-variants, thus increasing the overall 
number of differentially expressed mRNA species (adapted from NCBI Gene database, DMD gene 
card).  
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In muscle cells the mainly expressed isoform is the large 427 kDa molecule 
(Dp427) localizing at the sarcolemma and functioning as connector between the 
actin contraction machinery and the multimeric glycoprotein complex anchoring 
the cell to the extra-cellular matrix (Rafael et al., 1996). The dystrophin function 
is closely related to the physical forces acting on the myocyte membrane during 
contraction against the surrounding tissue, stabilizing it and protecting from 
shear damage (Pasternek et al., 1995). In dystrophin-deficient myocytes the 
sarcolemma is fragile causing membrane ruptures (Menke  and Jockusch, 1995), 
and in concurrence of an increased sensitivity to stretch-activated Ca2+ channels 
(Franco-Obregon and Lansman, 1994), in produces abnormal ion fluxes leading 
to protease activation (Fong  et al., 1990), reactive oxygen species production 
(Prosser et al., 2012) and activation of cell-death programs (Jung  et al., 2008). All 
these effects of dystrophin absence produce widespread muscle damage and 
degeneration, causing the clinical phenotype of muscle weakness and wasting 
leading to the patient’s death in early teens by respiratory failure (Wells and 
Wells, 2002).    
4.2.1 DMD cardiac phenotype 
Even if Duchenne Muscular Dystrophy is mainly associated with skeletal muscle 
dysfunction, the cardiac muscle is deeply affected becoming in some cases the 
predominant manifestation of the genetic disorder (Verhaert et al., 2011). With 
the improvement of the efficacy of palliative treatment and advances in 
respiratory care, the lifespan of the DMD patients has increased and the effects 
of dystrophin absence on the cardiac muscle is becoming a prominent issue, with 
nearly all patients surviving to the third decade of life developing severe 
cardiomyopathies (McNally, 2007) and approximately 20% of the deaths ascribed 
to arrhythmias and conduction system abnormalities (Spurney, 2011). Moreover, 
the lyonization process, in which one of the two female X chromosomes is 
randomly inactivated, can lead to pathological mosaicism in the heart causing 
female carriers to develop dystrophinopathic cardiomyopathy (Nolan  et al., 
2003). Besides the still unclear effects of the dystrophin at cellular level, the 
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DMD phenotype at heart level is characterized by sub-epicardial fibrosis of the 
inferolateral wall (Frankel and Rosser, 1976) that has been postulated to result 
from the mechanical stress imposed on a metabolically and structurally 
abnormal myocardium (Verhaert et al., 2011).  
Clinical data suggest that pharmacological treatment similar to standard heart 
failure therapy prevent or delay the onset of cardiomyopathic remodeling in 
DMD patients, thus proving how cardioprotection can further improve patients 
lifespan and quality of life (Ishikawa et al., 1999; Duboc et al., 2005).           
4.2.2 DMD study models 
Currently the most common study model for DMD is the mdx mouse (Collins 
and Morgan, 2003). It is historically the longest and best characterized animal 
model, despite being far from representative of human physiopathology and 
many attempts to model therapeutic approaches on this animal failed in the 
translation to human patients (Miller  et al., 1997). A part from the classical 
physiological species-related differences, the absence of dystrophin in the mdx 
mice results in a mild pathological phenotype, with low muscle functional 
impairment and fairly normal phenotype throughout most of the animal’s 
lifespan (Muller  et al., 2001). 
A much better DMD model is the Golden retriever muscular dystrophic (GRMD) 
dog, which physiology and dimensions are more closely resembling the human 
one, resulting in the pathological phenotype and the outcomes of therapeutic 
approaches to be highly similar between the two species (Howell  et al., 1997). 
This model shares the same drawbacks of all the other large animal models: 
expensiveness of maintenance, difficulty of genetic manipulation and the moral 
barrier of working with highly sentient and emotive animals (Collins and Morgan, 
2003). 
In vitro modeling of DMD relies mostly on the employment of myogenic  cell 
lines such as C2C12 immortalized murine cell line or primary culture of satellite 
cultures of satellite cells and myoblasts from both animal and human sources 
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(Huard  et al., 2003). The skeletal muscle in vitro modeling is one of the few 
human tissues allowing the possibility of genuine human cultures on-a-dish, with 
several cell banks around the world preserving myoblasts and satellite cells from 
affected patients. For the opposite reason, currently there are no in vitro human 
cardiac models for DMD as human cardiac primary material is hardly available 
and there are no progenitor sources for cardiomyocyte derivation. 
4.2.3 iPS-derived human DMD cardiomyocytes 
To obtain dystrophic hCMs, we differentiated toward the cardiac lineage an 
hiPS clone derived from a DMD patient with deletion of exons 4–43 of the 
muscle isoform Dp427m (DMD hiPS cells). First, DMD-hiPSC were cultured and 
expanded in their undifferentiated state for up to 10 passages. During expansion, 
hiPS cell colonies maintained the classical morphology of pluripotent stem cells 
cultures in colonies and expressed  pluripotency markers such as Oct4, Sox2, c-
Myc, Tra-1-60, and Tra-1-81, as evaluated routinely by immunofluorescence. The 
expanded colonies were then used for embryoid bodies (EBs) generation and 
differentiated towards the cardiac lineage with a protocol adapted from the 
“Keller protocol” (Kattman et. al., 2011) and outlined in Fig. 4.2A. This 16-day 
differentiation procedure resulted in contracting EBs around day 12 of 
differentiation. Data presented in Paragraph 2.4 show that proper cardiac 
differentiation requires cell-substrate interaction to promote functional and 
structural maturation of hiPS cell–derived CMs. For this reason, contracting EBs 
were cultured in suspension up to day 20 and then treated with collagenase and 
replated on 16 kPa hydrogels for additional 4 days. 
After adhesion the DMD-CMs were screened for expression of proteins of the 
functional cardiac machineries: α-actinin and cardiac troponin T for the 
contraction machinery, connexin-43 for the electrical conduction system and 
SERCA2a for the calcium handling machinery (Fig. 4.2B). Spontaneous 
contractions and electrically elicited one were observed and confocal imaging 
showed paired calcium transients with the contractions (Fig 4.2C&D). For further 
experiments two different control cell type were employed: hiPSC derived from a 
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healthy patient (ADHF#1 cell line) and a line of DMD-hiPSC corrected with a 
Human Artificial Chromosome (HAC) carrying the whole genomic sequence of 
the dystrophin gene (DysHAC-hiPSC).  
 
Fig. 4.2 Cardiac differentiation of DMD hiPSC. (A) The differentiation protocol adapted from 
Kattman et al., 2011. (B) Immunofluorescence against cardiac markers. (C) The cardiomyocytes 
display cardiac-like calcium transients visualized by fluo-4 dye loading under a line-scanning 
confocal microscope and (D) the transient kinetic parameters show fast Ca2+ release and re-
uptake rates.  
An HAC is an artificially created exogenous minichromosome having the ability 
to replicate and segregate autonomously in target human cells and to be stably 
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maintained at episomal level, without integration into the host genome. In 
addition, HACs have the capacity to carry large genomic loci with all their 
regulatory elements (Kazuki et al., 2011). An HAC vector carrying, for the first 
time, the whole dystrophin genomic locus including the associated regulatory 
elements (DysHAC) was developed by prof. Mitsuo Oshimura’s group (Hoshiya et 
al., 2009; Kazuki et al., 2010) demonstrating the complete correction of hiPS cells 
derived from a DMD patient. The use of HAC technology might have a great 
impact in therapeutic approaches of gene therapy and delivery of healthy copies 
of the mutated DMD gene in dystrophic patients. Furthermore, the DysHAC-
corrected DMD cells can be a unique tool for in vitro studies as they represent 
the rescue phenotype with the same genetic background of the diseased cells 
use to model DMD. 
We differentiated the DysHAC-hiPSC according to the same differentiation 
protocol summarized in Fig4.2A, following at each step the expression of EGFP, 
used as a molecular marker for the HAC vector. The green fluorescence was 
assessed by standard epifluorescence microscopy and proved the retention of 
the HAC construct throughout all the differentiation process (Fig. 4.3).  
Fig. 4.3 HAC maintenance during differentiation. Epifluorescence imaging for EGFP expression 
shows the retention of the HAC construct through differentiation from  pluripotent state (A) to 
the EB intermadiate phase (B) and in fully differentiated beating cardiomyocytes (C). 
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4.2.4 Dystrophin expression recovery with HAC technology 
DysHAC is the first vector carrying the whole dystrophin genomic locus, 
including all the associated regulatory elements. This potentially allows proper 
activation of the complex mechanism regulating dystrophin expression of tissue-
specific isoforms and exon-skipping and exon-scrambling events, which are finely 
regulated in both development- and tissue-specific manner. 
 
Fig. 4.4 Schematic representation of the human dystrophin gene. (Top) The deletion of the 
patient spans from exon 4 to exon 43. (Bottom) The positions relative to dystrophin exons of the 
primers employed for transcriptomic analyses are reported. The green arrows indicate different 
promoters driving tissue-specific isoforms of dystrophin transcripts. 
We proceeded to assess the expression of the dystrophin transcripts, first of all 
investigating the sequences deleted in the patient’s genome (Fig. 4.4). Exon 
junction-spanning primers were designed to target the deleted gene sequences 
and RT-PCR confirmed the absence of such transcripts in DMD-CMs (Fig. 4.5). As 
controls healthy hiPSC-CMs and heart- and skeletal muscle-tissues were used. 
The analyses showed as well the recovery of transcripts relative to the deleted 
exons in the DysHAC-CMs, highlighting the activation of transcription from the 
ectopic vector (Fig 4.5).       
Further investigation was performed on the transcription of specific isoforms of 
dystrophin. We assessed the presence of transcripts of the full length muscle-
specific Dp427m isoform, the cardiac- and brain-specific Dp260 isoform, the 
brain-specific Dp140 isoform and the ubiquitously expressed short dystrophin 
Dp71. 
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Fig. 4.5 Transcription of mRNA sequences from inside the deleted exons in the DMD-patient. 
Exon-junctions refer to the primer sets depicted in red in Fig. 4.4. 
All of the primer pairs were designed to fall in the unique 3’ UTR regions of all 
the isoforms in order to assess the effective initiation of transcription and we 
used cDNA samples from heart, skeletal muscle, brain, kidney and liver tissues as 
controls. For this reason, we observed even in DMD-CMs the presence of a 
transcript corresponding the Dp427m-specific amplicon (Fig. 4.5A). The promoter 
region of the full-length dystrophin transcript is fully functional, thus the 
transcription begins normally before it stops after the deletion. This is true as 
well for the Dp140 and Dp71 isoforms, both controlled by promoters outside of 
the deletion, thus functioning properly. The presence of Dp140 transcripts, a 
brain-specific isoform, is not surprising as the differentiation protocol employed 
does not yield pure cardiac populations and contaminants from the ectoderm 
layer, while low in percentage, are common. On the other hand, the Dp260 
promoter is in intron 29, right in the middle of the big deletion of the DMD-
patient, and the amplicon is absent in DMD-CMs, but is present in healthy 
cardiomyocytes and is recovered in DysHAc-CMs.       
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Fig. 4.6 Expression of tissue-specific dystrophin isoforms. (A) RT-PCR results for isoform-specific 
amplicons. (B) Real Time PVCR results for transcript levels. 
We then concluded that the HAC construct indeed managed to recover the 
expression of the missing transcripts in DysHAC-CMs, and we addressed the 
question whether it was able to regulate their levels as well. We performed Real 
Time PCR analyses on the samples aiming at the full-length isoform Dp427m, the 
missing Dp260 and the Dp71 as control. We decided to detect the presence of 
the Dp427m isoform with two sets of primers, one in the region preceding the 
deletion (exons 1 to 3) and one inside the deletion (exons 25 to 26). We assessed 
that indeed not only the cDNA sequences from inside the deletion were 
detectable again, but their levels of expression were comparable to those 
detected in healthy cardiomyocytes (Fig. 4.6B). Interestingly, the expression 
levels of the dystrophin isoforms present in DMD-CMs seemed abnormal, but 
never reached statistical significance (n=3). 
In healthy cardiomyocytes, dystrophin is a key structural protein creating a 
bridge across the sarcolemma, which provides a flexible connection between the 
ECM and the contractile machinery. For this important role, dystrophin should be 
correctly folded and localized under the plasma membrane of skeletal and 
cardiac muscle cells. For this reason, we verified the proper restoration of 
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dystrophin expression at protein level and its sub-cellular localization by 
immunofluorescence and confocal microscopy.  Analyses were performed 4 days 
after EB adhesion on substrate. EBs derived from healthy hiPSCs displayed a clear 
dystrophin expression at membrane localization, drawing the boundaries of 
cTnT-positive CMs (Fig. 4.7). Similar dystrophin staining was observed in DysHAC-
hiPSC-derived EBs. On the other hand, as expected, in DMD-EBs, no dystrophin 
staining was observed. 
Fig. 4.7 Dystrophin protein expression. Dystrophin is present at the correct sub-sarcolemmal 
localization in HAC-carrying cardiomyocytes. (A) Immunofluorescence analyses for dystrophin 
and cardiac troponin T in differentiated EBs. (B) and (C) Western Blot analyses for C-term region 
of the dystrophin protein detecting all dystrophin isoforms. 
These results were confirmed by Western Blot analyses, in which full-length 
high molecular weight dystrophin was not observed in DMD-CMs, whereas its 
expression was perfectly restored in DMD-CMs corrected with the DysHAC (Fig. 
4.7B). Although much less abundant, other dystrophin isoforms were also 
detectable in DysHAC-CMs when the employing an antibody recognizing a C-term 
epitope common to all dystrophin isoforms (Fig. 4.7C).  
4.2.5 Conclusions and perspectives 
In this paragraph is presented the set up of the first human model of cardiac 
cells affected by mutations in the dystrophin gene. We show that the 
differentiation into cardiomyocytes of DMD-hiPS cells is possible and the 
molecular pathological phenotype is conserved. In this work, we employ as 
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controls both healthy cells and DMD-corrected ones, providing a unique and 
valuable biological material to study the pathology in vitro. Moreover, we prove 
on a cardiac model, that the HAC technology is able of restoring the dystrophin 
mRNA transcript and proteins. In particular, the expression at correct levels of 
dystrophin isoforms absent in the diseased samples shows that the HAC vector 
can drive the expression of absent transcripts with proper physiological 
regulation of all the regulatory elements present in the genomic sequence. 
In ultimate analysis, we provide an excellent tool for in vitro studies of the DMD 
pathological mechanisms, with the best positive control available. 
 
 4.3 Arrhythmogenic Right Ventricular Cardiomyopathy/ 
Dysplasia 
The Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) is a 
hereditary cardiomyopathy, usually characterized by an autosomal-dominant 
pattern. The pathology presents itself with fibro-fatty infiltrations in the 
myocardium leading to life-threatening arrhythmias and sudden death. Because 
of the largely unknown pathogenesis, the proper designation for the disease has 
been a matter of debate evolving from “dysplasia” at its first comprehensive 
description in 1978 (Frank et al., 1978), to “cardiomyopathy” in 1995 (Angelini et 
al., 1996; Richardson et al., 1996) and subsequently it has been assigned the 
“Arrhythmogenic Ventricular Cardiomyopathy (AVC)” designation in 2011 by HRS 
and EHRA organizations, following the growing evidence of left ventricle 
involvement in many affected individuals (Ackerman et al., 2011). 
The genetic mutations behind ARVC/D pathological phenotype impair the 
function of proteins involved in the formation of intercalated disc structures. The 
incidence rates are generally reported as 1:2000, but regionally the numbers of 
individuals carrying mutations can dramatically increase (up to 1:200 in Italian 
Veneto region) making it a fairly frequent genetic condition (Basso et al., 2009). 
Characterized by a unique among primary cardiomyopathies early concealed 
Cardiac disease models Chapter 4 
 
80 
phase without gross structural abnormalities, ARVC/D is often diagnosed only 
post mortem with autoptic analyses and may be asymptomatic until the first 
ventricular tachycardic and fibrillatory events, which are the leading cause of 
sudden deaths in young adults under 35 years of age (Saguner et al., 2014). In 
affected patients with characterized pathogenic genotypes, mutations in three 
desmosomal proteins alone account for almost 80% of the cases: plakophillin-2 
(PKP2), desmoplakin (DSP) and desmoglein-2 (DSG2) (Herren et al., 2009). This 
evidence, together with the frequent association with cutaneous phenotypes, 
focused the research on ARVC/D pathogenesis on the cell-to-cell junctions 
(Delmar and McKenna, 2010), associating the disease to desmosome or 
desmosome-associated proteins (Table 4.2). 
Table 4.2 OMIM classification of Arrhythmogenic Ventricular Cardiomyopathies.  
TGF - Transforming Growth Factor; RyR - Ryanodine Receptor; TTN - titin; TMEM43 - 
transmembrane protein 43; DSP - desmoplakin; DSC - desmocollin; JUP - junction plakoglobin               
  
 
 
 
 
 
 
 
 
 
 
 
AVC 
subtype 
Chromosomal 
locus 
Inheritance Protein 
ARVC/D 1 14q23-q24 
Autosomal 
dominant 
TGFβ3 
ARVC/D 2 1q42-q43 
Autosomal 
dominant 
RyR2 
ARVC/D 3 14q12-q22 
Autosomal 
dominant 
- 
ARVC/D 4 2q32 
Autosomal 
dominant 
TTN 
ARVC/D 5 3p23 
Autosomal 
dominant 
TMEM43 
ARVC/D 6 14p12-p14 
Autosomal 
dominant 
- 
ARVC/D 7 10q22 
Autosomal 
dominant 
- 
ARVC/D 8 6p24 
Autosomal 
dominant 
DSP 
ARVC/D 9 12p11 
Autosomal 
dominant 
PKP2 
ARVC/D 10 18q12 
Autosomal 
dominant 
DSG2 
ARVC/D 11 18q12.1 
Autosomal 
dominant 
DSC2 
ARVC/D 12 17q21 
Autosomal 
dominant 
JUP 
Naxos 
disease 
17q21 
Autosomal 
recessive 
JUP 
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The precise origin of the fibro-fatty infiltrations characterizing the disease is still 
unclear, while the “defective desmosome” hypothesis is widely supported for 
being the key factor in the generation of arrhythmic events, often present in 
absence of overt structural abnormalities (Bauce et al., 2011). The desmosome 
(Fig. 4.8) is the mechanical junction between two cardiomyocytes, but its 
function has been extended in recent years to a structure tightly coordinated 
with other membrane complexes such as gap junctions and ion channel clusters 
(Gomes  et al., 2012). Evidence of connexon disruption with altered expression 
levels of connexin-43 in absence of functional desmosomes strongly supports 
this hypothesis (Oxford  et al., 2007). Moreover, ion channels such as voltage-
gated sodium channels (NaV1.5) have been reported to display aberrant 
localization and function in presence of mutations to desmosomal components 
(Sato et al., 2009). Overall, this reports provide a molecular basis of the 
aberrations of the intercalated disc structures that represent the interface 
between one cardiomyocyte and the other, forming the “functional syncytium” 
of the myocardial tissue. 
 
Fig. 4.8 The desmosome organization. An electron microscopy micrograph of a desmosome (left) 
and a schematic representation of its molecular components (right) 
The aberrations are exacerbated in later stages of the disease when the fibrotic 
and adipose tissues replace the muscle tissue. For this event, there are 
contrasting hypotheses: i) cardiomyocyte or cardiac progenitor trans-
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differentiation in adipocytes; ii) inflammatory response to damaged myocardium 
(Angelini  et al., 1996); and iii) fibroblast and pre-adipocyte invasion from the 
epicardium following cardiomyocyte apoptosis and the associated 
electromechanical instability (Mallat et al., 1996; Basso  et al., 2006). While in 
vitro observations often disprove the first hypothesis, the latter two could be 
different responses to myocardial damage in which infiltration of lymphocytes 
and fibroblasts are a common feature (Bauce  et al., 2005). It is worth noting, 
however, that epicardium-derived human primary culture from PKP2-mutated 
patients display abnormally enhanced migratory and proliferative features 
(Matthes  et al., 2011), consistent with the directional epi-to-endocardium 
infiltration often observed in clinic. 
4.3.1 ARVC/D study models 
Characterization of the molecular mechanisms underlying ARVC/D pathogenesis 
in human patients is highly limited by constrains inherent to human research, 
especially due to the strictly cardiac- and cardiomyocyte-related nature of the 
disease. As for DMD (Paragraph 4.2.2), the canine model is currently the most 
reliable and representative one, with the purebred boxer dogs displaying 
strikingly similar clinical phenotypes in spontaneous mutations (Basso et al., 
2004). The major drawback of this specific model is the unidentified genetic 
background for the pathology, at the same time well reflecting the human 
condition, in which at least 50% of cases have no characterized genetic 
abnormalities (Corrado et al., 2000; Basso et al., 2004). 
The murine models for the disease rely on knock-out/knock-in animals and 
recapitulate some of the molecular features of the disease, but mostly fail to 
provide the pathological phenotype for ARVC/D heart muscle, with often no 
evidence of effect on cardiac rhythm, sudden death and only minor 
electrophysiological aberrations (Delmar and McKenna, 2010). The complete 
knock-out of the desmosomal genes DSP, PKP2 results in high embryonic lethality 
(Grossman  et al., 2004; Gallicano et al., 1998), in the same way as 
overexpression of some human DSP mutants (Yang et al., 2006). Other models 
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relying on  over-expression systems, in which the mutant allele acts above the 
basal expression of wild-type proteins, must consider the evidence of studies in 
which the observed phenotype was deeply expression level-dependant (Pilichou 
et al., 2009). 
In vitro models rely mostly on animal primary cultures in which RNA silencing or 
standard overexpression techniques are employed to hamper with the cardiac 
molecular machineries. A human cell line of squamous carcinoma SCC9 has been 
used as well, as a model to study desmosome assembly in a human genetical 
background (Yang  et al., 2006). Although bound by the standard limitations of 
cellular models, the experiments carried out in vitro share remarkably consistent 
results with in vivo models providing confidence in their applicability (Delmar and 
McKenna, 2010).      
4.3.2 iPS-derived human ARVC/D cardiomyocytes 
To model the ARVC/D pathology in vitro, we first derived cardiomyocytes from 
hiPS derived from a patient affected by a homozygous mutation in exon 12 of the 
PKP2 gene, causing a cryptic splicing site generating a mutated frame-shift C-
terminus of the protein (Awad et al., 2006). The ARVD-hiPS and a control healthy 
line, αMHC-Puror (αSkin119) were kindly provided by prof. H-S. Vincent Chen, 
from the Sanford-Burnham Medical Research Institute in La Jolla, California. Both 
hiPS cell lines were characterized at the SBMR Institute and maintained a 
characteristic pluripotent morphology during all passages of culture. The 
monolayer cardiac differentiation protocol was successfully applied to both cell 
lines.  
We analyzed the derived cardiomyocytes for abnormal molecular phenotypes 
usually associated with ARVC/D-affected patients. The first target of enquiry was 
the protein mutated in the patient, the desmosomal PKP2. The mutation carried 
by the patient is a C-terminal frame-shift, without any early termination codon, 
thus a protein product is still predicted to be produced. We analyzed the 
ARVC/D-CMs with two antibodies raised against the N-terminal and C-terminal 
portions of the PKP2 protein, expecting the first one to recognize a proteic target 
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as the mutation affects the latter portion of the native protein. The specificity of 
the two antibodies was confirmed by staining in the healthy-hiPS controls, both 
correctly localizing at the junctional membrane portions between two 
cardiomyocytes (Fig. 4.9). 
Fig. 4.9 Molecular characterization of the PKP2-mutated cardiomyocytes. Expression and 
localization of the PKP2 protein in healthy (left) and ARVC/D-affected (right) hiPS-CMs. The two 
used antibodies recognize the same protein, but in different portions of the polypeptide 
sequence. (scale bar = 10 µm)  
As anticipated, the C-terminus antibody did not recognize any target in the 
mutated cardiomyocytes. Surprisingly, the N-terminus targeted antibody did 
positively stain the junctional membrane, providing evidence that a protein 
product of the mutated gene is stable and correctly targeted to the 
cardiomyocyte membrane (Fig. 4.9). Indeed, the N-terminal portion of PKP2 is 
reported to interact with the membrane, anchoring the protein to the 
sarcolemma domain of the desmosome, while the C-terminus is supposed to 
interact with molecular partners such as desmoplakin and connexin-43 (Joshi-
Mukherjee et al., 2008). Working on this hypothesis, we sought for aberrant 
localizations of important functional cardiac proteins, which could interact with 
PKP2 C-terminus. 
A recent report found tight association between the sodium current channel (in 
particular its subunit NaV1.5 encoded by the SCN5A gene) and PKP2 (Cerrone et 
al., 2014). Mutations in SCN5A are associated with cardiac conduction diseases 
such as Brugada syndrome and LQT3, and the abnormal localization of the 
NaV1.5 subunit in PKP2-mutated cardiac cells could generate an arrhythmogenic 
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substrate. Double immunostaining for PKP2 and NaV1.5 showed the close 
association between the two proteins in healthy cardiomyocytes, with vast co-
localization (Fig. 4.10) at the junctional membrane of both proteins. In ARVC/D-
cardiomyocytes, the co-localization was disrupted, despite the membrane 
localization of the mutated PKP2 protein (Fig. 4.9).     
Fig. 4.10 Co-localization of plakophillin-2 and sodium voltage gated channel, subunit alpha. Top 
panel shows the co-localization at the junctional membrane of PKP2 and NaV1.5, with nearly no 
staining of the latter in the cytosolic domains. In the bottom panel, the staining shows 
membrane-exclusion of the NaV1.5 subunit in cells with mutated PKP2 C-terminus. (scale bar = 
10 µm) 
ARVC/D cardiomyocytes display a wide-spread cytosolic staining for NaV1.5, 
indicative of the failed membrane anchoring oh the sodium channel. 
Another desmosome-associated protein often displaying abnormal localization 
and function in ARVC/D samples is plakoglobin (PKG) (Munkholm  et al., 2015). 
This protein, sometimes known as γ-catenin, is normally anchored to membrane 
at cell-to-cell junctions, but in abnormal conditions it is reported to translocate 
to the nucleus and alter the β-catenin transcriptional activity (Garcia-Gras et al.,  
2006), and this has been shown to occur in presence of mutated PKP2 C-
terminus (Kim et al., 2013). Staining for PKG in hiPS-derived cardiomyocytes 
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resulted in normal and exclusive membrane localization in healthy human 
cardiomyocytes, while its anchoring to the membrane domain was altered in 
PKP2-mutated ones (Fig. 4.11).      
Fig. 4.11 Localization of plakoglobin in ARVC/D-derived cardiomyocytes. PKG localizes 
exclusively at the membrane in healthy cardiomyocytes, while displays altered localization in 
PKP2-mutated hCMs. (scale bar = 10 µm)  
Taken together, these evidences provide a good picture of the aberrant 
molecular phenotype of the diseased cardiomyocytes in vitro, and although 
mutated, the ARVC/D cardiomyocytes still retain contractile function and do 
form cell-to-cell junctions. More interestingly, the targeting and localization of 
the mutant PKP2 is still intact and can form junctional structures between two 
cell, but its ability to coordinated partner proteins through the C-terminal 
portion is clearly impaired and provides an excellent model to address the 
function of that specific domain of PKP2 in the assemble of the intercalated disc 
structures. Nevertheless, standard monolayer cultures do not provide the same 
geometrical cues for cell-to-cell junction and structural organization as they 
display high isotropy in the arrangement of the culture. This reflects poorly on 
the ultrastructural organization of the cardiac features, especially as the 
cardiomyocytes maintain sustained contractions, thus generating mechanical 
forces in all directions and not in an organized fashion as in the native 
myocardium (Chan et al., 2013). 
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4.3.3 Intercalated disc reconstruction in vitro 
The heart muscle in vivo is organized in concentric layers of cardiomyocytes that 
form, unlike skeletal muscle, a “functional syncytium”, connecting their 
contractile apparatus to the adjacent cardiomyocytes and maintaining a tight ion 
continuity within communicating cells, but retain a separate and defined single-
cell identity. This follows an aligned pattern in which adjacent cells form a 
continuous array of synchronously contracting cells.    
The structure that functions as 
interface between one 
cardiomyocyte and the next is 
the intercalated disc (Fig. 4.12). 
These cardiac-specific structures 
enable mechanical and 
electrical coupling and account 
for the synchronous work of the 
aligned cardiac cells (Wang et 
al., 2012). The intercalated disc 
is composed mainly by the types 
of junctions: gap junctions, 
adherens junctions and desmosomes, each accounting for one type un functional 
communication between two cells, such as ion handling of mechanical force 
transmission (Perriard et al., 2003). The cardiac cell organization in this system is 
highly polarized and results in the elongation of the cell in an anisotropic 
manner, providing and receiving electric and mechanical stimuli in directional 
manner.  
In order to recreate such polarized organization inside the in vitro cultures, we 
employed techniques of cell patterning based on the generation of adhesion-
exclusion areas on the culture substrates. The correct chemical modification of a 
glass surface, with covalent bonding of cell-repellant polymers with a precise 
geometry, allows the cells to attach only on the unmodified areas. The 
Fig. 4.12 In vivo cardiac muscle organization. The 
myocardium is organized as a functional syncytium of 
polarized cardiomyocytes connected through 
intercalated disc structures with one another (inset) 
(Dr. S. Girod, Anton Becker, Wikipedia) 
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topological definition of the surface modification was achieved by 
photoactivation of the polymer (linear acrylamide) synthesis, and photomasks 
with the desired geometries were used to cover from the activating light the cell-
adherent areas. We designed photomasks with linear patterns of varying width, 
and analyzed the cell culture organization in every condition (Fig. 4.13).        
Fig. 4.13 Patterned human cardiac cultures. Geometrical patterning of cell cultures can be 
achieved by selective adhesion of the cell to the culture substrate. Microfabrication techniques 
allow precise control over the cell adhesion surface. Here are shown patterned cultures of human 
contracting cardiomyocytes in line-patterned of varying width. (scale bar = 100 µm) 
On wide patterns, such as 300 µm, h cardiomyocytes still retained an isotropic 
organization at the single cell level, although it is clear how precisely this 
technique can induce cell adhesion to the culture substrate. Decreasing the 
width of the lines, we scaled down to a 50 µm wide pattern and a low density 
seeding condition, in which we could observe aligned cardiomyocytes with a 
single cell-to-cell interaction (Fig. 4.13). Cardiomyocytes culture on these 
microengineered substrates displayed sustained spontaneous contractile activity, 
but the direction of contraction was anisotropic and all the cells contracted along 
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the cell long-axis, parallel to the patterned lines (Fig. 4.14). Moreover, the visible 
sarcomeric structures displayed a perpendicular to the lines organization, with 
an alignment homogeneity rarely seen in standard monolayer cultures. 
 
Fig. 4.14 Anisotropic contraction in patterned human cardiomyocytes. hCMs cultured on the 
linear patterns displayed contractions directed along the axis of the pattern. The sarcomeric 
organization of the contracting cells was clearly aligned along the same direction, in an organized 
fashion rarely observed in isotropic standard monolayers. 
We assayed the patterned cultures with immunofluorescence against proteins 
of the intercalated disc structure, in particular the components of the 
desmosomal mechanical junctions. As expected, standard monolayers show un-
polarized cells and cell-to-cell connections without defined orientation (Fig. 
4.15A). 
Plakophillin-2 staining was always absent or concentrated in a perinuclear 
region in single cells, not connected with other cardiomyocytes , as they localizes 
preferentially on the in junctional membrane domains (Fig. 4.15B). Aligned 
cardiomyocytes, on the other hand, formed linear structures with strong and 
polarized staining in the junctional portions of the sarcolemma, indicating big 
specificity in localization (Fig. 4.15C). Other desmosome-associated proteins 
screened, such as plakoglobin, displayed as well  polarized staining with targeting 
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on the cell-to-cell junctions (Fig. 4.15D). Interestingly, in many cases PKG staining 
in a striated organization was observed, with a pace of 1.5-2 µm very similar to 
the sarcomere pace in these cultures (Fig 4.14), thus providing evidence of 
ultrastructural maturation of the geometrically confined cardiomyocytes.   
Fig. 4.15 Cardiomyocyte polarization in patterned culture substrates. (A) Immunofluorescence 
for desmosomal protein PKP2 in standard not patterned human cardiac cultures show not 
polarized cell-to-cell junctions. (B) Cell-to-cell interaction is required in order to form 
desmosomes. (C) Aligned cardiomyocyte on linear pattern form cell-to-cell junctions in a 
polarized fashion. (D) Plakoglobin localizes at the cardiac membrane in a patterned culture and 
striations corresponding to co-localization with the contractile machinery can be observed along 
the direction of the linear pattern (inset). (scale bar = 50 µm) 
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4.3.4 Conclusions and perspectives 
In this paragraph, we presented the derivation of cardiomyocytes carrying a 
mutation of an ARVC/D patient. This cardiomyocytes display abnormal molecular 
features, often seen in the heart muscle in vivo in such pathological conditions 
and are suitable for modeling the disease in vitro. Moreover, the specific type of 
mutation (a C-terminal frame-shift in the PKP2 gene, producing a stable 
polypeptide) provides an excellent human cardiac cell substrate to study the 
interaction of palkophillin-2 with its molecular partners at the intercalated disc 
structure.  
The modeling of a disease affecting the structural organization of a functional 
cell domain is not easy, as it requires the recreating in vitro of such structure. The 
intercalated disc has been sometimes regarded as an “organelle” as multiple 
highly organized macro-complexes contribute to its structural complexity and 
define its very specific function (Delmar and McKenna, 2010). Regeneration in 
vitro of such structure requires improvement of the standard culture, integrating 
microengineered substrates to provide topological confinement and drive a 
polarized organization of the cardiomyocyte network. We provided here proof of 
the viability of such approach, obtaining human cardiac cultures with aligned 
contracting cells that display a highly polarized phenotype and show a correct 
directional localization of the desmosomal proteins.  
We envision that the integration of the cellular model set up from the patient-
specific hiPS cells with our engineered substrates could provide a good starting 
point for modeling both the desmosome-associated disease and the desmosome 
organization itself.     
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4.4 Conclusions 
In this chapter, we showed how human induced pluripotent stem cells can be 
used for derivation of a cell type not commonly available for in vitro studies, as is 
the cardiomyocyte. The hiPS technology and the availability of cell samples from 
patients affected by genetic diseases can provide big insights in both physiology 
and pathophysiology of the cardiac cells. 
In our particular case, we derived bona fide cardiomyocytes from patients 
affected by severe forms of Duchenne Muscular Dystrophy and Arrhythmogenic 
Right Ventricular Cardiomyopathy/Dysplasia, and showed how they recapitulate 
in vitro at least the molecular pathological phenotype of the patient. 
For DMD, we set up the first human cardiac in vitro model for the disease, 
finally published in close timing with two other reports of hiPS-based DMD 
models (see Table 4.1). The advantage of our experimental set up is the 
availability of a unique and valuable control represented by the patients genetic 
correction with an episomic human artificial chromosome carrying the whole 
dystrophin genomic sequence, thus providing the cell with a fully physiological 
control over the levels, timing and isoform-specific expression of dystrophin.  
For ARVC/D we derived cardiomyocyte from a patient carrying a homozygous 
mutation with very appealing characteristics both for the ARVC/D disease 
modeling and for molecular and structural studies. We provide as well an 
engineered method of culturing the cardiomyocytes that provides an unmatched 
possibility in regenerating in vitro a cardiac-specific structural and functional 
features rarely reported in literature. 
For the cardiac derivatives of both hiPS cell lines is possible to apply the 
maturation protocols described in Chapter 2 and Chapter 3 to drive their 
maturation towards more adult-like phenotypes and generating a good in vitro 
model to study pathogenesis and pathological cardiac phenotypes of DMD and 
ARVC/D.  
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Chapter 5 
 
Conclusions and Future Perspectives  
 
In this thesis we showed how the phenotype displayed in vitro by human 
cardiomyocytes derived by differentiation of pluripotent stem cells can be 
modified and driven towards later developmental stages than the fetal one. 
Promoting the maturation of hPSC-CMs is a desirable process for the generation 
of a robust and representative model of human cardiac physiology and 
physiopathology. The applications of such cellular models span across all the field 
of in vitro studies, from disease modeling to compound screening and drug 
testing, down to basic understanding of the cardiomyocyte biology. 
For most reported applications, the main reference nowadays are animal 
models and in vivo studies (De Ponti  et al., 2002). These approaches, despite 
being valuable sources of knowledge and still an unavoidable step in 
understanding cardiac physiology and pathophysiology on the background of a 
whole complex organism, are characterized by big economic and scientific 
shortcomings (Zaragoza  et al., 2011). From an economic point of view, the 
maintenance and experimentation on animals, especially those more 
representative of human anatomy and physiology, are a great burden and could 
be reduced by preceding “cheaper” models. Currently, this bottleneck is 
represented by animal cardiac primary cultures, that offer the advantage of a 
fully developed and bona fide cardiac cell (Chlopcíková et al., 2001), but are very 
limited considering the lack of consistency between preparations, the required 
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labor intensity and the insufficient cost-effective amount for proper high-
throughput screenings (Carlson  et al., 2013). 
In this scenario, the availability of a virtually infinite source of human cardiac 
cells provides a groundbreaking alternative to the animal models and will 
revolutionize the field of cardiac tissue modeling (Acimovic et al., 2014). The 
species-identity with human patients and the cardiac nature of hPSC-CMs will 
provide better insight in human cardiac function in physiological, pathological 
and pharmacologically-altered conditions, and will become a cost effective safety 
screening tool for therapeutic approaches (Dick  et al., 2010). In order to do so, 
though, hPSC-CMs must gain the status of bona fide cardiomyocytes and 
understanding the mechanisms of in vitro cardiac development and maturation 
is of paramount importance to consciously generate robust human 
cardiomyocytes, along with developing technologies for assaying their functional 
performance. 
In this thesis we showed, how the normally employed extension-of-time-in-
culture approach for hPSC-CMs maturation, which is ill-advised for routine 
manufacture (Prowse  et al., 2014), can be circumvented by enhancing cell-
substrate interaction and activating proper mechano-signaling. We prove that 
human cardiomyocytes cultured in adhesion improve their ultrastructural 
organization and functional performance and that the physical properties of the 
culture substrate constitute the driving force in such process. The molecular 
mechanotransduction plays a pivotal role in this structural and functional 
maturation, as its inhibition abrogates the substrate positive effect. 
From the metabolic perspective, we approached the issue of the fetal-like 
metabolism displayed by hPSC-CMs designing a functional assay that allows fast 
screening for the effects of maturation protocols. We proposed as the 
experimental read-out the resistance of the cardiomyocytes to prolonged 
hypoxic stimuli, and evaluated their survival rate upon ischemic-like stresses. The 
severity of an ischemic-stress experienced by the cardiomyocyte deeply depends 
on the preferred energetic substrate, genetic expression patterns and 
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mitochondrial performance (Chouchani  et al., 2014), thus hypoxia-sensitivity 
synthesizes in one cellular response a plethora of upstream features 
characterizing a mature metabolic profile. We prove as well that a metabolite-
driven maturation protocol of our design, analogous to those present in the 
literature, is a viable and easy approach to promote a more adult-like cardiac 
phenotype in vitro. 
Finally, taking advantage of the induced pluripotent stem cell-technology, we 
set up the basis for human in vitro cardiac models for two genetic diseases, 
generating cultures of patient-specific cardiomyocytes. We show how the 
generated cardiomyocytes from patients affected by Duchenne’s muscular 
dystrophy (DMD) and arrhythmogenic right ventricular cardiomyopathy/ 
dysplasia (ARVC/D) recapitulate the aberrant molecular phenotype of the disease 
in vitro, thus providing a good source material for further studies of the 
pathologies in the human genetic and physiological background offered by hPSC-
CMs.        
Modeling a disease in vitro requires in first instance the availability of a 
biological source material faithfully reproducing the in vivo counterpart. With the 
advent of the induced pluripotent stem cell-technology, the playground for 
disease modeling has been broadened from few spontaneously occurring animal 
conditions (for example the mdx mouse or the boxer cardiomyopathy (Fong  et 
al., 1990; Basso  et al., 2004)) or laboriously generated transgenic animals to the 
whole panel of human genetic backgrounds. Since, 2007 countless genetic 
pathologic conditions have been addressed with hiPSC generation and in vitro 
models have been set up through differentiation of those pluripotent stem cells 
towards the specific lineage of interest. In this thesis, we provide proof of such 
approach with derivation of the first in vitro cardiac model of DMD-affected 
hiPSC and we generated cardiomyocytes from an already established ARVC/D-
affected hiPS line (Kim et al., 2013). With the constantly developing 
reprogramming and differentiation technologies, the panel of available cell lines 
with different genetic backgrounds will keep increasing rapidly in the next years. 
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The issue of the maturation degree and target-cell resemblance has been 
widely discussed in this thesis and the strive for better and more adult-like hPSC-
derivatives will result in improved culture methods and understanding of basic 
developmental processes in human cells.  
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Appendix A 
 
Cell Culture and Substrate Engineering 
 
This appendix section reports the origin and culture methods of the cell cultures 
employed in this thesis. Not standard culture substrates, such as hydrogels and 
patterned surfaces, are presented in detail and the fabrication process is 
described.  
 
A.1 Pluripotent stem cell cultures 
For detailed compositions of the cited media and solutions please refer to the 
“Annex” section, at the “Materials and Methods” section of the attached papers. 
The designation and origin of the human pluripotent stem cells lines employed 
for the work described in this thesis are listed in the Table A.1. 
The lines HES2, ADHF#1, DMD-hiPS and DysHAC-hiPS were maintained and 
expanded in mitomycin-C inactivated MEF-feeder conditions and passaged 
enzimatically before reaching full confluence by 60 seconds incubation at 37°C 
with either trypsin 0.25%-EDTA solution (HES2, see Annex 1) or CTK solution 
(ADHF#1, DMD-hiPS and DysHAC-hiPS, see Annex 4). The cultures were checked 
daily under a stereomicroscope and spontaneously differentiated areas were 
removed by mechanical picking. The media were changed daily with fresh ones. 
The lines H9, mRNA-Clone1, αSkin119 and JK#11 were maintained and 
expanded in feeder-free conditions and passaged by mechanical dissociation (see 
Annex 4). 
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Table A.1 List of human pluripotent stem cell lines employed in this work. 
Line Type Origin Vector Mutation Reference 
HES2 hES 
WiCell cell 
bank 
-- healthy 
 
 
H9 hES 
WiCell cell 
bank 
-- healthy 
 
 
ADHF#1 hiPS 
Oshimura’s 
Lab 
Lentiviral 
infection 
healthy 
Kazuki et al., 
2010 
DMD-hiPS hiPS 
Oshimura’s 
Lab 
Lentiviral 
infection 
DMD gene, 
exon 4-43 
deletion 
Kazuki et al., 
2010 
DysHAC-hiPS hiPS 
Oshimura’s 
Lab 
Lentiviral 
infection 
and HAC 
insertion 
DMD gene, 
exon 4-43 
deletion 
Kazuki et al., 
2010 
mRNA-Clone1 hiPS 
Elvassore’s 
Lab 
mmRNA 
transfecti
on 
healthy 
 
 
αSkin119 hiPS Chen’s Lab 
Lentiviral 
infection 
healthy, 
αMHC-
Puror 
Kim et al., 
2013 
JK#11 hiPS Chen’s Lab 
Lentiviral 
infection 
PKP2 gene, 
c.2484C.T 
Kim et al., 
2013 
 
A.2 Cardiac differentiation of hPSC 
The cardiomyocytes described in this thesis were derived from pluripotent stem 
cells applying two different cardiac differentiation protocols based on the work 
of prof. Gordon Keller and colleagues (“Keller protocol”) (Kattman et al., 2010) 
and prof. Sean Palecek and colleagues (“Palecek protocol”) (Lian et al., 2012). 
All human cardiomyocytes described in Paragraph 2.4 and Paragraph 4.1 were 
derived with the “Keller protocol” (Fig. A.1), based on differentiation in embryoid 
bodies (EBs) maintained in suspension. 
For EB formation, the cells were passaged at high density on culture plates 
coated with 5 mg/ml Growth Factors Reduced Matrigel for 48 hours in hPSC 
culture medium. They were then detached and transferred to ultra-low adhesive 
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plates and maintained for 24 hours in StemPRO-34 medium, 2 mM L-glutamine, 
150 µg/ml transferrin, 50 µg/ml ascorbic acid, 0.4 mM monothioglycerol, 50 
units and 50 mg/ml penicillin and streptomycin, and supplemented with 10 
ng/ml rhBMP4. From day 1 today 4, EBs were cultured in basal medium with 10 
ng/ml rhBMP4, 5 ng/ml hbFGF, and 6 ng/ml hActivin A. From day 4 to day 8, the 
EB culture medium consisted of basal medium and 10 ng/ml hVEDF165 and 150 
ng/ml hDKK-1. Finally, from day 8 to day 14, the EB culture medium consisted of 
basal medium supplemented with 10 ng/ml hVEDF165, 150 ng/ml hDKK-1 and 5 
ng/ml hbFGF. Cultures were maintained in a 5% CO2, 5% O2, and 90% N2 
environment for the first 16 days and then transferred to a 5% CO2 air 
environment and maintained in basal medium supplemented with 10 ng/ml 
hVEDF165 and 5 ng/ml hbFGF before further experimental procedures. 
Fig. A.1 Schematic time course representation of the "Keller" cardiac differentiation protocol 
(adapted from Yang et al., 2008) 
All cardiomyocytes described in Paragraph 3.4, Paragraph 3.5, Paragraph 4.2 
were derived with the “Palecek protocol” (Fig. A.2), based on a chemically-
defined and small molecule-based monolayer differentiation. 
 
Fig. A.2 Schematic time course representation of the "Palecek" cardiac differentiation protocol 
(adapted from Lian et al., 2012) 
Before differentiation, the hPSCs were passaged in fresh culture plates coated 
with 50 µg/ml Growth Factors Reduced Matrigel and maintained in mTeSR1 
medium until confluence was reached. At that point, the medium was switched 
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to RPMI + 1x B27 supplement without insulin (basal medium) with CHIR99021 
inhibitor for 24 hours (concentrations of the inhibitor were optimized for each 
cell line and are reported in Table A.2). After 48 hours in basal medium, Wnt 
secretion was suppressed for 48 hours by medium change to basal medium with 
10 µM IWP-4. From day 7 the cultures were maintained in RPMI + 1x B27 
complete medium before further experimental procedures. 
Table A.2 Concentrations of CHIR99021 for optimal GSK3-β inhibition in the first 24 hours of 
cardiac differentiation. 
hPS cell line 
Optimal 
[CHIR99021] 
HES2 12 µM 
H9 6 µM 
mRNA-Clone1 8 µM 
αSkin119 10 µM 
JK#11 12 µM 
 
A.3 Human cardiac media 
For the maintenance of human cardiomyocytes differentiated from hPSCs, were 
used the media cited in Paragraph A.2. These two media are supplemented with 
proprietary synthetic nutrients in the form of StemPro-34 SFM Nutrient 
Supplement (Lifetechnologies cat#10641-025) and B27 Nutrient Supplement 
(Lifetechnologies cat#17504-044), which complete formulation is not disclosed. 
For the experiments on metabolite-driven metabolic maturation the following 
two media were prepared and the energetic sources are listed in Table A.3, while 
the complete media formulations are available on-line on the manufacturers 
website.    
Table A.3 Carbon sources in metabolic induction media from Paragraph 3.5. 
Essential cardiac medium Basic fatty acid medium 
D-Glucose 5.5 mM L-Glutamine 4mM 4 mM 
Sodium Pyruvate 1 mM BSA-Linoleic Acid 30 µM 
L-Glutamine 2mM 
 
Lipoic Acid 1 µM 
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Essential cardiac medium: αMEM (Lifetechnologies cat#22561-021) + 0.1% 
NonEssentialAminoAcids (Lifetechnologies cat#11140-035) + 0.1% Insulin-
Trasferrin-Selenite (Lifetechnologies cat#41400-045)   
Basic fatty acid medium: DMEM w/o D-Glucose (Lifetechnologies cat#11966-
025) + 1% BSA-Linoleic Acid (Sigma cat#L9530) + 0.1% Insulin-Trasferrin-Selenite 
(Lifetechnologies cat#41400-045) 
When “No Glucose” control is cited, the basic DMEM w/o D-Glucose was used 
without any other addition.  
 
A.4 Murine cardiac primary cultures 
Neonatal rat cardiomyocytes were obtained from Sprague-Dawley pups 1–3 
days old. The cell isolation process was carried out keeping the tissue samples 
constantly on ice after the heart extraction and during the blood removal and 
mincing processes. The tissue samples were then incubated over-night at 4°C in a 
1 mg/ml trypsin-HBSS solution with gentle rocking (75 rpm). After trypsin wash 
out, the samples were digested at 37°C with 1mg/ml collagenase A in HBSS for 2 
minutes rounds, collecting every single digestion suspension until complete 
tissue digestion. The suspension culture is then plated in MEM medium 
supplemented with 10% FBS for 1 hour to deplete the cell suspension of most of 
the present fibroblasts, recovered and ready for further experimental 
procedures. The cardiac cultures were maintained in MEM medium 
supplemented with 0.1% non-essential amminoacids, 0.1% insulin-transferrin-
selenium and 1% penicillin-streptomycin. The animals were housed and operated 
at the Animal Colonies of either the Venetian Institute of Molecular Institute or 
the Biology Department. All experiments with animals were approved by Padua 
University’s Institutional Animal Care Committee (CEASA). 
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A.5 Hydrogel fabrication 
In order to fabricate compliant culture substrate with different stiffness 
features, the polyacrylamide hydrogel technique was employed. When in 
presence of an initiator (such as ammonium persulphate (APS) or IRGACURE 
2959) a free radical-driven polymerization occurs, and the ratio between the 
monomer and the cross-linker in the solution defines the elastic modulus of the 
final hydrogel. In Table A.4 are summarized the concentrations of both reagents 
in the milliQ water-dissolved prepolymer (Tse and Engler, 2006).   
 
Table A.3 The percentages of monomer (acrylamide) and cross-linker (bis-acrylamide) in 
the solutions for hydrogel of different stiffness. 
Elastic modulus Acrylamide bis-Acrylamide 
4 kPa 5% 0.15% 
16 kPa 10% 0.15% 
40 kPa 8% 0.48% 
160 kPa 12% 0.6% 
 
The physical support for the gels were glass slides with surfaces previously 
chemically modified in order to covalently bond with the gel. The glass slide were 
plasma treated for 2 minutes immediately followed by a 4 minutes incubation 
with a solution of 94% ethanol, 5% acetic acid and 1% 3-(Trimethoxysilyl)propyl 
methacrylate (Fig. A.3). The glass slides were then washed once in ethanol and 
three times in ddH2O and air dried before hydrogel polymerization.  
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Fig. A.3 Schematic representation of the hydrogel chemistry covalently bound to the glass 
surface. 
Hydrogels were polymerized for 20 minutes against a flat glass surface 
pretreated with hexamethyldisilazane (HMDS), through chemical initiation with 
1% APS and 0.1% N,N,N',N'-Tetramethylethylenediamine (TEMED), in a solution 
volume calculated to yield an hydrogel height of 100 µm. 
Polyacrilamide hydrogels are naturally cell repellent. In order to perform cell 
cultures, after air drying and UV sterilization, the hydrogels were coated for 1 
hour at 37°C with a solution containing 100 µg/ml laminin and 50 µg/ml 
fibronectin and then air dried again before cell seeding. This coating protocol 
allows cultures up to 5 days without cell detachment from the substrate (see 
Annex 1).  
A.6 Production of patterned surfaces 
Patterned cultures of desired geometry were obtained by defining cell-adhesive 
and cell-repellant areas on the culture substrate.  
For glass surfaces, patterns were achieved by selective photo-polymerization of 
linear acrylamide (8% acrylamide solution in milliQ water in presence of 0.1M 
HEPES) on glass slides pretreated as described in Paragraph A.5. Photo-
polymerization was carried out by exposure to 365 nm UV light (delivered by 
optic fiber onto the sample) for a total energy amount of 900 mJ (Fig. A.4).            
The photo-initiator used was IRGACURE 2959, dissolved in methanol at a 
concentration of 350 mg/ml and diluted in the prepolymer 1:10. The desired 
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geometries (i.e. linear patterns 50-300 
µm wide) were printed on polyacetate 
transparent sheets with commercially 
available printers and the photo-mask 
was placed at close distance to the 
sample in order to prevent 
polymerization in the desired areas. 
Linear acrylamide polymers are cell-
repellant even after protein coating 
(either laminin/fibronectin coating or 
50 µg/ml Growth Factors Reduced 
Matrigel). 
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Appendix B 
 
Microfabrication techniques 
 
This appendix reports the microfabrication techniques employed for the 
construction of the microfluidic devices. Moreover, the quantification of oxygen 
concentration is described in detail. All the material details and procedure are 
reported as well in Annex 2 and Annex 3. 
 
B.1 Litography 
The microfluidic device was fabricated by photo-lithographic technique, 
followed by softlithografy replica molding (Gómez-Sjöberg  et al., 2007). The 
hypoxia microfluidic chip was designed as a multilayer platform, so 2 different 
silica-photoresist casts had to be made: one for the three-channel culture 
chamber layer and one for the climatic chamber. The procedure is described in 
detail below, but briefly: a hardened photoresist cast was made on 4” silica 
wafers, with the desired geometry and height, and was reused every time to 
produce PolyDiMethylSiloxane (PDMS) soft replicas (Fig. B.1). PDMS is a silicon 
biomaterial, made of a monomer and a cross-linker in liquid state that react 
upon heating forming a transparent, non-toxic, highly gas-permeable solid 
polymer. Thus, a solution of liquid monomer/cross-linker can be poured on the 
silica cast, baked and easily detached maintaining the impressed form of the 
cast.      
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Fig. B.1 Schematic representation of the photo-lithography and replica molding techniques. 
(adapted from Mazutis  et al., 2013) 
For the silica cast production 4” silica wafers are cleaned rinsing consecutively 
with Acetone, Methanol and distilled water and baked at 110 °C for 10 minutes 
to completely dry the surface. The wafer is then treated with 
hexamethyldisilazane (HDMS) vapor for 10 min at room temperature and spin-
coated with a thin layer of SU-8 2100 negative photoresist. The height set for the 
layer was 150 µm for the culture chambers and 200 µm for the climatic chamber. 
After two steps of soft-bake of 5 minutes at 65°C and 30 minutes at 90°C, the 
photoresist is exposed to 260-350 mJ/cm2 UV irradiation (365 nm)  through a 
high resolution transparency mask containing the design of the channels. The 
mask is printed at high resolution from an AutoCAD design file. The photoresist 
reticulation is then completed with a post exposure bake for 5 minutes at 65°C 
and 15 minutes and 95°C and developed with SU-8 developer for 2-5 minutes, 
rinsing with isopropanol. 
Microfabrication techniques  Appendix B 
 
113 
The silica wafer can be then used as the cast for soft-replica molding with 
PDMS. Prior to pouring an uncured PDMS solution of 10:1 monomer:cross-linker, 
the wafer is treated with HDMS vapor for 20 minutes to allow easy detachment 
of the baked PDMS. The PDMS liquid prepolymer is mixed and de-gassed by 
vacuum and baked for 2 hours at 70°C in order to achieve full PDMS reticulation. 
For the culture chamber layer, a thin membrane of PDMS was needed in order to 
achieve the best performance in oxygen exchange, thus the PDMS pre-polymer 
was spin-coated at 300 rpm for 90 second. This procedure results in a 200 µm 
layer of PDMS on top of the 150 µm thick photoresist cast. 
Once baked, the two PDMS layers are covalently bound by 2 minutes plasma 
treatment and brief 100°C baking, and the same procedure was performed to 
bond the PDMS layers to the glass slide, after and punching  inlet/outlet holes 
with a 21G stainless steel needle. The chip was then washed with isopropanol 
and sterilized by 90% ethanol flow and superficial UV irradiation.  
For cell adhesion, the cultures channels were coated with porcine gelatin 0.1% 
(neonatal rat cardiomyocytes) or 50 µg/ml Growth Factors Reduced Matrigel 
(human cardiomyocytes) for 2 hours at 37°C. 
 
B.2 Oxygen measures 
Oxygen measure inside the microfluidic chip described in Paragraph 3.4 were 
performed by use of an oxygen sensitive dye tris(4,7-diphenyl-1,10-
phenanthroline)-ruthenium(II)-dichloride. The fluorescence of this ruthenium 
complex is dynamically quenched by molecular oxygen, thus in presence of 
atmospheric pO2 it is weakly fluorescent when exited at 488 nm. The 
fluorescence intensity increases upon oxygen stripping, in a linear manner in the 
0-20% pO2 range, thus allowing precise quantification of pO2 inside the chamber 
in real time by fluorescence imaging.    
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 A 100 µM solution of Ru(ddp) in a 30% ethanol in PBS 1X solution was and 
fluorescence was detected by an inverted fluorescence microscope 
LeicaDMI6000B equipped with a mercury short-arc reflector lamp,  excited at BP 
450-490 nm and acquired at LP 590.  The degree of quenching can be correlated 
to the oxygen partial pressure of the sample by Stern-Volmer equation: 
                                  
                                                                         
where I0 is the fluorescence intensity at zero partial pressure of oxygen, I is the 
fluorescence intensity at a particular  and k is the Stern-Volmer constant 
which depends on the chemical composition of the sensor and on the 
temperature. The calibration of the system was performed by flowing gas 
mixture of known composition in the climatic chamber at a 100 ml/min flow rate 
and acquiring the fluorescence after 10 minutes of equilibration. There was no 
liquid flow inside the culture chamber during equilibration nor acquisition. The 
gas mixtures were generated by three EL-FLOW Mass FlowMeters/Controllers 
(Bronkhorst High-Tech) setting a volumetric ratio between N2, air and CO2.  
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Appendix C 
 
Cell Culture Analyses Protocols 
 
This appendix section reports the protocols for the molecular biology, immuno-
detection and histochemical assays performed on cell cultures. Detailed 
materials and procedure are also included in Annex 1, Annex 2, Annex 3 and 
Annex 4.  
 
C.1 Immunofluorescence 
All the immunofluorescence were performed according to standard five step 
protocol comprising fixation, permeabilization, blocking and two steps of 
antibody incubation (primary protein-specific antibody and secondary 
fluorescent-labeled antibody). The details of each step for each antibody used 
are summarized in Table C.1.  
The secondary antibodies employed were all from Life Technologies. Species-
specific antibodies were visualized by either Alexa Fluor-488 or Alexa Fluor-594 
fluorophores. Pictures were taken by epifluorescence Leica DMI6000B 
microscope equipped with a mercury short-arc reflector lamp or Leica SP5 
confocal microscope equipped with Ar laser. 
Supplementary information for the anybodies listed can be retrieved in the 
Annex Section. 
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C.2 Western blot 
For western blot analyses the antibodies listed in Table C.1 were used with 
slightly different antibody dilutions: dystrophin (1:500, 12 hrs at 4°C), cTnT 
(1:500 1 hour at RT). The reference protein was GAPDH (1:2,000; 60 minutes at 
room temperature; Abcam; #ab8245). The set up of the electropheresi was as 
follows: a NuPAGE 3–8% Tris-acetate polyacrylamide gel was resolved and 
transferred for 6 hours at 4°C on a polyvinylidene difluoride membrane with a 
BioRad cassette. Detection was performed with Novex ECL Kit after incubating 
for 45 minutes with rabbit anti-mouse secondary horseradish peroxidase–
conjugated antibody. For more detailed protocols, see Annex 4. 
 
C.3 Polymerase chain reaction 
Molecular biology analyses for mRNA transcript expression was carried out by 
standard RT-PCR or real-time PCR. RNA was isolated by means of Trizol 
extraction coupled with RNeasy Mini Kit by Qiagen. Briefly, the cells were lysated 
with Trizol and the first step of purification was carried out with chloroform 
addition and 12000x g centrifugation. The aqueous supernatant containing RNA 
was then recovered, diluted 1:1 with ethanol 70% and loaded in the RNeasy spin 
column and the purification was carried out according to manufacturer’s 
instructions. After RNA quantification, retrotrascription was performed by High-
Capacity cDNA Reverse Transcription Kit according to manufacturer’s 
instructions. For standard PCR on cDNA samples, Platinum Taq Polymerase kit 
was used, while for real-time PCR the Sybr Green detection approach was 
followed. In Table C.2 are reported the primer sequences for all the amplified 
genes. For more detailed protocols, see Annex 1 and Annex 4. 
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Table C.2 Summary of the PCR primer sequences employed for this thesis. 
 Forward primer Reverse primer 
Dp427m TCGCTGCCTTGATATACACTTTTCA GGTTCTCAATATGCTGCTTCCCA 
Dp260 AGGAAGCTGCGAAATCTGTCTTAC GGCAGACTGGATGCTCTGTTCA 
Dp140 ACCGAAAGAGGTTTTTGCACACC ACTGGCATCTGTTTTTGAGGATTGC 
Dp71 CATGAGGGAACAGCTCAAAGGC CAGTCTTCGGAGTTTCATGGCA 
Dys ex 5-6 CCTGACAGGGCAAAAACTGCCAA TGTGTGGCTGACTGCTGGCAA 
Dys ex 11-12 CGGAGCCCATTTCCTTCACAGCATT CCGGCCCTGATGGGCTGTCA 
Dys ex 24-25 GACTCGGGGAATTGCAGGCTT GGGCAGGCCATTCCTCCTTCA 
Dys ex 27-28 GGCCTGCCCTTGGGGATTCA TCTGGCATAGACCTGTTGGCACA 
Dys ex 37-38 TGCCTGGGGAAAGGCTACTCA GCAGTGGTCACCGCGGTTTG 
NKX2.5 GCGATTATGCAGCGTGCAATGAGT AACATAAATACGGGTGGGTGCGTG 
cTnT TTCACCAAAGATCTGCTCCTCGCT TTATTACTGGTGTGGAGTGGGTGTGG 
MLC2v ACATCATCACCCACGGAGAAGAGA ATTGGAACATGGCCTCTGGATGGA 
GAPDH 
RT-PCR 
CCCCTTCATTGACCTCAACTACA TTGCTGATGATCTTGAGGCTGT 
GAPDH  
real-time PCR 
GAAGGTGAAGGTCGGAGTCAAC CAGAGTTAAAAGCAGCCCTGGT 
TRDN CGTGATGCTATGGAGGAAACC GATGCTACCTCCAAACCCCT 
CSQ2 AAATCACAGCACCCACTACCA GCAAATCAACCTCCCATCCCA 
PLN CCCCAGCTAAACACCCGTAA TCCTGTCTGCATGGGATGAC 
 
C.4 Calcium imaging 
Calcium imaging was performed by mean of confocal line scanning of 
cardiomyocytes loaded with Ca2+ binding dye, fluo-4. Fluo-4 has been loaded as 
an acetyl-methyl ester in order to increase its liposolubility and facilitating the 
crossing of cell membrane, in presence of Pluronic F-127 as mild detergent. In all 
the incubation media sulphinpyrazone was included as anionic transporter 
inhibitor to reduce dye active extrusion from the cell. As cell membrane counter-
stain di-8-ANEPPS was used, in order to distinguish separate cells. Line scanning 
mode of the Leica SP5 laser confocal microscope was use, for faster acquisition. 
For more detailed protocols, see Annex 1 and Annex 2. 
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When cell were imaged simultaneously for calcium dynamics and membrane 
potential, Fura Red dye was employed instead. Fura Red 10 µM solution in 
DMEM with 2 µM Pluronic F-127 and 20 µM sulfinpyrazone was incubated for 60 
minutes at 37°C, followed by 20 minute of incubation at 37°C without the dye 
prior to acquisition. During the 20 minutes resting period, the voltage sensitive 
dye could be added the medium at a 0,2 µM concentration. 
 
C.5 Live and Dead assay 
Live & Dead assay was carried according to manufacturer’s instructions (Life 
Technologies). Briefly, cells were incubated for 60 minutes with DMEM 
containing 4 µM di-ethidium bromide, 2 µM calcein-AM and nuclei were counter 
stained with 1 µg/ml HOECHST 33342. Fluorescent pictures of the culture were 
taken immediately with epifluorescence Leica DMI6000B microscope equipped 
with a mercury short-arc reflector lamp.      
 
C.6 PAS staining assay 
PAS staining was performed according to manufacturer’s instructions (Sigma-
Aldrich). Briefly, cell were washed twice with 1x DPBS and fixed for 10 minutes 
with 4% PFA. Washed twice again with double distilled water (ddH2O) and 
incubated for 5 minutes with periodic acid. Washed 5 times with ddH2O and 
incubated for 15 minutes with Schiff’s base. Before imaging in bright field and 
contrast microscopy the cells were washed again 5 times in ddH2O for at least 10 
minutes. 
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Abstract 
Application of human pluripotent stem cell-derived cardiomyocytes in in vitro 
studies is limited by their early and immature phenotype. In vivo, the cardiac 
muscle develops in a dynamic environment, in which continuous active and 
passive mechanical signals drive cardiomyocyte organization and maturation. 
Integrating soluble signals in differentiation media with physical cues is 
necessary to activate proper genetic programs is required to avoid 
cardiomyocyte in vitro maturation arrest at an immature stage. 
Here, we report how proper cardiac differentiation requires cell-substrate 
interactions to promote maturation of hPSC-CM. In both hES-CMs and hiPS-CMs, 
calcium release and reuptake rates increased after adhesion culture regardless of 
EB age and both sarcoplasmic reticulum and contractile machinery structural 
organization improved significantly. This maturation depends heavily on the 
culture substrate stiffness as these physical cues activate mechanotransduction 
pathways needed for cardiac development. In particular, inhibition of 
RhoA/ROCK pathway prevented further maturation highlighting its importance in 
cardiomyocyte in vitro maturation. 
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Human cardiomyocytes derived through in vitro differentiation of pluripotent 
stem cells (hPSC-CM) represent a promising opportunity in regenerative 
medicine, pharmacological research and, in general, for in vitro cardiological 
studies. Although the ability of hPSC-CMs to engraft and improve cardiac 
function in compromised animal hearts (Chong et al., 2014; Shiba et al., 2012; 
Laflamme et al., 2007; Caspi et al., 2007) proves their viability in future therapeutical 
approaches in treating cardiac dysfunctions, a more straightforward application 
is in drug testing (Braam et al., 2010) and in the early pharmacological 
development pipeline (Kraushaar et al., 2012). However, the early and immature 
phenotype displayed by hPSC-CMs is the biggest concern for these applications 
(Davis et al., 2011), focusing research on understanding the molecular mechanisms 
underlying cardiac maturation and developing methods to improve their 
maturation in vitro. 
The cardiac differentiation protocols mimic processes of embryonic 
development driving the pluripotent cells towards early mesoderm specification 
and cardiac progenitors by chronologically defined delivery of cytokines, growth 
factors and small molecules up to the generation of early stage cardiomyocytes 
(Lian et al., 2012; Kattman et al., 2011; Laflamme et al., 2007; Mummery et al., 2003). 
The maturation arrest at this immature phenotype is represented by expression 
of embryonic isoforms of cardiac markers, poor calcium handling ability and 
immature electrical activity.  
Empirical observations showed that extended time in culture (which span 
several months) can result in limited enhancement of cardiac maturation (Lundy 
et al., 2013; Kamakura et al., 2013; Sartiani et al., 2007; Otsuji et al., 2010). Moreover, 
adult-like phenotypes can be achieved for single cardiac functional features such 
as calcium handling or action potential by ectopic overexpression of proteic 
components of mature cardiomyocytes (Lieu et al., 2013; Liu et al., 2009).  
Evidence of maturation of hPSC-CMs after myocardial engraftment (van Laake et 
al., 2007) highlights the importance of considering of a proper 
electrical/mechanical environment in designing the best conditions for cardiac 
maturation (Dick et al., 2010). In this perspective, the integration of electrical 
stimulation (Hirt et al., 2014; Chan et al., 2013) and mechanical strains (Mihic  et 
al., 2014) in cardiac differentiation protocols proved successful in improving 
structural features and functional performance of hPSC-CMs in vitro.  
Although integrating the signals from the soluble environment with mechanical 
cues better mimics the development of the highly dynamic cardiac tissue (Jacot et 
al., 2010), the mechanisms underlying this phenomena remain poorly understood.  
Here, we report that hPSC-CMs at single cell level require cell-substrate 
interaction to promote structural organization and improve functional 
performance. We show in human cardiomyocytes that this process relies upon 
the activation by the cell-substrate interaction of a specific mechanotransduction 
pathway, which inhibition by either change in substrate stiffness or biochemical 
inhibition negates the structural cardiomyocyte reorganization and prevents the 
improvement in functional performance. 
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Results 
hPSC-CM functional and structural features are enhanced by adhesion culture. 
We cultured and differentiated two pluripotent stem cell lines: a hES line (HES2) 
and a hiPS line. Both cell lines displayed undifferentiated morphology and were 
tested for common pluripotency markers (Fig. S1A) before undergoing embryoid 
bodies (EBs) formation and cardiac differentiation protocol. First contracting EBs 
were observed after 10-12 days for the HES2 line and after 7-9 days for the hiPS 
cells. Single cell cardiomyocytes obtained by disaggregation of EBs and cultured 
in monolayer expressed most of the cardiac specific markers, such as cardiac 
troponin T (cTnT), α-actinin (α-act), SERCA2a, Nkx2.5 and Cnx43 (Fig. S1B). 
Spontaneous and electrically stimulated contractions were accompanied by 
cardiac-like calcium transients (Fig. 1A). Intriguingly, calcium transients 
shortened upon extension of the monolayer culture time. Calcium transients 
lasting several seconds were recorded in the majority of cardiomyocytes early 
after single cell replating in adhesion culture. 
Long calcium transients were almost completely replaced by shorter transients 
after 1 week for both hES- and hiPS-derived cardiomyocytes populations, as 
showed by representative calcium traces (Fig. 1A) and calcium decay rate (n=21 
and n=34, respectively) (Fig. S2A and Fig. 1B). An improvement in calcium release 
rate was observed as well, as showed by the reduction of the time-to-peak (TTP) 
parameter (Fig. S2B and Fig. S3A).  
The observed calcium handling enhancement was associated with a marked 
improvement in organization of cardiac cell structural features. As opposed to 
cells clustered in embryoid bodies displaying round morphologies with high 
nucleus-to-cytoplasm ratio and disorganized myofibrils (Fig. 1C), cardiomyocytes 
cultured in monolayer showed increasing alignment and regular striation 
patterns of the cTnT staining (Fig. 1C). In terms of myofibril alignment (Fig. S2C), 
both cell lines displayed a marked increase in sarcomere organization after 1 
week in monolayer culture, reaching nearly parallel sarcomeres (Fig. 1D, hES 
n=37, hiPS n=44). Western Blot analysis confirmed an increased expression of 
cardiac troponin T isoforms on cardiomyocytes cultured in adhesion (Fig. S3B).  
We asked if there was a correlation between the observed calcium transient 
shortening and the expression of the major component of calcium handling 
machinery responsible for Ca2+ re-uptake, SERCA2a. Immunofluorescence 
staining showed a great increase in SERCA2a accumulation after 1 week in 
adhesion, with a striking reorganization of the SR, from a mainly perinuclear 
localization early after single cell replating, towards a whole-cell spreading after 
1 week (Fig 1E). We evaluated the spreading area of the SERCA2a staining (Fig. 
S2D) finding a significant increase in spreading area in hES-CMs (n=24) and in 
hiPS-CMs (n=31) (Fig. 1F). We assessed the expression of other SR calcium 
handling proteins (Triadin, Calsequestrin and Phospholamban) by means of RT-
PCR (Fig. S3C) and we found that cardiac calsequestrin was upregulated after 1 
week of adhesion culture. Interestingly, the expression of cardiac  calsequestrin 
was rarely reported in hPSC-CM literature (Robertson et al., 2013) and its 
transgenic over-expression have been proved to boost cardiomyocytes 
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maturation in terms of calcium handling (Liu et al., 2009). Consistently, as 
expected from a maturing sarcoplasmic reticulum, the cardiomyocyte 
performance in calcium handling improved after stimulation with 10 mM 
caffeine shown by representative traces at the two time points considered (Fig. 
S3D) and dynamics quantification (Fig S3E); in particular calcium release and re-
uptake rates significantly increased and a two-fold increase in peak relative 
amplitude between 2 days and 1 week in adhesion was observed. To assess 
whether the functional and structural maturation is a result of the time in 
adhesion or EBs age, we performed experiments with different preparations 
(n=3) of both hES- and hiPS-derived EBs cultures. EBs were maintained in 
suspension culture up to 3 months after differentiation protocol start. At 
different time points (early after cardiac differentiation protocol end, 1 month 
and 2-3 months later) single cell cultures of hPSC-CM in monolayer were set up 
and whole-cell calcium imaging was performed. All experiments recapitulated 
the functional maturation of the calcium handling machinery in terms of Ca2+ 
reuptake rate (Fig. 1G&H) for both hES-CMs (n=56) and hiPS-CM (n=74) as 
function of time in adhesion, from 2 days after EB disaggregation to 1 week of 
culture. A very strong correlation (Two-Ways ANOVA, p<.001) was found 
between the calcium transient shortening and the time in adhesion culture, but 
not EB age, thus highlighting the importance of mechanical cues from the 
adhesion substrate over the age of EB for the improvement in functional 
performance at later stages in human pluripotent stem cells cardiac 
differentiation.  
Substrate stiffness affects cardiomyocyte maturation. To assess whether the 
hPSC-CM were affected in their adhesion culture-driven functional maturation by 
the stiffness of the culture substrate, we cultured hPSC-CM after EB 
disaggregation on polyacrilammide hydrogels of 4 kPa (soft substrate), 16 kPa 
(muscle-like substrate) and glass (stiff substrate). Human cardiomyocytes 
cultured on 16kPa hydrogels (n=21) and on glass (n=17) recapitulated the 
previous results, with a positive correlation between time in adhesion culture 
and functional maturation, with calcium transients decreasing in duration (Fig. 
S4A), and increasing rate in Ca2+ re-uptake (Fig 2A). In these substrate conditions, 
the structural features of the cardiac cells improved in time showing SR 
maturation and SERCA2a spreading (Fig. 2B) and proper sarcomere alignment 
(n=37 and 44, respectively) (Fig. 2C). Instead, cardiomyocytes cultured on the 4 
kPa hydrogel (n=23), did not show functional maturation in terms of calcium 
handling (Fig 2A and Fig. S4A); consistently, the SERCA2a distribution maintained 
a perinuclear localization (n=35) (Fig 2D and Fig. S4B). The influence of the soft 
substrate on cardiomyocyte structural organization was evident as well in the 
lack of myofibril alignment and poor organization of sarcomeric structures (Fig 
S4C&D).  
We then asked if influence of the substrate’s stiffness on the hCMs was merely 
on the structural organization of cellular features or was driving transcriptional 
changes as well. We set up cultures in hydrogels of increasing elastic moduli 
(from 4 kPa to 160 kPa) and performed real-time PCR analyses on mRNA levels of 
cardiac transcripts. Experiments carried on mixed population of cardiomyocytes 
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and non-cardiac contaminants in the EBs resulted in high variability between the 
samples (data not shown) and urged for a more sensitive approach. In order to 
generate robust data on the sole cardiac population, we employed for this 
experiments an α-MHC-Puror hiPSC line enabling us to effectively select for the 
cardiomyocytes in differentiated EBs for further testing. The cardiomyocytes 
obtained from this new hiPS line recapitulated the structural/functional 
maturation observed previously (Supplementary Data). 
RhoA/ROCK pathway is involved in cardiomyocyte maturation. In order to 
assess the involvement of known mechano-sensing signaling pathways in 
cardiomyocyte maturation, we cultured hPSC-CM on a stiff substrate with or 
without 2 µM of ROCK inhibitor Y-27632 for 1 week and analyzed the cultures for 
calcium handling and structural features (n=21). As expected, the untreated 
cardiomyocytes recapitulated the results reported above (Ca2+ shortening and 
increased calcium reuptake rate) (Fig. 3A). This effect of adhesion culture was 
completely abrogated by the ROCK inhibition, with Ca2+ transients lasting several 
seconds even after 1 week and calcium reuptake rates fairly unchanged within 
this time in culture (Fig. 3A). In line with the previous results, in which calcium 
handling maturation was accompanied by pronounced SR maturation and 
SERCA2a enhanced expression and relocalization, we expected to observe the 
great inhibition in SERCA2a expression and spreading after Y-27632 treatment. 
As a matter of fact, SERCA2a staining revealed how the treated hPSC-CM 
maintains a perinuclear localization of the pump after 1 week (Fig. 3B) without 
significant spreading throughout the cell volume observed in the controls (n=18) 
(Fig. 3C). Interestingly, human cardiomyocytes did not display significant 
alterations in myofibrils alignment, which organized in a parallel fashion with the 
long cell axis, although presenting less degree of sarcomere organization, 
resulting in thinner myofibril compared to the controls (n=16) (Fig. 2B&D). 
 
Discussion 
In this work we demonstrate in human cardiomyocytes that cell-substrate 
interaction is required to activate mechanosensing pathway RhoA/ROCK in order 
to promote their maturation after differentiation from embryonic and induced 
pluripotent stem cells. Our data show that monolayer culture, with the 
associated morphological changes and enhanced mechano-associated signaling 
from the stiff culture substrate, allows structural and functional maturation of 
hPSC-CM. Progressive maturation of human cardiomyocytes has been reported 
by other groups upon extension of culture time and replating procedures of 
embryoid bodies, both in regard to electrophysiological properties (Sartiani et al., 
2007; Otsuji et al., 2010) and to the ultrastructural organization of the contractile 
apparatus (Kamakura et al., 2013). In these works, the maturation process spanned 
several months and the cells were maintained in beating clumps, thus the 
contribution of cell-substrate interactions and mechanotransduction associated 
processes could not be clearly investigated. Here, we show how monolayer 
culture promotes functional and structural maturation in a substrate-driven 
fashion within days, disregarding of the EB age up to three months (Fig. 1G&H).  
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Cardiomyocyte shape has been recently proven to be one of the regulators of 
functionally fundamental myocyte features, such as assembly and organization 
of sarcomeric structure and proper calcium handling ability (Yin et al., 2004; Kuo et 
al., 2012). Shape-dependent modulation of cardiac ion channel properties, 
including Ca2+ channels, has been reported as well (Walsh and Parks, 2002). In EB 
structures as well as in replated beating clumps, cells are clustered maintaining 
round-shaped morphology and disorganized myofibrils, while the cell-substrate 
interaction and the morphological changes in adhesion promote cardiac 
maturation and structural organization (Fig. 1C). This maturation is described by 
means of improved calcium handling (Fig. 1A&B and Fig. S3A) and of myofibrils 
alignment to the long axis of the cell, as for skeletal and cardiac muscle (Young 
and Engler, 2011) (Fig. 1D). Round cell morphology is characterized by high 
nucleus-to-cytoplasm ratio, thus preventing ultrastructural organization of cell 
compartments like the sarcoplasmic reticulum and further development of 
proper calcium handling. In adult human cardiomyocytes, the majority of Ca2+ 
after contraction is recovered by the SERCA2a pumps back into the SR (Bers, 
2002), whereas it has been often reported how for hPSC-CMs the diastolic 
calcium is extruded through Na+/Ca2+ exchanger (Fu et al., 2010). Upon extension 
of adhesion culture, we observed marked maturation of the calcium transient 
profile with an increased calcium re-uptake rate, temporally correlating to 
SERCA2a increased protein expression and re-localization (Fig. 1E&F). 
In the latter years, the influence of substrate mechanical cues on cell behavior 
has come to light as an important player in development and differentiation 
(Discher et al., 2009). Employment of compliant substrates, like polyacrilammide 
hydrogels, with defined elastic moduli, showed how the cell physical 
environment is an important determinant of stem cell state and commitment, 
capable even for itself of directing differentiation towards one cell type or 
another, according to the physiological stiffness of the cell type of destination 
(Engler et al., 2006). For cardiac and muscle cells the optimum elastic modulus 
was routinely estimated in a range between 10 and 16 kPa (Engler et al., 2004). 
In our study, we demonstrate how culturing hPSC-CMs on soft substrates not 
providing the necessary mechanical cues to cardiac maturation resulted in the 
abrogation of any type of functional or structural maturation (Fig 2A&B&C). 
Hydrogels with cardiac-like elastic modulus and stiff substrates, instead, allowed 
maturation in terms of calcium transient shortening, sarcomeric and SR 
organization. These findings highlight the importance in cardiac functional 
maturation of cues deriving from the mechanical environment and, particularly, 
the signaling activated by substrate stiffness.  
Cell sensing of the surrounding physical environment has its molecular basis in a 
limited number of signaling pathways (Jaalouk and Lammerding, 2009) which 
translate mechanical signals into kinases cascades, thus transducing mechanical 
cues through pathways such as the RhoA-ROCK pathway (Wei et al., 2001). The 
importance of this specific mechanotransduction pathway in cardiac 
development is demonstrated by severe alterations in heart morphogenesis of 
mouse and chick embryos (Zhao and Rivkees, 2003; Sakata et al., 2007). Neonatal rat 
cardiomyocytes subjected to prolonged exposure to RhoA/ROCK inhibiting 
      Annex 1 
 
128 
molecules show a reduction in contraction force (Jacot et al., 2008). Moreover, 
mechanotransduction pathways are sensitive to cell shape, as proven by our 
recent discovery of mechanotransduction pathways crosstalk through the ROCK 
kinase (Dupont et al., 2011). This evidence identifies Rho-associated kinase as a 
suitable target of inhibition in order to convincingly desensitize hPSC-CM from 
the mechanical environmental cues, thus providing insight in the molecular basis 
of their substrate-driven maturation. 
Culturing human cardiomyocytes in presence of 2 µM Y-27632 ROCK inhibitor 
maintained normal cell morphology, but prevented cardiac maturation in terms 
of calcium handling, with no improvement in calcium dynamics features (Fig. 3A), 
and SERCA2a relocalization, which maintained a perinuclear localization even 
after 1 week of culture (Fig. 3B&C). For this latter finding, our data are in 
accordance with reports of RhoA/ROCK pathway involvement in the 
transcriptional regulation of SERCA2a gene, identifying its promoter as 
downstream target of yet unknown effectors (Vlasblom et al., 2010). 
Cardiac differentiation protocols from pluripotent stem cells are, to date, the 
best promise for a human cardiac in vitro model feasible for drug screening and 
disease modeling. The immature phenotype of the derived cardiomyocytes is still 
a matter of concern for these applications and understanding the processes 
behind in vitro maturation is of great interest. Here, we showed how cell 
interaction with the adhesion substrate promotes cardiac maturation, identifying 
a mechanotransduction pathway involved in this process, allowing generation of 
cardiomyocytes more feasible for in vitro modeling of human mature cardiac 
cells within few days after EB disaggregation.  
 
Methods 
Pluripotent stem cell culture and differentiation. The hES cell line HES2 was 
obtained from WiCell and cultured according to suppliers guidelines. The hiPS 
line was kindly provided by prof. Mitsuo Oshimura laboratory and maintained in 
culture according to the protocol described by Kazuki and colleagues (Kazuki et 
al., 2010). Human cardiomyocytes were derived according to an EB based 
protocol described previously by Yang and colleagues (Yang et al., 2008). Briefly, 
pluripotent colonies of both cell lines were cultured for 24-48 hours Growth 
Factors Reduced Matrigel coated dishes (BD) and then detached and transferred 
to ultra-low adhesive dishes (Corning) for the EB formation in basal medium 
(StemPRO-34 (Invitrogen), 2 mM L-glutamine (Invitrogen), 150 µg/ml hTrasferrin 
(Roche), 50 µg/ml ascorbic acid (Sigma), 0.4 mM monothioglycerol (Sigma), 
50 U/ml  penicillin (Invitrogen), 50 µg/ml streptomycin (Invitrogen) 
supplemented with 10ng/ml hBMP4 (R&D). From day 1 to day 4 EB were 
cultured in basal medium with 10 ng/ml hBMP4, 5 ng/ml hbFGF (R&D) and 6 
ng/ml hActivin A (R&D). At day 4 to day 8, the medium consisted of basal 
medium and 10 ng/ml hVEGF (R&D) and 150 ng/ml hDKK (R&D). Finally, from day 
8 to day 14, the culture medium consisted of basal medium and 10 ng/ml hVEGF 
and 5 ng/mL hbFGF. Cultures were maintained in a 5% CO2, 5% O2, 90% N2 
environment for the first 14 days and then transferred into a 5% CO2 air 
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environment. The obtained EB were maintained in the last medium described 
until further experimental procedures. The α-MHC-Puror hiPS line used for Real-
Time PCR experiments was kindly provided by prof. H-S Vincent Chen and 
maintained in culture on Growth Factors Reduced Matrigel (BD) coated dishes in 
E8 medium (StemCell Technologies). The cardiac differentiation protocol was 
carried out as described above, the cytokines used were purchased from 
Peprotech.  
 Hydrogel preparation. Polyacrilammide hydrogels were prepared as previously 
described by Tse and Engler (Tse and Engler, 2010). In order to tune the hydrogel 
stiffness different ratios of acrilammide/bisacrilammide in milliQ water were 
prepared as follows: hydrogels of 4 kPa 5%/0.15%, 16 kPa hydrogels 10%/0.15%, 
40 kPa hydrogels 8%/0.48% and 160kPa hydrogels 12%/0.6%. The polymerization 
was induced by addition of 10% ammonium persulfate and 0.1% TEMED. All 
reagents were from Sigma. 
Cardiomyocyte adhesion culture. Fully differentiated EBs were disaggregated 
to single cells in order to perform experiments on monolayer adherent cultures. 
HES2-derived EBs were treated with 2 mg/ml Collagenase Type I (Invitrogen) for 
45 minutes at 37°C and with Trypsin-EDTA 0,25% (Invitrogen) for 5 minutes at 
37°C. Trypsin was quenched with 1:1 FBS/IMDM (Invitrogen). Resuspension of 
the loosened EBs ensured the obtainment of a single cell suspension. hiPS-
derived EBs were treated with digestion solution consisting in 2 mg/ml 
Collagenase Type I, 0,5 mg/ml Collagenase Type IV (Invitrogen) and 3 U/ml 
DNase I (Invitrogen) for 25 minutes at 37°C under gentle agitation, with 
subsequent digestion with Trypsin-EDTA 0,25% for 4 minutes quenched with 1:1 
FBS/IMDM. Single cell suspensions were then plated on glass slides incubated for 
1 hour with 20 µg/ml laminin (BD) at a 100-200 cells/mm2 density. For the 
different stiffness experiments, the hydrogels were incubated for 30 minutes 
with 100 µg/ml laminin and 50 µg/ml human fibronectin (Sigma), as well as the 
control glass slides. Cell cultures were kept at 37°C, 5% CO2, in the last EB 
medium. For experiments with ROCK inhibitor, 2 µM of Y-27632 (Sigma) was 
added to the culture medium since day 0 of adhesion culture. 
Calcium measurements. Confocal calcium measurements were performed as 
reported previously (Martewicz et al., 2012). Briefly, cardiomyocytes were 
loaded in serum-free 25mM HEPES D-MEM (Invitrogen) supplemented with 2,5 
µM fluorescent calcium dye Fluo-4 AM (Invitrogen) for 20 minutes at 37°C in the 
presence of 2 µM Pluronic F-127 (Invitrogen) and 20 µM sulfinpyrazone (Sigma), 
then incubated for additional 10 minutes at 37°C without Fluo-4 AM to allow 
complete de-esterification of the dye, and added with 0.2 µM di-8-ANEPPS 
(Invitrogen). Cell dynamics were acquired in recording solution: NaCl 125 mM, 
KCl 5 mM, Na3PO4 1 mM, MgSO4 1 mM, Hepes 20 mM, CaCl2 2 mM, glucose 5.5 
mM, to pH 7.4 with NaOH. Line scans were acquired with a Leica TCS SP5 
confocal microscope equipped with a 63x, 1.4 NA oil immersion objective, with 
488 nm Ar laser line as an excitation source, 400 Hz acquisition frequency. To 
reduce dye photo-bleaching and photo-toxic effects on the analyzed cells, the 
laser power was set at minimum possible. In experiments with caffeine (Sigma), a 
20 µl puff of 10 mM caffeine (in recording solution) was administered in the 
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proximity of the acquired field. All experiments were performed at room 
temperature within 20-30 minutes from the end of loading procedures.  
Immunofluorescence analysis. A standard immunofluorescence protocol was 
used. Primary antibodies for pluripotency markers were Oct3/4 (Santa Cruz), 
Sox2 (Millipore), c-Myc (Santa Cruz), TRA1-81 (Millipore) and TRA1-60 
(Millipore). Primary antibodies against cardiac markers were troponin T 
(NeoMarkers), α-actinin (Sigma), connexin 43 (Chemicon), Nkx2.5 (Santa Cruz), 
SERCA2a (Santa Cruz). Secondary antibodies used were: Alexa-488 goat anti-
mouse (Invitrogen), Cy3 donkey anti-goat (Jackson ImmunoLab). Nuclei were 
counterstained with DAPI (Sigma) and samples were mounted with Elvanol and 
viewed under Leica TCS SP5 confocal microscope. Immunofluorescence on EB 
samples were performed on 20 µm cryosections of OCT (Kaltech) enclosed EBs 
mounted on poly-L-lysine coated glass microscope slides. 
Real-Time PCR analysis. Analysis of mRNA expression was assessed on EBs and 
monoloyer α-MHC-Puror cultures pretreated with 1,5µg/ml of puromycin (Sigma) 
for 24 hours.  Expression levels were analyzed by Power SYBR Green Master mix 
kit (Invitrogen). Data are presented as expression fold change relative to the 16 
kPa sample, normalized for GAPDH expression. Pfaffl method for relative fold 
expression change was applied.  
Data analysis. For evaluation of the calcium re-uptake rate after contraction, 
the half-life of the calcium decay was used. A first order exponential decay curve 
was fitted to the acquired calcium transient, as shown in Fig. S2A, and the value 
of τ was extrapolated. For the calcium release phase, the time to peak value was 
calculated considering time from base-line to minimum of the second derivative 
of the calcium transient, as depicted in Fig S2b. All numerical data were 
manipulated with Origin 8.1 software. Calculation of the orientation correlation 
function (OCF) was performed as previously described by Young and Engler20 and 
as depicted in supplementary figure (Fig. S2C). Briefly, a long cellular axis was 
identified and was calculated the incident angle to the axis of at least 10 major 
cTnT fibers. OCF was calculates as OCF = 0.5(cos(2θ)+1) where θ is the mean 
incident angle of the cardiomyocytes: an OCF equal to 1 mean a perfectly parallel 
aligned myofibril, while an OCF of 0,5 represents an unaligned diagonal myofibril. 
Quantification of SERCA2a spread area were performed as depicted in 
supplementary figure (Fig. S2D). Briefly, immunofluorescence images of single 
cardiomyocytes were thresholded with the IJ_IsoData algorithm and the 
percentage of red areas over cell area (nuclei excluded) was calculated. Cell 
edges were identified with selection tool. All image analysis were performed 
with ImageJ software.  
Statistical analysis. Data are presented as means ± standard error of means 
(SEM). Data pairs were compared by non-directional Student’s t-test, while 
group data by one-way ANOVA followed by Bonferroni’s mean comparison. The 
EB vs. Adhesion culture was evaluated with two-way ANOVA. All data 
manipulation and computation was performed with Origin 8.1 software. 
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Main figures 
 
Fig. 1 hPSC-CM maturation in monolayer culture. (A) Representative calcium traces of hES-CMs 
and hiPS-CMs and different times of adhesion culture. (B) Evaluation of calcium re-uptake rate by 
the half-life of calcium decay. (C)  Cardiac troponin T staining of hES-CMs and hiPS-CMs at 
different time points. Bar= 10 µm. (D) Sarcomeric alignment in terms of orientation correlation 
factor (OCF). (E) SERCA2a staining of hES-CMs and hiPS-CMs at different time points. Bar= 10 µm. 
(F) Evaluation of cell surface coverage of the SERCA2a staining. (G) Evaluation of the calcium re-
uptake rate as function of time in EB culture and adhesion culture for hES-CMs. (H) Evaluation of 
the calcium re-uptake rate as function of time in EB culture and adhesion culture for hiPS-CMs. 
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Fig. 2 Culture substrate stiffness influences cardiomyocyte maturation.  (A) Calcium transient 
shortening in terms of half-life of calcium decay in hCMs on different substrates. (B) SERCA2a 
spreading in hCMs cultured on different substrates. (C) Sarcomeric alignment in hCMs cultured 
on different substrates. (D) Immunostaining for SERCA2a (upper panel) and cardiac troponin T 
(lower panel) on different substrates after 5 days in adhesion culture. Bar=10 µm. 
 
Fig. 3 Mechanotransduction through ROCK kinase is necessary for cardiac in vitro maturation. 
(A) Evaluation of the effect of ROCK inhibitor on the calcium re-uptake rate. (B) Immunostaining 
for SERCA2a (upper panel) and cardiac troponin T (lower panel) in hCMs treated with ROCK 
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inhibitor for 1 week in adhesion culture. Bar=10 µm (C) Evaluation of cell surface coverage of the 
SERCA2a staining. (D) Evaluation of sarcomeric alignment after 1 week of culture in presence of 
ROCK inhibitor Y-27632. 
 
Supplementary experimental procedures. 
RNA isolation and RT-PCR. RNA was isolated from differentiated EBs or 
monolayer cultures with TRIzol Reagent (Invitrogen) followed by purification 
with RNeasy Mini Kit (Qiagen). 1 µg of extracted RNA was retrotranscribed with 
High Capacity cDNA Reverse Transcription Kit (Invitrogen) and used as template 
for standard 30-cycle PCR analysis with Platinum Taq DNA polymerase 
(Invitrogen). Primer sequences (Sigma) were: GAPDH Frw 5’-
CCCCTTCATTGACCTCAACTACA Rev 5'- TTGCTGATGATCTTGAGGCTGT; Triadin Frw 
5’- CGTGATGCTATGGAGGAAACC Rev 5’- GATGCTACCTCCAAACCCCT; 
Calsequestrin Frw 5’- AAATCACAGCACCCACTACCA Rev 5’- 
GCAAATCAACCTCCCATCCCA; Phospholamban Frw 5’- CCCCAGCTAAACACCCGTAA 
Rev 5’- TCCTGTCTGCATGGGATGAC. 
Real-Time PCR. Analysis of mRNA expression was assessed by Power SYBR 
Green Master mix kit (Invitrogen). Data are presented as expression fold change 
relative to the 16 kPa sample, normalized for GAPDH expression. Pfaffl method 
for relative fold expression change was applied.  
Western Blot analysis. Protein samples were recovered from the organic phase 
of the TRIzol Reagent extraction. SDS-PAGE was performed on 4-12% Bis-Tris gels 
(Invitrogen) in MES buffer (Invitrogen). Primary antibodies were: cardiac 
troponin T (NeoMarkers, clone 13-11)1 and GAPDH (Abcam). For chemo-
luminescent detection were used anti-mouse HRP conjugated secondary 
antibody (BioRad) and ECL Kit (Invitrogen). 
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Supplementary figures 
Fig. S1 Molecular markers of pluripotent and differentiated cells. (A) Expression of pluripotency 
markers in hES HES2 cell line and hiPS cell line. (B) Expression of cardiac markers in human 
cardiomyocytes derived from pluripotent stem cells. 
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Fig. S2 Data analysis. (A) First order exponential decay fitting on experimental calcium transient 
(upper picture) and examples of tau value related to calcium traces (lower picture). (B) 
Evaluation of time to peak through analysis of the second derivative of the calcium transient. (C) 
Evaluation of the sarcomere alignment through calculation of the orientation correlation function 
(OCF). (D) Evaluation of the cell surface covered by SERCA2a immunostaining. 
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Fig. S3 Human cardiomyocyte maturation as function of adhesion culture time. (A) Time to peak 
decrease in maturing human cardiomyocytes derived from hES and hiPS cells. (B) Western Blot 
for cTnT and GAPDH in EB and adherent differentiated cells. (C) RT-PCR for components of the SR 
calcium handling machinery. (D) Response to 10 mM caffeine stimulation in hCMs at different 
time point of adhesion culture. (E) Quantitative parameters of the caffeine response in hCMs. 
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Fig. S4 Human cardiomyocytes culture on substrate of different stiffness. (A) Representative 
calcium traces on substrates of increasing stiffness. (B) Immunostaining for SERCA2a in hCMs on 
cultured different substrates. (C)  Immunostaining for cardiac troponin T in hCMs on cultured 
different substrates. (D) Evaluation of SERCA2a spread area and sarcomere alignment in hCMs 
after 5 days of adhesion culture on different substrate stiffness. (E) Real-Time PCR results for 
cardiac genes in hCMs cultured on hydrogels of different stiffness. 
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Abstract 
 
Heart diseases is the leading cause of mortality in western countries. Apart from 
congenital and anatomical alterations, ischemia is the most common agent causing 
myocardial damage. During ischemia, a sudden decrease in oxygen concentration alters 
cardiomyocyte function and compromises cell survival. The calcium handling machinery, 
which regulates the main functional features of a cardiomyocyte, is heavily 
compromised during acute hypoxic events. Alterations in calcium dynamics have been 
linked to both short- and long-term consequences of ischemia, ranging from arrhythmias 
to heart failure.  
In this perspective, we aimed at investigating the calcium dynamics in functional 
cardiomyocytes during the early phase of a hypoxic event. For this purpose, we 
developed a microfluidic system specifically designed for controlling fast oxygen-
concentration dynamics through a gas micro-exchanger allowing in line analysis of 
intracellular calcium concentration by confocal microscopy. Experimental results 
show that exposure of Fluo-4 loaded neonatal rat cardiomyocytes to hypoxic 
conditions induced changes in intracellular Ca2+ transients. Such behavior was 
reversible and was detected for hypoxic levels below 5% of oxygen partial pressure. 
The observed changes in Ca2+ dynamics were mimicked using specific L-type Ca2+ 
channel antagonists, suggesting that alterations in calcium channel function occur at 
low oxygen levels. Reversible alteration in ion channel function, that takes place in 
response to changes in cellular oxygen, might represent an adaptive mechanism of 
cardiopreservation during ischemia. 
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Insight, innovation, integration 
Recreating in vitro a low oxygen environment is fundamental for a better 
understanding of the cellular consequences of hypoxia and to screen novel 
therapeutic strategies targeting common ischemic diseases, e.g. coronary heart 
disease. Here, we present a microfluidic platform specifically developed to 
expose cultured cardiomyocytes to acute hypoxic stimuli, allowing robust and 
high quality live confocal imaging. 
Thanks to this novel technology, we were able to observe rapid and reversible 
changes in the electrically-induced cardiomyocyte calcium transients following 
the acute decrease of oxygen partial pressure in the cell environment. Similar 
changes in calcium dynamics were observed upon pharmacological inhibition of 
L-type Ca2+ channels, suggesting a possible target of hypoxia in cardiac cells. 
 
Introduction 
Cardiovascular diseases are the leading cause of mortality and morbidity in the 
Western countries. Heart diseases due to coronary dysfunction alone were 
responsible for nearly 22% of all deaths in Europe in 2008.1 Cardiac ischemia 
occurs when blood supply to part of the organ is suddenly reduced or completely 
interrupted for a discrete amount of time. Ischemic tissues undergo rapid 
changes in cellular environment such as reduced nutrient supply, accumulation of 
metabolic wastes, drop in oxygen concentration and increase in carbon dioxide 
concentration. In a highly energy demanding tissue, like the myocardium, hypoxic 
conditions that are generated when oxygen demand exceeds oxygen supply are 
reached in very short time.2 
The time scale of the changes in oxygen concentration has a great importance 
for cell physiology, viability and adaptation to stress conditions. In particular, the 
cellular response to hypoxia depends on its onset kinetics and duration: (i) rapid 
acute hypoxia (seconds or minutes) leads to alterations of the preexisting protein 
pool through post-translational modifications and protein interactions; (ii) 
sustained chronic hypoxia (hours or days) results in whole proteome changes 
through activation of different gene expression patterns.3 
In order to recreate in vitro ischemia pathological models, accurate gas 
concentration dynamics are one of the most difficult parameters to control; for 
instance, in hypoxia studies, gas leakage through liquid-air interface or gas 
permeable materials is extremely difficult to detect and may lead to low 
experimental reproducibility. Studies on chronic hypoxia (lasting hours or days) 
can be easily performed by culturing the cells in airtight chambers in which the 
oxygen concentration control is exerted by tuning the gaseous partial pressure 
inside the chamber. In this steady state experiments, the cell response at desired 
time points is commonly independent from the oxygen dynamics at the initial 
experiment set up.4 On the other hand, observing cellular responses to fast 
hypoxic transients, simulating the early phase of acute ischemic events, is 
essential in understanding how cell biology and physiology are affected by 
sudden changes in oxygen concentrations. However, investigating the immediate 
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effects of a rapid drop in oxygen partial pressure requires tight control on the 
cellular environment, a condition hard to achieve with standard culture methods. 
As such, current technological limitations have hindered cellular experiments on 
hypoxia. 
In this perspective, we aimed to develop a novel tool for in vitro investigation of 
the acute cellular response of cultured cardiomyocytes to fast changes in the 
environmental conditions, including components of the culture medium, drugs 
and oxygen concentration. In this work, we used such approach to investigate 
the effect of acute hypoxic events on Ca2+ homeostasis, through in line confocal 
image acquisition.  
Cardiomyocyte function relays upon proper ion handling during contraction 
cycles, involving both ion channels regulating membrane potential and 
intracellular calcium release. Hypoxia has been proven to modify the activity of 
most of the molecular components concerned in these features, resulting in 
unbalanced ion fluxes and generation of arrhythmias.5 Rat ventricular 
cardiomyocytes in low pO2 conditions displayed an increase of the late Na
+ 
current (INa-L) while the fast Na
+ (INa) current appeared reduced.
6,7 Effects on 
potassium channels were also described in guinea-pig cardiomyocytes as a 
decrease in the slow component of the delayed rectifier K+ channel (IKs) current, 
without affection of the rapid component (IKr).
8 Ca2+ handling, essential in both 
action potential generation and contraction triggering, seems to be influenced by 
hypoxia as well. In particular, the activity of the L-type Ca2+ channel is altered 
with a decrease of basal current (ICa-L) and unchanged current–voltage (I-V) 
relationship.9,10 Sensitivity of the channel to β-adrenergic stimulation appears to 
be increased resulting in a pro-arrhythmic substrate during ischemic events.11 
The precise mechanism through which hypoxia modifies the function of the L-
type Ca2+ channel is still unclear. Both direct modifications in the C-terminal 
region of the channel12,13 and indirect modulation of its function through 
mechanisms involving mitochondrial ROS formation14 or protein kinases A and 
C15 have been proposed. 
All these studies clearly show that rapid changes in oxygen concentration affect 
ion handling in cardiac myocytes, but so far no hypoxia-induced effects on 
calcium handling during excitation-contraction coupling were reported, although 
many components of this machinery appear to be altered in ischemia-mimetic 
conditions.16,17 
In this work, we aimed at analyzing calcium dynamics in Fluo-4-loaded 
functional rat cardiomyocytes in response to brief and sudden transients of 
hypoxia. In particular, we focused on the early response to hypoxia induction and 
re-oxygenation, by monitoring electrically stimulated Ca2+ changes.  
For this reason, we designed and developed a device enabling confocal 
microscopy analysis while finely tuning the oxygen concentration in the culture 
medium and maintaining proximal cell environment isolated from atmospheric 
conditions. In addition, the device allows exposure of the cells to fast transient 
changes in the environment without perturbing the data acquisition process. 
Particular care has been placed to avoid, manipulation of the liquid phase that 
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could generate pressure waves in the cell culture chamber and cause loss of focal 
plane leading to artifactual changes in fluorescence signals.  
As mentioned above, conventional humidified chambers or incubators with a 
controlled pO2 in the gas phase show equilibration time of the order of hours,
19 
due to the great volumes involved and the low oxygen diffusion coefficient in the 
culture medium (2.1 × 10-5 cm2 s-1).18 Such characteristic time can only be slightly 
decreased using particular expedients like gas-permeable membrane-based 
dishes20 or by forcing gas exchange through bubbling of gas mixtures in 
chemostats or flasks.  
In this perspective, technology developed at the microscale level can be an 
effective practical solution for obtaining a system able to accurately control 
oxygen partial pressure for two main reasons: 
   (i) at microscale liquid flow regime is typically laminar, allowing to accurately 
control the delivery of nutrients, soluble species and gas in the culture 
medium;21-23  
   (ii) the time scale of diffusive mass transport phenomena are related to the 
characteristic length of the system and scaling down the system highly 
accelerates the gas exchange dynamics. 
For this reason, many microfluidic bioreactors were developed to provide solely 
moderate to long-term control of the cellular environment, including dissolved 
gas concentrations.24-27 Some miniaturized devices include gas-microexchangers 
that generate spatial gradients of oxygen partial pressure by on-chip gas mixing 
and allow to study the influence of the oxygen concentration on the cell 
growth.28-30 
However, only few microfluidic devices for rapid generation of hypoxic 
conditions in cell culture were designed, due to the difficulty in obtaining fast 
oxygen concentration transients from a saturated level to a very low partial 
pressure, without perturbing the cell culture environment and the data 
acquisition system. For instance, Oppergard et al. have developed a 
microfabricated insert that nests into a standard multiwell plate and serves as a 
passive microfluidic gas network with a permeable membrane aimed to 
modulate oxygen delivery to adherent cell with an equilibration time on the 
order of few minutes,31 however no in-line analysis can be made with such 
device. Other groups have developed an ad hoc system to rapidly set the oxygen 
partial pressure in the cell culture and study particular cellular responses under 
hypoxic conditions.32,33 
The complexity of the devices previously described induces to find out a 
structurally simpler microfluidic platform able to perform and control fast oxygen 
concentration dynamics and that could be coupled with any other miniaturized 
bioreactor or culture chamber. Unlike other works, we are aimed to engineer a 
new oxygen micro-exchanger to carry out on line analysis on the cell culture, for 
example using confocal microscopy, during an oxygen shift in the culture 
medium, and acquire particular cellular responses without any perturbation of 
the detection system. 
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Experimental methods 
Experimental set up 
Our investigation on calcium transient requires a fine tuning of oxygen partial 
pressure inside a microfluidic cell culture chamber by a multilayer microfluidic 
gas-exchanger. The device has to ensure a fast and accurate oxygen concentration 
control inside the culture chamber in order to provide a precise and repeatable 
hypoxic stimulus to the cell culture. Hypoxic stimuli on a cardiomyocyte 
population are generated by setting only the oxygen partial pressure in the gas 
phase without perturbing flowing medium. Cellular calcium dynamics were 
analyzed directly on line by a fluorescence confocal microscope. An external 
system for control and data acquisition allowed to precisely set gas phase partial 
pressures and flow rates, while an uniform medium flow rate was maintained 
during all the experiments (Fig.1).  
 
Figure 1. Schematic view of experimental set up. Fast and accurate control of oxygen partial 
pressure inside a microfluidic cell culture chamber is performed by a multilayer microfluidic gas-
exchanger. Hypoxic stimuli on a cardiomyocytes population are generated by setting gas oxygen 
partial pressure and cells’ calcium dynamics are analyzed in line by a confocal microscopy. An 
external system for control and data acquisition ensures fine tuning of gas phase partial pressure 
and flow rate, whereas a stable medium flow rate is maintained during experiments. 
 
Microfluidic gas exchanger fabrication 
Fig. 2A shows a schematic view of the multilayer microfluidic gas exchanger. 
The oxygen exchange process between the gas and liquid compartments takes 
place through a thin, non-porous, permeable membrane. Microfluidic gas 
exchanger consists in a three-layer structure: a fluidic layer containing cell 
culture medium, a gas chamber for gas flow with defined oxygen partial pressure 
and an oxygen permeable membrane. The fluidic layer is formed by a network of 
microfluidic channels in an oxygen non-permeable glass substrate to achieve 
complete gas sealing. The micrometric thickness of the gas permeable 
membrane ensures low oxygen diffusion resistance. The gas domain is a milliliter 
rectangular chamber that allows high gas flow rate and, consequently, almost 
uniform oxygen partial pressure within the gas chamber. 
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Figure 2. Microfluidic gas exchanger. (A) Schematic representation of the three-layered 
microfluidic system; inlet/outlet flow rates and oxygen partial pressure are shown for both gas, 
G, and liquid, L, phase. (B) Top view of the fluidic layer channel network (all dimensional values 
are in µm). (C) Image of glass-etched microfluidic channels network obtained by wet-etching 
technique and observed under inverted optical microscope. (D) Schematic view of the three 
different layer of the gas exchanger. Red and blue arrows show gas and liquid phase inlet and 
outlet inside the platform. (E) Image of the gas-exchanger with inlet/outlet connections for liquid 
and gas phase perfusion. The microfluidic channels are perfused with 1 mM fluorescein solution. 
 
In the fluidic layer, the flow channels network is characterized by a series of gas 
exchanger unit and each unit is formed by 8 parallel microchannels 100 µm wide 
(Fig. 2B). This modular design allows to add series of units, up to obtain the total 
length required for a given exchange efficiency. The imprinting of microchannels 
in the glass slide was achieved by wet-etching technique. A borosilicate glass 
slide 50 × 75 mm was cleaned using MICRO90 Cleaning Solution (Sigma-Aldrich, 
USA), placed in an oven for 1 h at 403 K, cooled at 303 K and silanized with 
hexamethyldisilazane, HDMS, (Sigma-Aldrich, USA) for 3 minutes at 403 K. The 
glass slide was spin-coated with 5 g of SPR220-7.0 positive photoresist 
(Rohm&Haas, Dow, USA), to obtain an homogeneous film with a thickness of 15 
µm and subsequently photolithografically patterned using standard 
procedures.34 The glass slide was immersed in an aqueous 40% fluoridric acid 
solution (HF, Sigma-Aldrich, USA) at 298 K and only exposed areas were etched. 
After patterning, the slide was washed with distilled water, deep into an aqueous 
98% sulfuric acid solution (H2SO4, Sigma-Aldrich, USA) to remove etching-
reaction byproducts and rinsed with distilled water. The protective photoresist 
layer was removed with 1-methyl-2-pyrrolidone (Sigma-Aldrich, USA) and the 
patterned glass slide was cleaned in piranha solution (H2SO4:H2O2, 3:1). Fig. 2C 
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shows an image of the etched microchannels on glass under an inverted 
microscope (Leica, Germany).  
Channels section shape and depth were analyzed with a profilometer (Alpha 
Step IQ surface profiler, KLA Tencor, USA). Rounded cross-section shape was 
observed, while channels depth resulted etching-time dependent; depths of 40, 
70 and 100 µm were obtained with an immersion time in HF solution of 2.5, 5 
and 7.5 min, respectively. 
A thin polydimethylsiloxane, PDMS, permeable membrane with defined and 
homogenous thickness was obtained by spinning the unpolimerized solution on a 
silicon wafer. A premixed 10:1 ratio of PDMS prepolymer and curing agent 
(Sylgard 184 kit, Dow Corning, USA) was spin-coated on a previously silanized 5 in 
Si wafer at 1400 rpm for 1 min to obtain a thickness of 40 ± 5 µm and cured on a 
hotplate at 353 K for 1 h.  
The gas layer consists in a 5 cm3 PDMS chamber in which gas phase flows at 
defined flow rate and pO2. Residence time is only of few seconds to maintain an 
uniform oxygen partial pressure during steady-state experiments. 
PDMS layers were punched with a 22G stainless steel needle (Small Parts Inc, 
USA) to obtain gas and liquid inlet/outlet holes. A 50 × 75 mm glass cover slide, 
gas chamber, PDMS membrane and fluidic layer were assembled and sealed by 
plasma bonding (Plasma Cleaner, Harrick Plasma, USA). All fluidic connections to 
the microfluidic device were made using PTFE microtubing (Cole Parmer, USA). 
Fig. 2D shows a schematic view of the assembled layers. The red arrows indicate 
gas inlet/outlet, whereas blue lines show the liquid track inside the platform.  
Different liquid flow rates through the fluidic microchannels were obtained by a 
syringe pump (Harvard Pump, Harvard Apparatus, USA). A constant gas flow rate 
and oxygen composition were maintained in the gas chamber using air and 
nitrogen mass flow meters (Bronkhorst, The Netherlands), controlled through 
software FlowDDE32.  
Oxygen measurement 
A 100 µM solution of tris(4,7-diphenyl-1,10-phenanthroline)-ruthenium(II)-
dichloride, Ru(ddp), (Sigma-Aldrich, USA) in a 30% ethanol in PBS 1X (Invitrogen, 
USA) solution was used to measure oxygen partial pressure inside the 
microfluidic channels. Fluorescence of Ru(ddp) was detected by an inverted 
fluorescence microscope LeicaDMI6000B equipped with a mercury short-arc 
reflector lamp (Leica, Germany) excited at BP 450-490 nm and acquired at LP 590 
(Fig. 2E). 
Oxygen partial pressure was also continuously monitored with a fiber optic 
oxygen sensor (OceanOptics, USA) at the microchannel outlet. Fluorescence 
intensity is linearly correlated to the oxygen partial pressure in the sample. Both 
sensors are based on fluorescence quenching that increases with the oxygen 
partial pressure. The degree of quenching can be correlated to the oxygen partial 
pressure of the sample by Stern-Volmer equation:  
                                  
                                                                        (1)  21
0
OkpI
I
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where I0 is the fluorescence intensity at zero partial pressure of oxygen, I is the 
fluorescence intensity at a particular  and k is the Stern-Volmer constant 
which depends on the chemical composition of the sensor and on the 
temperature. Calibration of the sensor at 298 K was achieved using five liquid 
standards, obtained by bubbling a gas mixture with a partial pressure of 0%, 5%, 
10%, 15% and 21%. Complete oxygen removal was achieved with 8 hours of 
humidified argon bubbling (Rivoira, Italy). Stern-Volmer constant value was 
obtained by correlating experimental data. 
Microfluidic cell culture chamber  
Microfluidic cell culture chamber was made by standard soft-litography 
technique.34 Briefly, design shown in Fig. 3A was produced by CAD program and 
patterned in a silicon substrate using negative photoresist SU8-2100 
(Microchem, Germany). After silanization with HDMS under vacuum for 1 h, 10:1 
ratio of PDMS prepolymer and curing agent was casted and cured for 2 h at 343 
K in an oven. Through a 27 mm punch, PDMS mold was extracted. In order to 
ensure an electrical stimulation to the cell culture, a platinum wire was inserted 
in the PDMS mold and wired to an electrical stimulator. The glass slide hosting 
the cell culture was located in a standard microscopy aluminum holder (20 mm 
diameter hole), covered by the PDMS mold and pressure sealed by a teflon cover 
(Fig. 3B).  
 
 
Figure 3. Cell culture chamber and calcium dynamic acquisition. (A) Microfluidic cell culture 
chamber top view. The chamber is characterized by 1 inlet and 2 outlets and by 2 platinum wires 
placed in the lateral walls to electrically stimulate cells. (B) Assembly of the microfluidic chamber 
within microscope holder to perform on line detection. (C) Confocal image and calcium dynamic 
of a cardiomyocyte under electrical stimulation. Line scan (yellow line) is placed between nucleus 
and sarcolemma of the cell and calcium transient are continuously detected as a function of time.     
 
The perfusion culture chamber was connected to the  microfluidic exchanger 
through silica tubings in order to avoid external oxygen infiltrations. All the 
experiments were performed with a 100 µl min-1 flow rate using syringe pumps 
(Harvard Pump, Harvard Apparatus, USA) allowing fast exchange of medium 
without any apparent change in cellular calcium dynamics. 
 
2O
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Cardiomyocytes isolation and culture 
Neonatal rat cardiomyocytes were obtained from Sprague-Dawley pups 1-3 days 
old. The cells were plated on 20 µg/ml laminin-coated (BD Bioscience, USA) glass 
coverslips in Day1 medium: 25 mM Hepes Dulbecco’s Modified Eagle’s Medium 
(Gibco, USA), 17% Medium M199 (Gibco, USA) 10% Horse Serum (Gibco, USA), 
5% Newborn Calf Serum (Gibco, USA), 2 mM L-Glutammine (Gibco, USA), 
Penicillin-Streptomycin (EuroClone, Italy). After 24 hours, the Day1 medium was 
replaced with Day2 medium: Day1 medium with 5% Horse Serum and 0.5% 
Newborn Calf Serum. Experiments were performed 4 days after plating. The 
animals were housed and operated at the Animal Colony of the Venetian 
Institute of Molecular Institute. All experiments with animals were approved by 
Padova University’s Institutional Animal Care Committee (Comitato Etico di 
Ateneo per la Sperimentazione Animale). 
Calcium dynamic acquisition and analysis  
Confocal Calcium measurements were performed as reported in Fig. 3C. 
Cardiomyocytes were loaded in serum-free D-MEM (Gibco, USA) supplemented 
with 3 µM fluorescent calcium dye fluo-4 AM (Invitrogen, USA) for 20 minutes at 
310 K in presence of 2 µM Pluronic F-127 (Invitrogen, USA) and 20 µM 
sulfinpyrazone (Sigma-Aldrich, USA), then incubated for additional 10 minutes at 
310 K in Fluo-4-free D-MEM to allow complete de-esterification of the dye, and 
added with 0.2 µM di-8-ANEPPS (Invitrogen, USA). After loading, the coverslips 
were transferred to the microfluidic chamber and perfused with recording 
solution: NaCl 125 mM, KCl 5 mM, Na3PO4 1 mM, MgSO4 1 mM, Hepes 20 mM, 
CaCl2 2 mM, Glucose 5.5 mM, to pH 7.4 with NaOH. Line scan was acquired with 
Leica TCS SP5 confocal microscope equipped with a 63, 1.4 NA oil immersion 
objective, with 488 nm Ar laser line as excitation source, 700 Hz acquisition 
frequency. To reduce dye photo-bleaching and photo-toxic effects on the 
analyzed cells, the laser power was set at minimum possible. During all the 
experiments, the culture was constantly filed-stimulated with electrical pulses at 
0.7 Hz, 20 V cm-1, to overcome spontaneous beating activity allowing acquisition 
at the same beating rate in all cells. Nifedipine and Verapamil (Sigma-Aldrich, 
USA) were dissolved in DMSO (Sigma-Aldrich, USA) or deionized H2O, 
respectively, at a 10 mM starting concentration and diluted to the desired 
concentration in recording solution immediately prior to the experiments. All 
data analysis were performed with ImageJ and Origin7 software. 
Data are presented as means of percentage decrease normalized on the 
reference conditions ± standard error of mean (SEM). The effects of different 
oxygen concentrations on calcium transients were compared by a one way 
ANOVA followed by Bonferroni's mean comparison. We considered P < 0.01 to 
be statistically significant.  
Mathematical modeling 
The oxygen concentration profile, and consequently the oxygen partial 
pressure, within the liquid phase domain of the microfluidic gas exchanger was 
described by simplified analytical model and by computational solution of the 
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species mass balance. The simplified model was validated with computational 
analysis and used for a proper gas exchanger design. 
Mass transfer was assumed to be governed by convective transport in the gas 
phase, diffusive resistance in the permeable membrane and convective-diffuse 
regime in the liquid phase. The concentration in the gas phase was assumed 
constant along spatial coordinates because, according to the high gas flow rate, 
the permanence time in the gas chamber is much smaller than the characteristic 
time of the membrane oxygen exchange process. 
On the other hand, the oxygen concentration in the liquid phase changes from 
the inlet (x = 0) to the outlet (x = CL) of the microfluidic gas exchanger. For this 
reason, in order to describe oxygen concentration profile along y-coordinate 
(height of the microfluidic channel), both hydrodynamic and mass transport 
models should be solved simultaneously. Due to the low Reynolds numbers 
(1÷10) an analytical solution of fully developed hydrodynamic profile between 
flat planes was assumed.35 Considering that Péclet number (convection/diffusion 
ratio) is much greater than 1 for all experimental conditions tested in this work, 
we assumed that diffusive flux is relevant only in the y-direction, whereas 
convective flux occurs in the x-direction. Moreover, we define hL as the 
equivalent channel height, which is obtained as the area of the cross-section 
divided by the width of the channel. 
Under these assumptions and considering all mass transfer resistances localized 
at the interfaces, the steady-state mass balance equation in the liquid domain 
takes the following form: 
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where 
L
Op 2   is the oxygen partial pressure of the liquid phase, u is the axial 
velocity, H is the Henry’s constant of oxygen solubility in water at experimental 
temperature condition,  LyO hyxN ,,2  is the total oxygen flux at liquid-
membrane interface along x-coordinate and 
INL
Op
,
2  is the boundary condition at 
channel inlet. The total oxygen flux at liquid-membrane interface,
 LyO hyxN ,,2 , can be expressed as the product of the overall mass transfer 
resistance and the total driving force:  
    apxpKhyxN GOLOGLyO )(, 222 ,                                                                             
(3) 
 is the constant oxygen partial pressure in gas phase, a is specific surface, 
which corresponds to the inverse of the equivalent channel height hL, whereas 
 is the averaged overall mass transfer coefficient. The analytical 
expression of  is derived by equating oxygen fluxes for the three different 
domains and its general form can be expressed as follows: 
G
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.                                                                                        (4) 
kG and kL are the mass transfer coefficients in the gas and liquid phase 
respectively, p the oxygen permeability in PDMS and s the membrane thickness. 
Integration of equation (2) from the inlet to the outlet of the channel leads to 
the following relation: 
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Equation (5) relates the oxygen partial pressure in the microchannel to the 
length and geometry of the channel, operative conditions and mass transfer 
properties. This relation is used to calculate the minimal channel length 
necessary to ensure a defined oxygen concentration at the outlet of the system.  
The solution of equation (5) requires a proper estimation of the mean overall 
mass transfer coefficient by equation (4). Due to the high oxygen diffusivity in 
the gas phase compared to those in the liquid and solid phase, the first 
resistance term in equation (4) results negligible.  
The mass transfer coefficient in the liquid phase, kL, can be evaluated from 
empirical correlations for laminar flow which relate together dimensionless 
groups (Péclet, Reynolds and Sherwood numbers). In the developing diffusive 
concentration profile and for boundary layers which are extremely thin relative 
to the channel width, the following relation has been proposed:36 
                                                                          (6) 
where D is the oxygen diffusion coefficient in the liquid phase. c1 and c2 are 
constant values that can be evaluated by computationally solving oxygen mass 
balance equations for the system shows in Fig. 2A.   
The numerical solution of the convective-diffusion equation for the fluidic 
domain and the diffusive equation for the solid domain were obtained with the 
support of the software COMSOL Multiphysics 3.4 at different operative 
conditions. Boundary and initial conditions were set as follows: the top of the 
membrane domain is taken to be at a constant concentration in equilibrium with 
the adjacent gas phase, whereas oxygen concentration at the bottom surface is 
equilibrated with that in the fluidic domain. In the inlet section of the fluidic 
domain it was set a constant concentration, whereas at the outlet section it was 
considered only a convective flux. The remaining walls were assumed to be 
impermeable to oxygen. All values for the parameters used for the simulations 
are listed in Table 1. 
 
 
LGG k
H
p
s
kK


11
















122
12
3/1
2
,
,233.1
c
uh
xDc
D
hk
c
uh
xD
uh
xD
D
hk
L
LL
LL
LL
      Annex 2 
 
153 
Table 1. Summary of physical properties. 
Property U.M. Value       Ref. 
D, oxygen diffusion in PBS m2 s-1 
2.1×1
0-9 
37 
p, oxygen permeability in 
PDMS 
(10-10 cm3(STP) × cm/cm2 × s × 
cmHg) 
800 38 
O2 solubility in PBS at 1 
atm and 298K 
mol m-3 1.045 39 
 
 
Results and discussion 
Microfluidic platform validation 
Fig. 4A shows the oxygen concentration distribution in the microfluidic channel 
obtained by computational simulation of oxygen mass balance equations. 
Boundary conditions were set as follows: inlet oxygen partial pressure, , 
was set to 21%, whereas oxygen partial pressure in the gas phase, , is 
assumed to be constant at 0%. Oxygen flux through the PDMS membrane is 
directed from the liquid phase to the gas compartment according to the oxygen 
partial pressure gradient. Oxygen flux at the membrane interface decreases 
along the x-coordinate due to the progressive reduction of the gradient for 1 mm 
channel length as shown in Fig. 4B.  
 
Figure 4. Mass transport model development and validation. (A) 2D representation of oxygen 
INL
Op
,
2
G
Op 2
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concentration obtained by computational solution of mass balance equations in the microfluidic 
channel longitudinal cross-section. Empty arrows show oxygen flux directed from liquid phase to 
the gas one, in which oxygen partial pressure is assumed to be 0%. Full arrows show y-direction 
velocity profile. (B) Profile of the oxygen flux normal to the PDMS membrane interface along x-
coordinate. (C) Comparison of computational and analytical solution in term of adimensional 
numbers according to Eq. 6. (D) Oxygen partial pressure profile obtained from analytical solution 
given by Eq. 5 as a function of x-coordinate, parametric in liquid flow rate, L , and channel height, 
hL. Red line shows design target value of 2%. (E) Fluorescence imaging of fluidic layer filled with 
Ru(ddp) solution, using L =100 µl/min and hL=40 µm. White mark shows the region of interest for 
fluorescence quantification reported in Fig. 4F (values of x-coordinate are in cm). (F) Comparison 
of LOp 2 experimental profile inside the fluidic layer and the analytical solution obtained by Eq. 5. 
In order to properly design the gas exchanger, the application of computational 
simulation to a larger portion or overall microfluidic channel could be time 
consuming and computational intensive. For this reason a simplified analytical 
theory to fairly describe mass transport inside the microfluidic device was 
derived. The mass balance analytical expression (Eq. 5) can describe oxygen 
profile inside the channel as a function of all operative parameters that affect 
mass transfer process and of the mean overall mass transfer coefficient (<KG>) 
and, in particular, liquid mass transfer coefficient (kL).  In this work, we adopt the 
model proposed by Vollmer and coworkers 36 to our system using computational 
results to estimate model parameters. We found out that c1 and c2 constant 
values of Eq 6 are 0.10 and 2.62 respectively. Fig. 4C shows a comparison 
between computational simulation and modified analytical model (Eq. 6) in 
terms of adimensional numbers. This analytical model allows to fairly estimate 
the liquid mass transfer coefficient for several experimental conditions, in 
particular for different liquid flow rates )(L  and channel heights (hL).  
On the other hand, the minimal channel length for achieving a target  
reduction using specific liquid flow rate and channel height can be easily 
estimated by Eq. 5. Fig. 4D shows  profiles as a function of x-coordinate, 
obtained by varying both  and hL. 
In order to experimentally validate the developed theory we mapped 
fluorescence intensity of the oxygen sensitive dye in the overall fluidic layer of 
the oxygen exchanger (Fig. 4E). Fig. 4E shows a fluorescence intensity increase 
along x-coordinate from the inlet to the outlet according to . Fig. 4F shows a 
comparison of experimental  measured at different x-coordinate values 
(reported in Fig. 4E) and analytical solution obtained from Eq. 4. Very good 
agreement between profiles within the experimental uncertainty has been 
observed. Finally, using the simplified analytical theory, we designed a gas 
exchanger that is able to perform a  reduction of 95% with a steady state 
flow rate of 100 µl min-1. The gas exchanger configuration consists in 8 exchanger 
units in series formed by 8 parallel channels with 80 mm total length, 40 µm 
height and 100 µm width. 
Calcium dynamics in hypoxia 
The microfluidic cell culture chamber and gas exchanger must preserve 
cardiomyocytes physiological characteristics while providing fast transient 
L
Op 2
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biochemical stimulation. The cell culture chamber was properly designed to 
obtain a uniform laminar flow avoiding unpaired velocity profile, back flow and 
stagnant dead volumes. This ideal condition was experimentally verified by 
observing the dynamic of a pulse of fluorescein in the cell culture chamber at 
different flow rates (data not shown). In addition, before each experiment, the 
culture was maintained in perfusion for 1 hour in normoxic solution while 
recording calcium dynamics. The cardiomyocytes displayed normal calcium 
dynamics during electrical stimulation. In order to test the time course of 
substance delivery to the microfluidic chamber, we injected a 50 µl bolus of 10 
mM caffeine solution in the perfusion line. The caffeine stimulated Ca2+ release 
from sarcoplasmic reticulum (SR) had a rapid onset and resulted in the change in 
fluorescence intensity. Such effect lasted 45 s, after which the calcium transients 
amplitude returned to normal indicating complete caffeine wash out (Fig. 5A). 
This time is consistent with the estimated permanence time of caffeine within 
the microfluidic chamber, as evaluated through fluorescence dye experiments. 
 
Figure 5. Effect of hypoxia on calcium transients. (A) Calcium dynamic in a cardiomyocyte 
under electrical stimulation revealed through fluo-4 in the microfluidic culture chamber during 
perfusion of 50 µl of 10 mM caffeine solution; cardiomyocyte displays normal Ca2+ transients and 
response to caffeine with full recovery after wash out. (B,C) Liquid phase oxygen dynamic during 
step impulse of the oxygen partial pressure in the gas phase monitored by Ru(ddp) with three 
different flowrates (B) and by optic fiber sensor with L  = 200 µl min
-1 (C) at exchanger outlet. (D) 
Calcium transients sequence at different time points after hypoxic stimulus to the cell culture. (E) 
Comparison of single normalized calcium transients at different time points after hypoxic 
stimulus.  
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In order to analyze the early effect of hypoxic events on cardiac physiology it is 
fundamental to fully characterize the oxygen partial pressure dynamics after set 
point variations. For this reasons, oxygen partial pressure at the outlet of the gas 
exchanger were measured by continuously detecting intensity fluorescence of 
oxygen sensitive dye during a 
G
Op 2  set point change from 21% to 0% at three 
different flow rates: 50, 100 and 200 µl min-1 (Fig. 5B). The
L
Op 2  half decay value of 
10 s for all different flow rates ensures fast oxygen dynamics. Different hypoxic 
steady state levels (
L
Op 2 < 5%) can be achieved by varying medium flow rate (Fig. 
5B). In order to exclude gas leakage between the gas exchanger and the culture 
chamber, oxygen partial pressure values, 
L
Op 2 , were continuously monitored at 
cell culture chamber inlet by fiber optic probe. Fig. 5C shows
L
Op 2  steady state 
values (black line) reached after two 
G
Op 2  set point variations (red line): 21% to 
0% and 0% to 21%. Consistent measurements reported in Fig. 5B-C confirms an 
efficient gas insulation.  
All together, these results show that the microfluidic experimental set up (as 
reported in Fig. 1) is able to accurately control oxygen partial pressure on cell 
culture in terms of steady state levels and rapid set point variations. It is worth to 
underline that oxygen partial pressure control is achieved without any 
perturbations on liquid media, allowing long term confocal acquisitions on same 
region of interest. These technical improvements make possible to perform 
experimental investigations using the same cell as its own control, continuously 
acquiring biological data prior and during the hypoxic stimulation. 
In order to rationally study the hypoxia-induced effects on calcium handling 
during excitation-contraction coupling it is important to investigate the duration 
of hypoxic stimulation that could exert a cell physiological response.  
In this context, Fig. 5D shows a sequence of calcium dynamics in response to 
fast 
L
Op 2  drop as a function of time. A comparison of normalized calcium transient 
peaks at different time points (Fig. 5E) shows a significant alteration of the 
fluorescence intensity peak maximum after 5 min from hypoxic stimulus. All 
other experiments were performed considering this time frame as a minimal 
value to elicit a hypoxia-induced physiological response. 
We then sought to determine the hypoxic level at which hypoxia-induced 
effects on calcium handling during excitation-contraction coupling can be 
recorded. A multiple step experiment was designed by setting 
G
Op 2  at 5 different 
values from 21% to 0% with 5% interval and the resulting 
L
Op 2  step profile is 
shown in Fig. 6A. Corresponding values of 
L
Op 2  and 
G
Op 2  were correlated to obtain 
operating curve shown in Fig. 6A insert. Interestingly, the operating curve differs 
slightly from the equilibrium curve within the accuracy used in the gas exchanger 
design (
L
Op 2 = 2% as target value (Fig. 4D), corresponding to 95% reduction from 
normoxic conditions). 
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Figure 6. Oxygen level threshold. (A) LOp 2 profile for five different 
G
Op 2  with L =100 µl min
-1. Insert 
shows equilibrium and operating curve obtained by calibration. (B) Calcium transients sequence 
at different LOp 2 measured 7 minutes after
G
Op 2  set-point change. Blue arrows show 
correspondence between GOp 2  set-point and calcium transient sequence (Fig. 5A). (C) Comparison 
of single normalized calcium transients at different oxygen partial pressure. (D) Averaged values 
of normalized calcium transients peak height at different oxygen partial pressure. The histogram 
is based on 5 replicates of same conditions.      
 
Fig. 6B shows the corresponding sequence of calcium transients acquired for 6 s 
at different 
L
Op 2  levels measured 7 minutes after the 
G
Op 2  set-point change. Blue 
arrows show correspondence between 
G
Op 2  set-point values and calcium 
transients. The baseline fluorescence maintained the same intensity for all the 
duration of the experiment and the effect of hypoxic stimulation emerged with a 
decrease of the maximum of the normalized calcium transient peak (Fig. 6C). The 
analyzed cells did not display calcium cycling alterations for 
G
Op 2  > 5% (n=5). At 
5% a poor significant difference (P<0.05, n=5) decrease was observed, whereas 
at 
G
Op 2 = 0% the alteration of calcium transient was observed with high statistical 
relevance (P<0.01, n=5) (Fig. 6D). These data show that the observed effect 
reveals itself only in highly hypoxic nearly anoxic conditions, remaining latent at 
higher oxygen concentrations. 
To test the reversibility of the hypoxia induced Ca2+ changes and, concurrently, 
exclude artifact deriving form long term confocal acquisition such as dye photo-
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bleaching, the cardiomyocyte culture was subjected to a fast drop of 
L
Op 2  and 
maintained in hypoxic conditions for 10 min followed by 10 min of reperfusion 
with normoxic medium (Fig. 7A).  
 
Figure 7. Reversible effect of hypoxia on calcium cycling. (A) Calcium transients sequence 
measured in normoxic, hypoxic ( GOp 2 = 0%) and normoxic conditions. (B) Comparison of single 
normalized calcium transients in normoxic, hypoxic ( GOp 2 = 0%) and normoxic condition. (C) 
Averaged values of normalized calcium transients peak height in normoxic, hypoxic ( GOp 2 = 0%) and 
normoxic condition. The histogram is based on 5 replicates of same conditions. (D,E) Normalized 
calcium transients for different concentrations of L-type Ca2+ channel antagonist Verapamil (D) 
and Nifedipine (E). 
 
Whole-cell calcium dynamics were acquired every 10 min. In response to 
hypoxic stress we observed a decrease of the maximum calcium transient peak 
(Fig. 7B) with no alteration of the baseline fluorescence (n=8). After recovering 
the normoxic conditions, the cardiomyocytes displayed again the same 
fluorescence intensity, indicating a recovery of calcium cycling towards basal 
conditions. By analyzing the variation of fluo-4 fluorescence after 10 minutes of 
hypoxia and subsequent 10 minutes of reperfusion by means of percentage 
decrease against normoxic fluorescence intensity, a statistically relevant 
decrease (~15%, P<0.01) emerged (Fig. 7C). The recovery of normal calcium 
transients after the return to normoxic conditions highlights the reversibility of 
the biological effect and excludes the responsibility of dye photo-bleaching from 
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the observed decrease of fluorescence. 
All together, these results show that there is a significant reversible alteration 
of calcium homeostasis in excitation-contraction coupling during fast hypoxic 
stimuli. This experimental evidence underlines the ability of the cell to sense 
oxygen level and rapidly adapt to normoxic/hypoxic/normoxic transitions by 
regulating either directly or through secondary pathways the molecular 
machinery involved in cardiac Ca2+ homeostasis.3 In addition to direct channel 
sensing or specifically target protein modification (such as phosphorylation and 
cysteine reduction), hypoxia may also alter the regulation of these channels via 
indirect bulk mechanisms, such as changes in cell redox state by action of ROS.3 
However, all these hypoxia-induced phenomena affect membrane depolarization 
and concurrently alter of L-type voltage-gated calcium channels (VGCC) function, 
which provide the main entry pathway for extracellular Ca2+ into cardiomyocytes 
and are a major component of excitation-contraction coupling machinery. L–type 
VGCCs trigger the calcium-induced calcium release (CICR) process through 
extracellular calcium influx; calcium entry through VGCCs, which are 
topologically associated to calcium-release channels (ryanodine receptors) in the 
sarcoplasmic reticulum (SR) membrane, cause further calcium SR release within 
cytosol compartment. These secondary calcium dynamics can be easily measured 
as reported in this study. 
In this context, the alterations in excitation-contraction coupling under hypoxia 
could be related to impaired CICR for hypoxia-dependent desensitization of L-
type VGCCs. 
In order to explore this hypothesis, experimental investigation of calcium 
transients upon inhibition of the L-type Ca2+ channel with two antagonists was 
performed. Fig. 7D and 7E show normalized calcium transient at different 
concentrations of channel blocker ranging from 1 nm to 1000 nM in normoxic 
conditions. Similar calcium peak reductions recorded for hypoxia below 5% 
L
Op 2  
were observed with 100nM of Verapamil and 10 nM of Nifedipine Fig. 7D and 
Fig. 7E, respectively. 
These findings confirm that a hypoxia-induced alteration of primary calcium 
entry through L-type VGCCs could turn in a reduced calcium concentration 
during excitation-contraction coupling and consequently, in an alteration of the 
physiological activity of cardiomyocytes. 
Our results suggest that a cardioprotective mechanism during early phases of 
acute ischemia takes place through the reduction of calcium homeostasis in 
excitation-contraction coupling.  
A reversible adaptation of myocardium after short ischemic stress (5 min and 15 
min ischemia/reperfusion) in vivo was first observed by Heyndrickx and co-
workers.40 They demonstrated that a fully reversible dysfunction of the ischemic 
heart is prolonged after hypoxic stress, named “myocardial stunning”. The 
molecular basis behind this physiological behavior is still unclear. Myocardial 
stunning results from different adaptive mechanisms such as down-regulation of 
myocardial metabolism, and leads to activation of long-term cardioprotective 
responses including activation of cell survival pathways resulting in changes in 
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gene and protein expression.41 
In this context, we first show that a fully reversible adaptive mechanisms of 
cardiopreservation might take place during the early events of ischemic stress 
through fast alteration in ion channel function in response to changes in cellular 
oxygen. 
 
Conclusions 
A microfluidic gas exchanger was designed to accurately and very quickly 
regulate 
L
Op 2  without perturbing medium flux and consequently on line 
acquisition. By developing an ad hoc mass transfer theory, supported by 
computational simulations, we were able to predict 
L
Op 2  inside cell culture 
chamber as a function of operative parameters (liquid flow rate). Experimental 
validation of 
L
Op 2  profile inside the gas-exchanger microchannels confirmed that 
both constructive method and analytical model were valid.  
With the support of the developed technological system we observed a 
significant calcium handling alteration in a neonatal rat cardiomyocyte 
population after an exposure to 5 min of hypoxic conditions. Thanks to accuracy 
in tuning oxygen level in our system we found a threshold value of 5% 
L
Op 2 , above 
which no significant calcium transients peak decreases were observed. 
The recovery of normal calcium transients after the return to normoxic 
conditions highlights the reversibility of the biological effect and excludes the 
responsibility of sample damaging phenomena like dye photo-bleaching from the 
observed decrease of fluorescence. 
We also explored the hypothesis that calcium-handling alteration in hypoxia 
could be affected by the desensitization of voltage gated calcium channels. In 
order to support our hypothesis we compared calcium transients peak obtained 
during a hypoxic stimulus and those obtained under effect of L-type calcium 
antagonist, Verapamil and Nifedipine. 
Rational understanding of how the cardiomyocyte adapts to acute ischemic 
stress and sustains its survival represents an important challenge because it 
might help in finding novel strategies to enhance cardiomyocytes survival in 
patients. 
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Abstract 
Micro-engineering human tissues and “organs-on-chips” remains an open 
challenge from both scientific and technological points of view. Here, we 
described a robust and efficient microfluidic-based approach for the 
differentiation of human pluripotent stem cells into functional cells. Specific 
frequency of periodic medium perfusion enhances the selectiveness of early 
germ layer differentiation and cell commitment through extrinsic signal 
microfluidic modulation. Human cardiomyocytes and hepatocytes generated on 
chip from human pluripotent stem cells through multi-stage approach show 
functional differentiation and proper response to drug pharmaco-kinetics, which 
opens a new perspective for multi-parametric and large scale human cell-based 
screening assays. 
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The development of human organs-on-chips, in which the microscale 
engineering technologies are combined with cultured human cells to recapitulate 
the whole living organ microenvironment, offers a unique opportunity to study 
human physiology and pathophysiology in an organ-specific context1,2,3. This 
technological perspective could provide an effective solution to the limitations of 
conventional cell culture models that fail to recapitulate complex, organ-level 
disease processes in humans and it could overcome the use of costly and time-
consuming animal testing, which often shows poor predictive power of human 
biology and physiology. Moreover, the scientific community, the major 
pharmaceutical companies and the government agencies are recognizing the 
paramount importance of developing new technologies, which allow to perform 
cost-effective and multi-parametric assay for ad hoc studies in development, 
disease and pathogenesis, or for screening specific therapeutic strategies. 
Recently, successful examples of organs-on-chips development have been 
provided4,5,6,7, however, they were obtained from primary animal cells and, in 
few cases, from primary human cells. The possibility of developing direct 
organogenesis-on-chip from human pluripotent stem cells (hPSCs) could 
overcome the limited availability of human primary cells, such as human 
hepatocytes or cardiomyocytes. Human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (hiPSCs) grown in culture have the potential to 
give rise to any fetal and adult cell type. Furthermore, they show intrinsic and 
unexpected levels of emergent self-organization for generating highly ordered 
structures and tissues8,9,10, thus opening a wide perspective for multi-organ 
generation on a chip.  
Biomimetic scale-down of multi-stage developmental process (from germ layer 
specification and phenotypic differentiation to tissue morphogenesis) could take 
advantage of the intrinsic properties of micro-technologies and microfluidics that 
allow accurate control of cell culture microenvironment, of temporal evolution of 
chemical gradients and of mechanical features, which support specific tissue 
differentiation11,12,13. Few studies reported on mouse embryonic stem cell 
cultures using microfluidic systems and highlighted the importance of accurate 
soluble microenvironment regulation to maintain pluripotency and self-
renewal14,15,16. We reported for the first time on hESCs culture on a chip17 and 
few other works dealt with hESCs modulating flow perfusion, mainly for 
maintaining pluripotency18,19. Integrated functional hPSCs differentiation on a 
chip, which certainly requires step-by-step control of hPSCs programming for 
resembling early stages of tissue morphogenesis, has not been developed yet. 
Here, we explored whether we can control stem cell expansion, selective germ 
layer commitment and derivation of functional tissue-specific cells on a chip from 
both hESCs and hiPSCs through a multi-stage microfluidic-based technology. The 
different developmental stages required cell niche specification in terms of 
accurate balance between extrinsic and intrinsic cell signaling. The identification 
of the essential role of autocrine-paracrine factors in pluripotency, self-renewal, 
and germ layer commitment20, suggests a synergic mechanism of specific 
extrinsic exogenous and endogenous factors in controlling transcriptional activity 
as schematized in Fig. 1a.  
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The extrinsic factors modulation requires an optimal in vitro delivery of 
exogenous factors and removal of endogenous cell-secreted factors, in principle 
either providing continuous perfusion or periodic delivery of medium change. 
However, continuous microfluidic flow perfusion generates soluble factors 
spatial gradients14 and, consequently, heterogeneous up/downstream hESC 
culture conditions (Fig. S1). On the other hand, discontinuous periodic medium 
delivery allows proper factors supply, while avoiding up/downstream effects 
throughout the channels, in terms of colony size, cell density and pluripotency 
markers expression of both hESCs and hiPSCs (Fig. S1 and S2).  
We hypothesized that a discontinuous periodic medium delivery with stage-
dependent frequency (number of cycles of medium change per day) is an 
effective method for modulating soluble microenvironments and, consequently, 
stem cell niche specification in vitro, according to scheme in Fig. 1a. Intuitively, 
low frequencies allow endogenous factors accumulation within the channel. 
Conversely, high frequencies promote sustained exogenous factors supply, but 
lead to continuous wash-out of endogenous secreted factors. As also 
qualitatively described by a simplified computational model (see Supplementary 
Methods for model details and Fig. S3), the frequency of medium delivery, f, 
strongly impacts on the balance between extrinsic exogenous and endogenous 
factors (Fig. 1b). 
Thus, we investigated the optimal frequency for both hESCs and hiPSCs 
expansion in microfluidic channels to maintain high stemness and homogeneous 
morphology among colonies at different regions along the channels. HPSCs were 
injected into multiple microfluidic platforms, each containing 10 independent 
channels and connected to a multi-port syringe pump (Fig. 1c), and cultured with 
different frequencies for up to 6 days (Fig. 1d). Both hESCs (hES2) and hiPSCs 
(ADHF#1) homogeneously express pluripotency markers such as OCT4, SOX2, 
TRA-1-60 and TRA-1-81, as revealed by immunofluorescence staining (Fig. 1e). A 
frequency-dependent expression level of pluripotency markers OCT4, NANOG 
and DNMT3B was observed in hES2 cells after 6 days of culture (Fig. 1f). 
Statistically significant differences were observed among frequencies for OCT4 
and NANOG. Specifically, a significantly higher OCT4 expression was observed for 
f=2d-1, compared to all other frequencies and continuous perfusion (CP), and a 
higher NANOG expression for f=2d-1, compared to other frequencies and CP. 
DNMT3B results highly expressed for all the investigated frequecies and highly 
reduced only in f=1d-1, f=4d-1, f=8d-1 and CP. Overall this result shows that f=2d-1 
is the optimal frequency for pluripotency maintenance, with OCT4, NANOG and 
DNMT3B expressions comparable to the standard static condition (Petri dish), 
used as positive control.  
To further demonstrate that this optimal low-frequency culture conditions 
(f=2d-1) is strongly related to an appropriate balance of exogenous molecules and 
endogenous cell-secreted factors, we designed an ad hoc experiment where 
HES2-conditioned medium collected in f=2d-1 experiment was used to culture 
HES2 cells at higher frequency. Fig. 1g shows statistically significant 3-fold 
increase in OCT4 expression when conditioned medium is used at f=8d-1 
compared to fresh medium at the same frequency. Expression levels 
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comaparable with f=2d-1 were achieved, providing evidences that microfludic-
conditioned media could potentially alter cell fate. 
We first verified that this behavior is not strictly related to the medium 
alterations derived by nutrients depletion (glucose) and waste-products 
accumulation (ammonia and lactate) in microfluidic channels (Fig. S4). On the 
other hand, as TGF/Activin/Nodal pathway greatly contributes to pluripotency 
and self-renewal in hPSCs21,22, we further investigated whether the observed 
frequency-dependent differences were correlated to the levels of endogenous 
TGF/Activin/Nodal ligands released by the cells into the conditioned medium. 
To quantify these factors we used a functional read-out, namely their ability to 
activate SMAD2/3 transcriptional activity, measured through the established 
synthetic CAGA12-luciferase reporter in HaCaT cells23,24. HES2 cells were first 
adapted to feeder-free culture conditions using defined Essential 8 (E8) medium; 
then, they were plated in microfluidic channels or in Petri dish and cultured in 
the absence of exogenous TGF1, by using E7 medium. Conditioned media were 
then collected from Petri dish and microfluidic channels in two different 
conditions, i.e. f=8d-1 and f=2d-1, and used to treat HaCaT cells (Fig. S5 and 
Supplementary Methods). As shown in Fig. 1h, conditioned medium with f=2d-1 
contained higher levels of TGF ligands when compared to both f=8d-1 and static 
condition. In line with these results, the expression levels of NANOG, a known 
direct transcriptional target of SMAD2/3 in hESCs25, was up-regulated in f=2d-1 
conditions when compared to both lower frequency and static condition (Fig. 1i). 
Together, these data suggest that the endogenous TGB/Activin/Nodal ligands 
are released or accumulated in a frequency-dependent manner, thus promoting 
pluripotency. 
We next investigated whether the frequency of periodic perfusion could also be 
used for directing early germ layer commitment according to microfluidic 
modulation of extrinsic endogenous and exogenous factors (Fig. 2a). HESCs were 
expanded for 3 days and differentiated for 4 days at different frequencies in 
spontaneous differentiation conditions (Supplementary Methods). Expression 
levels of early germ layers markers were analyzed through qRT-PCR analysis of β-
III TUBULIN and OTX2 (ectoderm), BRACHYURY-T, GATA4 and αSMA (mesoderm), 
alpha-fetoprotein (AFP), EOMES and FOXA2 (endoderm). Under these conditions, 
static culture showed higher ectoderm but not mesoderm and endoderm marker 
expression. On the other hand, frequency-dependent germ layer commitment 
was observed in microfluidic culture. Ectoderm markers result highly expressed 
at lower frequencies (f=1d-1 and f=2d-1) and completely down regulated at higher 
frequency (f=8d-1), whereas mesoderm and endoderm expression are enhanced 
at higher frequency (f=8d-1). We also showed that conditioned medium from 
f=1d-1 up-regulates OTX2 expression and down-regulates BRACHYURY-T when 
delivered at high frequency, i.e. f=8d-1 (Supplementary Fig. S6). These 
experimental observations are consistent with the hypothesis that high 
accumulation of extrinsic endogenous factors promotes ectoderm 
differentiation, while inhibiting meso-endoderm specification14,20.  
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To verify whether an efficient and selective induction of the three germ layers 
could be achieved, hPSCs were induced to ectoderm, mesoderm and endoderm 
by specific differentiation media and with ad hoc frequency (Fig. 2b). Particularly, 
consistent with previous results, f=4d-1 was used for endoderm, f=3d-1 for 
mesoderm and f=1d-1 for ectoderm specification. Selective germ layers 
commitment was successfully obtained as reported by qRT-PCR analysis, which 
showed high expression of germ layer-specific genes for each differentiation 
protocol. Interestingly, endoderm is significantly more highly expressed in 
microfluidic condition compared to conventional static differentiation. As 
previously demonstrated for pluripotency maintenance, it seems that 
microfluidic environment effectively washed out endogenous factors, which 
could inhibit endoderm differentiation, and efficiently delivered exogenous pro-
endoderm factors. Immunofluorescence analyses (Fig. 2c) confirmed that highly 
selective commitment for all germ layers, with low level of contaminations by 
other ones, can be achieved also at protein level in each specific differentiation 
protocol. Next, we examined if perfusion frequency can be further adjusted for 
optimizing germ layer microfluidic induction when specific differentiation 
protocols are used. As proof of concept, results in Fig. 2d show how selective 
induction of mesoderm was achieved by adjusting frequency of periodic 
perfusion. In particular, 3-fold higher BRACHYURY-T expression was observed at 
f=2-3d-1, compared to f=1d-1 and almost null expression at f=12d-1. High 
homogeneity within the channels was maintained also during hPSCs early 
commitment and differentiation (Fig. S7). 
Collectively, our findings indicate that frequency of periodic perfusion is an 
additional parameter to enhance robustness and efficiency of early germ layer 
specification, also when specific protocols are adopted.  
To further prove that microfluidic cell culture with periodic perfusion could 
potentially yield to greater efficacy than conventional protocols in Petri dish, we 
provided a screening of different media developed for endoderm specification. It 
is worth to underline that endoderm differentiation simultaneously requires 
large quantities of exogenous compounds (Activin-A) while washing out of 
endogenous inhibiting factors, which is almost unachievable in conventional 
Petri dish. As expected, intermittent perfusion with optimal frequency (f=4d-1) 
yielded to significant higher cell viability (in 5 over 6 conditions) and to significant 
3-fold increase in SOX17+/FOXA2+ cells (in 3 over 6 conditions) compared to Petri 
dish culture (Fig. S8).  
We then demonstrated how functional tissue-specific cell generation on chip 
could be achieved. We focused on cardiac and hepatic cells derived from 
mesoderm and endoderm germ layers, respectively, which are extremely 
relevant for tissue-on-a-chip applications. Cell differentiation was achieved by 
combining ad hoc hPSCs differentiation stages, germ layer specification and 
mature differentiation, with proper frequencies of periodic perfusion and 
chemical regulation of soluble microenvironment. Cardiac and hepatic 
differentiation protocols are described in Supplementary Methods. 
First we showed how cardiac cells on chip were derived after 15 days of 
frequency-dependent multi-stage differentiation protocol (Fig. 3a), consisting on 
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Wnt-dependent mesoderm induction, early cardiac commitment (by Wnt 
inhibition) and functional cardiac maturation (by pro-cardiac factors supply). 
Typically 5 to 10 thousands cardiac cells per channel were obtained. We robustly 
achieved spontaneous contractile activity from both HES2 and ADHF#1-derived 
cardiomyocytes (Supplementary Videos 1, 2 and 3), and 65.4 ± 11.9% of cardiac 
troponin-T positive cells showing defined cardiac sarcomeric organization (Fig. 
3b). HPSC-derived cardiomyocytes show spontaneous calcium transients and 
excitation-contraction coupling. In the line scan magnification in Fig. 3c both 
calcium transients and spark-like spontaneous activity are presented. Analyzing 
calcium handling of hPSC-cardiomyocytes in microchannels, we observed 
cardiomyocyte functional response to 0.5 µM Verapamil with reduced calcium 
release after L-type channel inhibition, and response to 10 mM caffeine with 
cytosolic calcium increase after ryanodine channel activation. We successfully 
showed that it is possible to generate functional cardiac cells on chip and to 
directly perform dynamic biochemical stimulations taking advantage of the 
microfluidic environment, which allows robust, accurate, fast, and cost-effective 
spatio-temporal control of cell microenvironment11. 
We next applied our methodology to derive hepatocytes on chip, consistently 
with the previously endoderm-optimized conditions, which showed higher 
efficiency in endoderm differentiation than conventional cell culture (“+ B27 + 
NaB” medium in Fig. S8). Hepatic cells were robustly obtained from hESCs and 
hiPSCs by early endoderm commitment, definitive endoderm specification and 
hepatocyte-like cell maturation steps, driven by specific periodic medium 
delivery (Fig. 3d). Characteristic polygonal-shaped hepatocyte-like cells were 
obtained, with presence of bi-nucleate cells at the late stage, showing high 
expression of the specific hepatic markers albumin and cytochrome CYP450-3A 
(Fig. 3e). The hepatic cells show functional activity by high glycogen storage 
capacity (75.0 ± 7.5%) and indocyanine green uptake and clearance (Fig. 3f). 
Compared to static conditions, we obtained a shortening of the time required for 
differentiation (from 16d to 14d) and 40% greater albumin secretion rate on the 
last day of maturation (Fig. 3g). Similar results were obtained by applying our 
method to other hiPSC lines derived with non-integrating methods: SEN#1, 
derived with non-integrating Sendai viruses, mRNA#1 and mRNA#2, derived with 
mRNA technology (Supplementary methods and Fig. S9). An albumin production 
rate comparable with hESC-derived hepatocytes was obtained with the different 
hiPSC lines, confirming the robustness of the method. Quantification of 
immunofluorescence of late stage albumin and CYP450-3A in HES2 shows higher 
expression in microfluidic differentiated cells compared to static differentiation 
control (Fig. 3h and Fig. S10). 
To prove how this system could be used for monitoring cell drug response and 
pharmacokinetics, we performed a series of experiments on hepatocyte drug 
cytotoxicity. Acetaminophen was chosen for its widely used applications, its 
fundamental hepatic metabolism and its toxicity on hepatic cells at high doses. A 
first experiment was performed on HepG2 cells exposed to different drug 
concentrations for 24h. Cell death caused by drug cytotoxicity was comparable 
between static control and microfluidic culture conditions (Fig. S11 and 
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Supplementary Methods). Higher cytotoxicity in microfluidic cells clearly 
correlated with nuclear area reduction, compared to lower correlation in the 
static control. Next, hESC-derived hepatocyte-like cells were exposed to 
acetaminophen in static culture, and at f=2d-1 in microfluidic culture for 24h (Fig. 
3i). A 25 mM concentration of acetaminophen caused 75% of dead cells in micro-
channels compared to 20% in the static control, although the overall amount of 
acetaminophen per cell was 10 times lower in microfluidics. This result is 
consistent with a higher level of differentiation of microfluidic hepatocyte-like 
cells which show well developed CYP450-3A-mediated drug metabolism26 
compared to less functionally cells differentiated in static condition (Fig. 3h). 
Drug cytotoxicity also affected cell morphology and membrane integrity. An 
acetaminophen concentration of 25 mM caused abnormal cell morphology (Fig. 
S12).  
The tight temporal control of medium delivery achievable by microfluidic 
technology makes it particularly suitable to test not only drug concentration 
cytotoxicity but also different posologies of acetaminophen administration to 
hESC-derived hepatic cells in a 24 h timespan (Fig. 3j). Results show that, even at 
low dose, repeated drug administration (4 times per day for 3 h each) has a 
significantly higher cytotoxic impact than a one-shot at high dosage, regardless 
of the higher overall amount of drug in the single-administration case. This is 
consistent with literature data of serum alanine aminotransferase (ALT) elevation 
after repeated administration of low doses of acetaminophen in healthy young 
adults27. However, this chronic cytotoxic effect is not linearly dependent on drug 
concentration. Taken together, these results show that the microfluidic 
environment together with optimized periodic perfusion frequency provides an 
effective methodology for generating hepatic-like tissues on a chip with 
remarkable functional differentiation suitable for high-throughput drug testing in 
terms of drug concentration and posology. 
In conclusion, we derived functional tissue-specific cells on a chip through a 
robust multi-stage microfluidic technology, which allows accurate spatio-
temporal control of cell soluble microenvironment through regulation of periodic 
perfusion frequencies. Moreover, functionally differentiated cells derived in the 
microfluidic channels can be directly used for dynamic multi-parametric large-
scale drug screening or for developing micro-engineered human organ models. 
This technology opens a new perspective in generating organs-on-chips from 
hPSCs overcoming the issues related to the limited availability of human primary 
cell sources. This last aspect will require strong scientific and technological 
efforts for further mimicking the organogenesis in vitro. 
 
Methods 
Computational Model 
Mathematical model of signaling pathway, describing gene transcriptional 
activity promoted by synergic positive effect of extrinsic exogenous and 
endogenous factors is shown in Fig. 1a. The model takes into account only 
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relevant phenomena to highlight the effect of dynamic changes in extrinsic 
factors modulated by medium delivery frequency, f, on a hypothetic 
transcriptional activity. Black arrows in Fig. 1a indicate chemical reactions 
involved in the pathway. In particular, reactions (1) and (2) describe the coupling 
of exogenous, Ex, and endogenous, En, factors to specific membrane receptors, 
which promotes the activation of transcriptional factor, Tr. In addition, Tr is 
activated at a basal level through reaction (3) and induces expression of 
pluripotency-associated genes through reaction (4). Gene transcripts, Gt, in turn, 
produce newly En, as indicated by reaction (5). The model consists of four 
ordinary differential equations describing dynamic mass balance equation for the 
involved species Ex, En, Tr and Gt:  
 
 
 
                                                                                                                                                          
                                                                                                                             
(1) 
 
 
c are concentrations of species involved in the pathway (Ex, En, Tr and Gt); ~ 
symbol indicates adimensional concentration normalized for the initial 
concentration value c0. N is the molar flux, given from the product between the 
medium flow rate and the concentration of each species, at the inlet and outlet 
of the microfluidic channel. Exogenous inlet flux is constant, as exogenous 
factors are continuously supplied with medium, whereas outlet fluxes are time-
dependent. All chemical reaction rates are assumed first order kinetics as 
follows: 
 
 
                                                                                                                                                                               
(2)                                                        
 
, 
where ki are constant of reaction with arbitrary value and dimension [t
-1]. As an 
intermittent medium delivery is used, system of equations (1) can be solved 
throughout an interval time equivalent to the reciprocal of the frequency, 1/f, 
and for a defined number of cycles, Ntot. Consequently, null inlet and outlet 
fluxes and opportune initial periodic conditions were set. Time for medium 
change in the microfluidic channel was assumed negligible and periodic 
concentration values of Ex and En were set equal to 1 and 0 respectively after 
every time period (1/f). The system was solved for different values of f with 
periodic initial conditions written as follows: 
V1  k1cEx
V2  k2 cEn
V3  k3
V4  k4 cTf
V5  k5 cGt
dcEx
dt
 NEx
IN - NEx
OUT -V1
dcEn
dt
 - NEn
OUT -V2 V5
dcTf
dt
V1V2 V3
dcGt
dt
V4 -V5











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System of ordinary equations (3) was computationally solved with MATLAB, by 
using ode15s function. Constant rates k1, k2, k4 and k5 were arbitrarily set equal 
to 1, whereas k3 was taken equal to 0.1. Ntot was chosen in order to achieve a 
pseudo-stationary of all species concentrations. 
Microfluidic device fabrication and functionalization 
Each microfluidic device, containing 10 independent channels 18 mm long and 
1.5 mm wide, was fabricated by standard soft-lithographic techniques9. The 
master was photo-lithographically patterned through SU8-2100 negative 
photoresist (MicroChem, Newton, MA) to obtain a final thickness of 200 m, 
according to manufacturer’s indications. A premixed 10:1 ratio of 
polydimethylsiloxane, PDMS, pre-polymer and curing agent solution (Sylgard 184 
kit; Dow Corning, Midland, MI) was casted on the silicon wafer and cured at 70 C° 
for 2 h. The PDMS mold was cut, peeled off, and punched with a 21G stainless 
steel needle (Small Part Inc., Logansport, IN) to obtain inlet/outlet holes. The 
PDMS mold was assembled and sealed to a 5075 mm cleaned glass slide by 
plasma bonding. 10 independent medium reservoirs (with 70 L capacity), one 
for each channel, were obtained by sealing an additional PDMS block to the top 
of the device by plasma bonding. The assembled device was cleaned with 
isopropanol (Sigma-Aldrich-Aldrich, St. Louis, MO) and sterilized in autoclave. 
Microfluidic channels were filled with 20% Matrigel Reduced Factor, MRF (BD) 
and incubated overnight at 4°C. Before cell seeding, protein solution was 
aspirated and microfluidic device was incubated at 37°C and 5% CO2 atmosphere 
for 1 h. 
Cellular reprogramming 
Send#1 hiPSCs were derived through Sendai viruses-mediated reprogramming. 
Human fibroblasts derived from skin-biopsy were plated and cultured in a 24-
well plate and cultured to 70% confluence in fibroblast medium (DMEM 
supplemented with 10% FBS). CytoTune iPS Sendai Reprogramming Kit (Life 
Technologies) based on replication incompetent Sendai virus was used to deliver 
the four transcription factors Oct4, Sox2, Klf4 and c-Myc and induce 
reprogramming to iPSc, according to manufacturer instructions. After 24h 
transduction, cells were fed every other day for 7 days. Transduced cells were 
then transferred onto inactivated MEF feeder cells at a density of 1 x 104 cells on 
a 6-well plate and expanded as reported below. mRNA#1 and mRNA#2 hiPSCs 
were generated through mRNA-mediated reprogramming following the protocol 
reported in Warren et al (2010)10. Briefly, inactivated human newborn foreskin 
dcEx
dt
 k1 cEx
dcEn
dt
 k2 cEn k5 cGt
dcTf
dt
 k1k2 cEx cEn k3
dcGt
dt
 k4 cTf k5 cGt











cEx(t 
i
f
)1
cEn(t 
i
f
) 0
cTf (t  0)  0.1
cGt (t  0)  0.1
i  0,1,..., N
(3) 
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fibroblast feeders (NuFF-RQ, AMS Biotechnology) were seeded in 6-well tissue 
culture plates, coated with gelatin 0.2%, at a density of 260 cell/mm2, and 
cultured in Dulbecco's modified Eagle medium (DMEM, Life Tecnologies) 
supplemented with 10% fetal bovine serum, FBS (Life Tecnologies). After 24 h, 
human foreskin BJ fibroblasts (Miltenyi Biotec) were seeded at 10 cell/mm2 and 
cultured in Eagle's minimal essential medium (EMEM, Life Tecnologies) with 10% 
FBS. After another 24 h, medium was switched to Pluriton reprogramming 
medium (Miltenyi Biotec) supplemented with B18R interferon inhibitor (Prodotti 
Gianni) at a final concentration of 200 ng/mL, and transfections using mmRNA 
(Miltenyi Biotec) were started and repeated for 18 days, 4 hours prior to daily 
medium changes. The transfection mix was prepared pooling two solutions: the 
first obtained diluting 5X 100 ng/µL mmRNA of  Oct4, Sox2, Klf4, c-Myc, Nanog, 
Lin28, and nuclear GFP in OptiMEM (Life Technologies), and the second diluting 
10X lipofectamine RNAiMAX (Life Technologies) in Opti-MEM. After mixing, the 
final solution was incubated for 15 min and then added to the culture medium. 
At day 6 after the first transfection, Pluriton reprogramming medium was 
replaced with B18R-supplemented NuFF-conditioned Pluriton medium, which 
was produced culturing in parallel NuFF cells in T75 flasks with Pluriton medium 
supplemented with bFGF (Peprotech) at 4 ng/mL. Two days after the last 
transfection, iPS colonies were picked and passaged to MEF-coated 12-well 
plates and expanded as reported below. 
HPSCs culture and integration in microfluidic devices 
HiPSCs ADHF#1 (obtained from Center for iPS Cell Research and Application, 
iCeMS, Kyoto University), Send#1, mRNA#1 and mRNA#2 and hESCs HES2 (from 
National Stem Cell Bank, Madison, WI) were cultured in gelatin-coated multiwells 
with mitomycin C-treated mouse embryonic fibroblasts (MEF; Chemicon) co-
culture, in DMEM F-12 (Life Technologies) supplemented with 20% KO serum 
(Life Technologies), 10% MEF conditioned medium (only for hES2), 20 ng/mL or 
10 ng/mL of basic fibroblast growth factor, bFGF (Life Technologies) for hESCs 
and hiPSCs respectively, 0.1 mM β-mercaptoethanol (Life Technologies), 1% non-
essential amino acid (Life Technologies) and 1% Pen/Strep (Life Technologies). 
HPSCs were passaged to new feeder using CTK solution (trypsin 0.25% - 
collagenase IV - Ca2+) for hiPSCs or trypsin 0.25% for hESCs (Life Technologies). 
HES2 cells were also adapted in feeder-free culture conditions using Essential 8, 
E8, medium (Stemcell Technologies). Celle were cultured in 50% Matrigel 
Reduced Factor, MRF, coated multiwall plates and passaged through EDTA 
0.5mM (Life Technologies). HPSCs were integrated within microfluidic devices by 
injecting cells suspension into each channel and incubating devices overnight at 
37°C and 5% CO2 atmosphere without perfusion, to allow cell adhesion. We used 
proper cell seeding concentration to achieve 70% confluence cell culture at 24 h 
after seeding. A 11-port pump (Cavro® XLP pump, TECAN, San Jose, CA) was used 
to independently deliver the medium from the reservoirs into each microfluidic 
channels. 0.5 ID Tygon tubings (Cole-Parmer, Vernon Hills, IL) and 21G stainless-
steel needles with a polypropylene luer (Microtest, Taipei, Taiwan) were used to 
connect the microfluidic chip to the pump. Discontinuous medium delivery with 
defined temporal frequencies was achieved by automatically controlling the 
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multi-channel syringe pump through LabView 8.2 (National Instruments, Austin, 
TX). Every medium change was performed using a flowrate of 6 L min-1 for 2 
min, which corresponds to perfuse the twice the equivalent of channel volume. 
For pluripotency maintenance, hPSCs were cultured with f=2d-1.  
HPSCs differentiation into germ layers 
For spontaneous differentiation, no exogenous factors and cytokines were 
used. Basal medium was composed of KnockOut DMEM, FBS 20%, NEAA 1%, L-
glutamine 0,5% and P/S 1% (all from Life Technologies). Ectoderm differentiation 
was induced with DMEM F-12 and Neurobasal medium (both from Life 
Technologies), 1:1 ratio, supplemented with 1% B27 (Life Technologies), 1% N2 
(Life Technologies) and β-met 0.1 mM11,12. Mesoderm differentiation was 
induced with StemPro-34 (Life Technologies) supplemented with 2 mM L-
glutamine (Life Technologies), transferrin 200 ng/mL, 0.5 mM ascorbic acid 
(Sigma-Aldrich), Activin-A 0.3 ng/mL (R&D) and BMP-4 3 ng/mL (R&D)13. 
Endoderm differentiation was induced with RPMI1640 containing 1% B27 (both 
from Life Technologies), 1mM sodium butyrate, NaB (Sigma-Aldrich), 100 ng/ml 
Activin-A (Peprotech) and 50 ng/mL Wnt3a (R&D)14 for the first 2 days. The 
second endoderm medium was KO DMEM with KO serum 20%, L-glutamine 1 
mM, NEAA 1%, DMSO 1%, β-met 0.1 mM, P/S 1% for other 2 days. HPSCs 
specification was induced for 4 days in all three germ layers.  
Cardiac and hepatic specification 
For cardiac differentiation cells were cultured with in RPMI/B27 w/o insulin. 
After 24 h, the medium was changed to RPMI/B27 w/o insulin supplemented 
with 5 ng/mL BMP4 (R&D) for another 4 days. At day 5, the medium was 
changed to RPMI/B27 w/o insulin. At day 7 the cells were transferred to 
RPMI/B27 complete and cultured for other 10 days15. From day 12-15 cells start 
contracting spontaneously. Endoderm differentiation was induced with 
RPMI1640 containing 1X B27 (both from Life Technologies), 1 mM sodium 
butyrate (Sigma-Aldrich), 100 ng/ml ActivinA (Peprotech), 50 ng/mL (R&D) 
Wnt3a and 1% P/S for 1 day, then changed to the same medium with reduced 
0.5 mM sodium butyrate for 2 days. Medium was changed to KO-DMEM, 20%SR 
(both from Life Technologies), 1 mM L-glutamine, 1% NEAA, 0.1 mM β-met, 1% 
DMSO (Sigma-Aldrich) and 1% P/S for 6 days. Hepatic-like cells were maturated 
with L15 medium (Sigma-Aldrich) supplemented with 8.3% FBS, 8.3% tryptose 
phosphate broth, 10 µM hydrocortisone 21-hemisuccinate, 1 µM insulin (all from 
Sigma-Aldrich) and 2 mM L-glutamine containing 10 ng/ml hepatocyte growth 
factor and 20 ng/ml oncostatin M (both from R&D) and 1% P/S for 6 days6. For 
adult specification and maturation, cells were cultured with f=2d-1 maturation 
medium change. The functional differentiation of cardiac and hepatic cells was 
performed in 30 and 50 independent microfluidic experiments, respectively. 
HepG2 cell culture 
HepG2 cells were cultured in 0.6% gelatin-coated glass slides in 24-well plates 
for static culture and gelatin-coated micro-channels for microfluidic culture. Cells 
were expanded in DMEM 88%, FBS heat inactivated 10%, NEAA 1% and P/S 1%. 
Glucose and metabolites analysis 
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Media glucose concentration was measured with FreeStyle Lite glucometer and 
stripes (Abbott). Enzimatic detection of ammonia and L(+)-Lactate 
concentrations in exhaust media were performed through Ammonia assay kit 
(AA0100, Sigma-Aldrich) and Lactate assay kit (MAK064, Sigma-Aldrich), 
respectively, following manufacturer’s instructions.  
Functional tests 
HPSCs-derived cardiomyocytes were analyzed at confocal microscopy (Leica 
SP5) for calcium transient during caffeine and verapamil treatments16. HPSCs-
derived hepatocyte-like cells were stained with PAS staining (Sigma-Aldrich) 
according to manufacturer’s instructions, for glycogen storage analysis. 
Indocyanine green test, ICG, (Sigma-Aldrich) was performed by incubating living 
cells for 15 min with dye solution, according to manufacturer’s instructions. 
Green cells retaining ICG were photographed. After 6 hours, same fields were 
photographed in order to see complete clearance of ICG by functional 
hepatocyte-like cells. Albumin production and secretion was assessed by 
collection of spent medium (10 L from each micro-channel) and performing 
enzyme linked immune-sorbent ELISA assay (Immunology Consultants 
Laboratory, Inc.) following manufacturer’s instructions. Albumin levels were 
detected at 450 nm by using plate reader Infinite F2000 PRO (Tecan). 
Cytotoxicity experiments were performed using hepatotoxic acetaminophen 
drug, on HepG2 cells and hESC-derived hepatocyte-like cells. Acetaminophen 
BioXtra ≥99.0% (Sigma-Aldrich) was dissolved in DMSO to a 5 M starting solution. 
Following dilutions of 50, 25, 12.5, 10, 5, 1, 0.5 mM were done on HepG2 culture 
medium, and hepatic maturation medium for hepatocyte-like cells. As controls, 
untreated cells were cultured in their media, and control cells were treated with 
only DMSO 1% diluted in media. Cells were treated for 24h at f=2d-1 or with 
multiple 3h administrations using a multiple-port microfluidic switch17. For 
nuclear area calculation, treated cells were fixed and stained with Hoechst, and 
fluorescence images were taken at 80X magnification. For cytotoxic effects on 
cell morphology and integrity, treated cells were fixed and stained with 
phalloidin for f-actin and albumin. Live and dead assay (Life Technologies) was 
performed on living cells after 24h, for dead cells quantification. Cell were 
washed with PBS and incubated with 4 M ethidium homodimer-1 (stains red 
dead cells), 4 M calcein AM (stains green live cells) and 4 M Hoechst (stains 
blue cell nuclei) for 45 min at room temperature. Cells were then washed with 
PBS and analyzed at fluorescence microscopy. Cytotoxicity was expressed as 
fraction of dead cells over total cells per 20X image. 
Luciferase assay 
CAGA12 SMAD2/3 reporter HaCaT cell line were obtained form Stefano 
Piccolo’s Lab (Department of Molecular Medicine, University of Padova) cultured 
in DMEM supplemented with 10% FBS18,19. For luciferase assay cells were plated 
in 12-well plates at 70% confluency and incubated overnight in DMEM without 
serum and then treated with media containing recombinant Tgf1 (Peprotech) or 
Tgf receptor inhibitor SB431542 (Peprotech) or to conditioned medium for 8 h. 
In the last case media were heat-treated for 5 min at 95°C. Luiferase expression 
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was detected as described in Inui et al.19. Data were normalized on total protein 
content, determined through Bradford assay. 
Immunofluorescence 
Immunofluorescence analyses were performed on paraformaldehyde 4% fixed 
cells for 15 min. Blocking and permeabilization was performed with 5% heat 
inactivated bovine fetal serum, TritonX-100 (Sigma-Aldrich) 0.1% for 1h. Cells 
were stained using primary antibodies in blocking buffer 1 h room T, or overnight 
4°C, depending on the antibody: Oct4 1:200 (sc-5279 Santa Cruz), Sox-2 1:200 
(AB5603 Millipore), Tra-1-60 1:200 (MAB4360 Millipore), Tra-1-81 1:200 
(MAB4381 Millipore), -III tubulin 1:500 (T3952 Sigma-Aldrich), -fetoprotein 
1:250 (A8452 Sigma-Aldrich), Brachyury 1:100 (ab20680 Abcam), cardiac 
troponin T 1:100 (MS-295-P Thermo Scientific), albumin 1:100 (MAB1455 R&D), 
CYP-3A 1:150 (GTX117120 Genetex), cytokeratin-18 1:150 (GTX105624S 
Genetex). For SOX17 (AF1924, R&D) and FOXA2/HNF3b (D56D6, Cell Sgnaling) 
staining, cells were incubated in 5% horse serum in 0.3% TritonX-100 blocking 
solution for 1h at room temperature. Primary antibodies were diluted 1:400 and 
1:20 respectively and incubated in 1% BSA in 0.3% TritonX-100 overnight at 4°C. 
Immuno-staining was done with secondary antibodies Alexa Fluor 488, 594 (Life 
Technologies) and Cy3 (Jackson ImmunoLab) and DAPI nuclear staining 
incubation for 1 h at 37°C. Pictures were taken on Leica DMI 6000 B. 
Gene expression analysis 
For RNA extraction, cells were lysed with 0.5 mL of TRIzol (Life Technologies) 
per replicate and incubated with 0.1 mL of chloroform (Sigma-Aldrich) for 3 min. 
Cells were centrifuged at 12500 g for 15 min at 4°C. Aqueous supernatant was 
collected and diluted 1:1 with 70% ethanol. Total RNA was then extracted from 
solution using RNeasy Mini Kit (Qiagen), following manufacturer’s instructions. 
RNA was quantified using NanoDrop spectrophotometer and quality for each 
extraction was assessed. RNA was used with A(260/280)nm = 2.0  0.1, 
A(260/230)nm = 2.0  0.1 and A(320)nm  0.05. RNA retro-transcription was 
performed using the High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies), according to manufacturer’s instructions. The qRT-PCR was 
performed with TaqMan gene expression assay probes (Life Technologies) 
according to manufactures instructions. Following genes were used: GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase), POU5F1 (OCT4), NANOG 
(homeobox protein NANOG), DNMT3B (DNA cytosine-5-methyltransferase 3 
beta), TUBB3 (beta-III tubulin), OTX2 (orthodenticle homeobox 2), T 
(BRACHYURY-T), GATA4, ACTA2 (alpha-smooth muscle actin), AFP (alpha-
fetoprotein), EOMES, FOXA2 probe sets (all from TaqMan Life Technologies). 
Reactions were performed on ABI Prism 7000 machine and results were analyzed 
with ABI Prism 7000 SDS software. GAPDH expression was used to normalize Ct 
values of gene expression, and data were shown as relative fold change to 
control cells, using the delta-delta Ct method. 
Statistical analysis 
For statistical analyses, single pairwise comparisons were analyzed using 
Student's t-test with P < 0.05 (*) or P < 0.01 (**) indicating significance. Multiple 
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comparisons were performed by one-way ANOVA with Tukey post-test, with P < 
0.05 (*) or P < 0.01 (**) indicating significance. The number n used throughout 
the text indicates the number of independent biological replicates, referred to 
experiments performed on different chips (with different passages of cells) and 
on different independent channels within the same chip (with same passages of 
cells).  
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Main figures 
Figure 1 | Culture of human pluripotent stem cell on a chip. (a) Hypothetic pluripotency-
aasociated signaling model in microfluidic stem cell culture. Both exogenous (Ex) and 
endogenous (En) factors, with frequency-dependent concentration, contribute to transcriptional 
activity of pluripotency genes through activation of target transcription factors (Tr). Black arrows 
indicate chemical reactions involved in the pathway. Reactions (1) and (2) describe the coupling 
of exogenous, Ex, and endogenous, En, factors to specific membrane receptors, which promote 
the activation of transcriptional factor, Tr. Tr is also activated at a basal level through reaction (3) 
and induces expression of pluripotency-associated genes through reaction (4). Gene transcripts, 
Gt, produce newly En, as indicated by reaction (5). (b) Temporal profiles of normalized Ex and En 
factors concentrations in the microfluidic channel at increasing frequencies. Low frequencies 
promote endogenous factors accumulation and depletion of exogenous factors, compared to 
higher frequencies, which allow sustained exogenous factors supply, but continuous endogenous 
factors wash out, leading to different level of mean concentration values over time (straight 
lines). (c) Experimental set-up. Medium delivery in microfluidic platform is controlled by a multi-
port delivery system with 10 independent operating channels and 1 single discharge channel. 
Flow rate, frequency of medium delivery, temporal delay between cycles and total number of 
cycles are set independently in every channel and automatically controlled through Labview 
software. (d) HESCs and hiPSCs were integrated within microfluidic channels and expanded up to 
6 days with f=2d-1. Insets show maintenance of typical stem cells colonies morphology. Scale bar 
100 m. (e) HESCs and hiPSCs immunofluorescence analysis of pluripotency markers OCT4, SOX2, 
TRA-1-60 and TRA-1-81 after 6 days in microfluidic channels. Scale bar 50 m. (f) Frequency-
dependent qRT-PCR analysis of pluripotency markers OCT4, NANOG and DNMT3B expression 
after 6 days of hES2 cells culture. An optimal frequency of 2d-1 has been observed, which allows 
the highest OCT4, NANOG and DNMT3B expression levels comparable to standard static 
conditions. Data are normalized on GAPDH expression. A statistical higher OCT4 expression for 
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f=2d-1, compared to all other frequencies and continuous perfusion (CP), and NANOG expression 
for f=2d-1, compared to f=1d-1 f=4d-1 f=8d-1, and CP, was observed. Data are shown as mean ± s.e. 
(n=6). ((g) HES2 cells were first seeded in microfluidic channels and cultured with f=2d-1. Exhaust 
medium was collected from at least 4 micro-channels (8L per channel) every 12h for 5 days and 
stored at 4°C. This conditioned medium was subsequently used to culture HES2 cells with f=8d-1. 
HES2 cells cultured in non-optimal frequency conditions, i.e. f=8d-1, with conditioned medium 
(f=8d-1 conditioned) collected from HES2 cutured in optimal condition (f=2d-1) display a significant 
3-fold OCT4 expression increase and a higher but not significant NANOG expression increase 
compared to cells cultured with fresh medium (f=8d-1). Data are normalized on GAPDH 
expression. Data are shown as mean ± s.e. (n=6) (h) Luciferase assay based on the CAGA12 
SMAD2/3 reporter HaCaT cell line. HES2 cells were adapted in feeder-free culture conditions 
using defined Essential 8 (E8) medium, plated in microfluidic channels or in Petri dish and 
cultured in E7 medium, which has the same composition of E8 medium but without addition of 
exogenous recombinant TGF1. Conditioned media were collected from Petri dish and 
microfluidic culture in two different conditions, i.e. f=8d-1 and f=2d-1, and heat-treated to induce 
latent TGF activation28. The amount of the TGF/Activin/Nodal ligands was indirectly quantified 
by exposing CAGA12-luciferase HaCaT cells to the collected media. f=2d-1 medium contained 
higher amounts of TGF ligands compared to both f=8d-1 and Petri dish. Fresh E8 and E7 media 
(with no TGF1) were used as positive and negative controls. Addition of the small-molecule 
TGF receptor inhibitor SB431542 confirms that the inductions are caused by extracellular 
factors in the medium. Data are normalized on total protein content, determined through 
Bradford assay. See Supplementary Fig. S3 for controls of the heat-activation procedure. Data are 
shown as mean ± s.e. (n=6). (i) QRT-PCR analysis of NANOG expression of hES2 cells cultured in 
feeder-free conditions with E8 medium or E7 medium (in absence of TGF) in microfluidic 
channels and in Petri dish. Compared to standard conditions a significant higher NANOG 
expression was achieved in microfluidic culture compared to static conditions and by using f=2d-1 
compared to f=8d-1. NANOG expression in f=2d-1 conditions using E8 medium confirmed the result 
shown in Fig. 1f, in which standard non-defined medium was used. Data are shown as mean ± s.e. 
(n=6). 
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Figure 2 | Early germ layer induction of hESC on-a-chip. (a) Frequency-dependent differentiation. 
Schematic of frequency, f, relation to En and Ex factors balance (up). The qRT-PCR analysis (gene 
expression normalized on GAPDH) of β-III tubulin and OTX2 for ectoderm, brachyury T, GATA4 
and alpha-smooth muscle actin for mesoderm, alpha-fetoprotein, EOMES and FOXA2 for 
endoderm in hESC spontaneous differentiation on chip, under different f. Cell morphology in 
phase contrast for each differentiation condition. Scale bar 50 µm. Data are shown as mean ± s.d. 
(n=6). (b) Early germ layer induction with specific media. QRT-PCR analysis of β-III tubulin, 
BRACHYURY-T and AFP, and comparison between standard static control and microfluidic 
condition. Data are shown as mean ± s.d. (n=6). (c) Specific differentiation markers expression. 
Differentiation protocols applied on hESC line cultured on micro-channels. Immunofluorescence 
analysis of each differentiation protocol, with expression of β-III tubulin in ectoderm, 
BRACHYURY-T in mesoderm and AFP in endoderm. Scale bar 50 µm. (d) Mesoderm microfluidic 
optimization. QRT-PCR analysis of BRACHYRY-T expression at different frequencies of medium 
change for germ layer commitment optimization. BRACHYRY-T expression is comparable 
between f=2d-1 and f=3d-1, while there is a significantly lower expression at higher and lower 
frequencies. Data are shown as mean ± s.d. (n=6).  
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Figure 3 | Cardiac and hepatic functional differentiation on-a-chip. (a) Microfluidic cardiomyocyte 
differentiation protocol and morphology changes from pluripotent state to differentiated cell 
type. Scale bars 200 m. (b) Immunofluorescence of hES-derived CM showing cardiac troponin T 
organization (scale bars 20 m). CTNT positive cells immunofluorescence quantification results in 
65.4 ± 11.9% (s.d. n=6). (c) Microfluidic calcium dynamics. Spontaneous calcium transients in 
hESC-cardiomyocytes recorded with Fluo-4 indicator. Functional cardiomyocytes response to 0.5 
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µM verapamil with reduction in calcium release, and to 10 mM caffeine with increase in cytosolic 
calcium. (d) Hepatic differentiation protocol and cell change in morphology up to hepatocyte-like 
cells. Red arrows indicate bi-nucleated cells in late stages.  Scale bars 200 m. (e) 
Immunofluorescence stain for hepatocyte-like markers albumin and cytochrome P450-3A. Scale 
bars 20 m. (f) Periodic acid-Schiff stain of hepatic cells derived on chip; nuclei are stained in 
blue, pink-violet colored cells show glycogen storage. Indocyanine green staining (ICG) of live 
hepatic cells. Colorant is absorbed and metabolized in 6 h by functional hepatocyte-like cells. (g) 
ELISA albumin secretion quantification [ng/mL/day/2x105 cells]. Microfluidic-derived hepatocyte-
like cells secrete 40% more albumin, than in static control at the last day of differentiation. Data 
are shown as mean ± s.d. (n=6). (h) Quantification of immunofluorescence markers. Microfluidic 
hepatic cells show significant higher expression of ALB and CYP-3A compared to static control. 
Data are shown as mean ± s.d. (n=10). (i) Concentration-dependent cytotoxicity of 
acetaminophen in hepatocyte-like cells. Higher degree of maturation is shown by microfluidic-
cultured cells, which respond linearly to drug concentration compared to static culture, when 
exposed to constant 24 h treatment at f=2d-1. Data are shown as mean ± s.d. (n=6). (j) 
Microfluidics allows multiple administrations in the 24 h for dose-dependent cytotoxicity of 
acetaminophen in hepatic cultures. Four administrations per day result in higher concentration-
dependent cytotoxicity compared to reduced (3, 2, 1) administrations. According to 2-way 
ANOVA test, group 4 results significantly different from the other 3 groups (P<0.01). In group 4, 
data at 5, 10 and 25 mM are significantly different from control and 1 mM. Data are shown as 
mean ± s.d. (n=6). 
Supplementary figures 
Fig. S1 | Discontinuous vs. continuous perfusion culture in microfluidic channel. (a) Cell colonies 
morphology and nuclei distribution of hES2 cells cultured with continuous perfusion (flowrate 
8nL/min) and discontinuous flow (f=2d-1) for 72h. In order to make a fair comparison between 
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the two conditions, we used in both experiments the same overall amount of medium (12µL per 
day). By using continuous perfusion, HES2 cell line shows OCT4 and NANOG expression, but high 
inhomogeneity of cell growth is present along the channel, with higher growth at the inlet 
compared to the outlet. Scale bars 100 µm. (b) Graphs showing measurement of HES2 colonies 
diameters at inlet, center and outlet of micro-channels, after continuous perfusion and 
discontinuous medium change for 72 h. Colonies in continuous perfusion show high 
inhomogeneity, with statistically significant differences between each paired conditions. Data are 
shown as mean ± s.d. (n=12). 
Fig. S2 | Pluripotency marker expression in human pluripotent stem cells cultured in micro-
channels with f=2d-1. (a) HES2 cells showing OCT4 and SOX2 expression. (b) ADHF#1 hiPS cell line 
showing OCT4 and SOX2 expression. High homogeneity in markers expression is shown along the 
micro-channels with no upstream and downstream effects (quantitative analysis of OCT4 and 
SOX2 mean fluorescence intensity between inlet and outlet show differences smaller than 10%). 
Scale bars 100 µm. 
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Fig. S3 | Signaling model output. Temporal profiles of normalized Ex and En factor concentrations 
in the microfluidic channel at increasing frequencies (top). Gene transcript (Gt) concentration 
profile plotted versus corresponding Transcription factor (Tr) variation during a single medium 
perfusion at increasing frequencies. C tilde represents normalized concentration. 
 
Fig. S4 | Glucose and metabolites (ammonia and lactate) analyses of conditioned media collected 
from hESCs cultured in microfluidic channels, compared to static culture in Petri dish. HES2 cells 
were plated into microfluidic platforms and in standard Petri dish with same cell density and 
cultured up to 5 days. Conditioned media were sampled from Petri dish after 24h every day and 
from microfluidic channels after every perfusion cycle. Specifically, 8 L exhaust medium were 
collected from each channel every 3, 12 or 24h corresponding to f=8, 2, 1d-1 for 5 days from cells 
seeding. Fresh medium was used as positive (for glucose) or negative (for ammonia and lactate) 
control. (a) Glucose concentration of medium inside a microfluidic channel (with no cells seeded) 
is equivalent to fresh medium. Glucose concentration of medium in microfluidic channel 
collected at the end of the cycle of perfusion is reported for three different frequencies of 
medium change. Interestingly only a 25% statistical decrease of glucose concentration was 
observed for low frequencies f=2d-1 and f=1d-1, compared to standard condition in Petri Dish. (b) 
Ammonia and lactate concentrations result equal or lower than those measured in static culture 
for every condition analyzed. Surprisingly, ammonia concentration (left) results statistically lower 
in media collected from micro-channels than that collected in static condition. This is probably 
due to the high ammonia diffusion through in PDMS1, which causes ammonia depletion from 
micro-channels. Lactate concentration (right) in exhaust medium of micro-channels is 
comparable or lower than the one observed in standard Petri dish. Data are shown as mean ± s.d. 
(n=6).  
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Fig. S5 | Determination of the optimal conditions to detect Tgfβ ligands present in conditioned 
media. Tgfβ ligands are secreted from cells in a latent form that is not able to bind and activate 
Tgfβ receptors. To measure its biological activity, it is thus necessary to release Tgfβ ligands from 
the latency-associated peptide (LAP), either by heat treatment or medium acidification2,3,4,5. (a) 
We first checked which method was less detrimental for the activity of recombinant Tgfβ1 (i.e. of 
the ligand in absence of LAP), by using active recombinant Tgfβ1 (1ng/mL), either untreated (NT) 
or treated (95°C or acid pH). Media were then added to HaCaT cells bearing the stable SMAD2/3 
CAGA12-luciferase reporter. Addition of the Tgfβ receptor inhibitor SB431542 (10M, +SB) to 
untreated medium sets the reporter background in absence of any SMAD activation. Acid 
treatment was detrimental for exogenous recombinant Tgfβ activity and excluded from further 
analyses. (b) E7 medium without exogenous Tgfβ1 was conditioned by hES2 cells, cultured in 
standard Petri Dish in feeder-free conditions, and used to treat HaCaT CAGA12-luciferase cells for 
8h. Untreated conditioned medium (E7) was barely active; heat-treatment of the same medium 
(95°C) instead released latent Tgfβ ligands and caused a strong activation of the SMAD2/3 
reporter; addition of the Tgfβ receptor inhibitor to the heat-activated medium (+SB) ensures that 
luciferase activation depends on extracellular factors. Data are normalized on total protein 
content, determined through Bradford assay. Data are shown as mean ± s.d. (n=3). 
Fig. S6 | Germ layer specification with conditioned media in microfluidics. (a) Experimental 
design. HES2 cells were plated in microfluidic chips, cultured for 3 days and induced to 
differentiate into early germ-layers under spontaneous differentiation conditions for 4 days as 
reported in experiment of Fig.2a. During spontaneous differentiation, fresh medium was 
perfused with f=1d-1 and f=8d-1. Conditioned medium was collected from the f=1d-1 experiment, 
diluted with 1:1 ratio with fresh medium and used to differentiate same cells with f=8d-1 as 
schematically shown. (b) Expression of representative genes for each germ layer (OTX2 for 
ectoderm, BRACHYURY-T and EOMES for meso-endoderm) measured through realtime PCR 
analysis. Consistently with data reported in Fig.2a, OTX2 results more expressed at low 
frequency. Conversely, higher frequency promotes BRACHYURY-T and EOMES markers 
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expression. By using conditioned medium, a significant 2.5-fold OTX2 expression increase and a 
3-fold BRACHYURY-T decrease were observed. These data support the hypothesis that 
conditioned medium containing higher accumulation of cell-secreted endogenous factors induces 
cell fate switch between ectoderm and meso-endoderm commitment even at high frequency. 
Data are shown as mean ± s.e. (n=6). 
Fig. S7 | Cell homogeneity during differentiation in endodermal differentiating hESCs. (a) 
Differentiation at f=4d-1 in micro-channels at day 4 of early endoderm. Cells show high and 
homogenous expression of alpha-fetoprotein (quantitative analysis of AFP mean fluorescence 
intensity between inlet and outlet show differences smaller than 15%, which is within 
experimental variability). (b) Day 10 of definitive endoderm commitment. Cells show polygonal 
epithelial shape at day 10 along microfluidic channel, and homogenous cell distribution. Scale 
bars 100 µm.  
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Fig. S8 | Endoderm differentiation in static vs. microfluidic culture condition. HES2 cells were 
seeded in 24-well plates or microfluidic channels and induced to differentiate into endoderm 
after 3 days. Six different differentiation protocols were tested in order to demonstrate possible 
advantages of microfluidic environment in terms of cells vitality (final number of cells/initial 
number of cells) and efficiency of 5-days endoderm specification. Basal medium for endoderm 
commitment contain high concentration of Activin-A (100ng/mL) and Wnt3a (50ng/mL) for the 
first 2 days and Activin-A (100ng/mL) for the following 3 days. A frequency of 4d-1 was used for 
microfluidic differentiation. Different basal medium supplementations include B27-supplement, 
FBS (not chemically defined) and KSR at two different concentrations, i.e. 0.5 and 5%. Efficiency 
of endoderm specification after 5 days was determined by double immuno-staining with 
endoderm-specific markers SOX17 and FOXA2. B27-supplement with sodium buthyrate (NaB) 
was previously used for specific endoderm commitment (Fig.2c), ensuring high efficiency near 
100% both in static and microfluidic condition. However, addition of NaB, which is recognized to 
promote homogeneous hepatocyte differentiation and, if combined with Activin-A, an efficient 
definitive endoderm commitment6, causes dramatic cell death upon treatment both in static and 
microfluidic condition, whereas NaB removal allows increased cell survival and reduced 
efficiency. Nevertheless, a statistical significant 4-fold increase of SOX17+/FOXA2+ cells was 
observed in microfluidic channels compared to standard Petri dish. Low concentration FBS-
supplemented medium is widely employed for endoderm commitment, as higher concentrations 
inhibit endoderm commitment, even though promoting cell survival7. Consistently, increasing FBS 
concentration promotes cell survival and proliferation, whereas reducing efficiency in static 
condition. Surprisingly, intermittent perfusion allows increased proliferation compared to Petri 
dish and efficiency comparable with that obtained in low serum condition. Particularly, a 
significant 4-fold increase of SOX17+/FOXA2+ cells in microfluidic compared to static condition 
was observed, when 0.5% FBS supplementation is used. Knock out serum replacement (KSR) is 
also recognized to inhibit hESCs differentiation and promote self-renewal, by means of PI3K 
signaling activation8. Again, a significant 3-fold increase of SOX17+/FOXA2+ cells in microfluidic 
compared to static condition was observed, with 0.5% KSR supplementation. No significant 
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differences were observed with higher concentration of KSR. Scale bars 100m. Data are shown 
as mean ± s.e. (n=6). 
 
Fig. S9 | Comparison between different cell lines differentiated in hepatocyte-like cell through 
microfluidic technology. (a) Immunofluorescence panel shows cell morphology in bright field and 
F-ACTIN (green) staining, and hepatic markers (red) CYTOKERATIN-18 and ALBUMIN. 
Differentiated cell lines are HES2 (human embryonic stem cell line) and human induced 
pluripotent stem cell lines ADHF#1 (adenovirus-derived), Send#1 (Sendai virus-derived), 
mRNA#1-2 (modified mRNAs-derived). (b) Graph shows ELISA quantification of secreted human 
albumin for the different cell lines at day 16 of differentiation. Scale bar 75 µm. Data are shown 
as mean ± s.d. (n=6). 
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Fig. S10 | Comparison between standard static (a) and microfluidic (b) hepatocyte-like cells. 
HESC-derived hepatocyte-like cells differentiated in standard Petri dish condition cells show 
similar expression of CK-18 hepatic endoderm marker compared to microfluidic condition. 
Microfluidic hepatocyte-like cells show higher expression of albumin and CYP-3A compared to 
standard static differentiated cells. 
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Fig. S11 | HepG2 cell line drug treatment. (a) Graph showing cell death in response to 
acetaminophen cytotoxicity in HepG2 cell line after 24 h treatment. Control cells (CTR) were 
cultured in medium with DMSO 1% (drug solvent), while treated cells were cultured with growing 
acetaminophen concentrations (0.5, 1, 12.5, 25, 50 mM). After live and dead assay calculation, no 
notable differences in dead cell fraction are found between static control cells and microfluidic 
cultured cells (at f=2d-1). (b) HepG2 treated with different hepatotoxic acetaminophen drug 
concentrations for 24 h. Untreated cells were cultured in standard culture medium, control cells 
were cultured in medium with DMSO 1% and treated cells were cultured with growing 
acetaminophen concentrations (1, 25, 50 mM). Nuclei areas of static control cells and 
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microfluidic cultured cells were calculated and represented as probability density function (top) 
and cumulative density function (bottom). Cell nuclei area diminishes at higher acetaminophen 
concentrations in response to growing cell cytotoxicity (50 mM static data is missing because of 
cell detachment). The reduction in nuclear area at growing drug concentrations is more 
appreciable and clean in microfluidic cultured cells, compared to static control cells. 
 
 
Fig. S12 | Drug treatment of HESC-derived hepatocyte-like cells in microfluidic condition. 
Immunofluorescence panel shows f-actin staining for cell morphology (green) and albumin (red) 
in cells treated with different acetaminophen concentrations at day 22 of differentiation, for 24 h 
at f=2d-1. At growing drug concentrations cell morphology is disrupted, in response to 
acetaminophen cytotoxicity, especially at 25 mM with almost complete loss of cell structure and 
function. Scale bar 30 µm. 
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Abstract 
Duchenne muscular dystrophy (DMD)–associated cardiac diseases are emerging 
as a major cause of morbidity and mortality in DMD patients, and many therapies 
targeted to skeletal muscle failed to improve cardiac function. The 
reprogramming of patients’ somatic cells into pluripotent stem cells, combined 
with technologies for correcting the genetic defect, possesses great potential for 
the development of new treatments for genetic diseases. In this study, we 
obtained human cardiomyocytes from DMD patient– derived, induced 
pluripotent stem cells genetically corrected with a human artificial chromosome 
carrying the whole dystrophin genomic sequence. Stimulation of cytokines was 
combined with cell culturing on hydrogel with physiological stiffness, allowing an 
adhesion-dependent maturation and a proper dystrophin expression. The 
obtained cardiomyocytes showed remarkable sarcomeric organization of cardiac 
troponin T and α-actinin, expressed cardiac-specific markers, and displayed 
electrically induced calcium transients lasting less than 1 second. We 
demonstrated that human artificial chromosome carrying the whole dystrophin 
genomic sequence is stably maintained throughout the cardiac differentiation 
process and that multiple promoters of the dystrophin gene are properly 
activated, driving expression of different isoforms. These dystrophic 
cardiomyocytes can be a valuable source for in vitro modeling of DMD-associated 
cardiac disease. Furthermore, the derivation of genetically corrected, patient-
specific cardiomyocytes represents a step toward the development of innovative 
cell and gene therapy approaches for DMD. 
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Introduction 
 
Duchenne muscular dystrophy (DMD) is one of the most common and severe 
inherited neuromuscular disorders, affecting 1 in 3,500 newborn males. DMD is 
caused by mutations in the dystrophin gene encoding a key structural protein of 
the dystrophin glycoprotein complex, which connects the contracting 
cytoskeletal machinery of skeletal and cardiac muscle fibers to the extracellular 
matrix scaffold.1 The absence of dystrophin in DMD patients causes a broad 
spectrum of physical consequences, eventually leading to a premature death.2 
Approximately 20% of deaths are the result of cardiomyopathies and/or cardiac 
conduction abnormalities. The increased life span of patients affected by DMD 
allowed by the improvements in treatments of respiratory muscle disease made 
cardiomyopathies (present in ~90% of patients) emerge as a major cause of 
morbidity and mortality.3 In addition, many experimental therapies have mainly 
focused on skeletal muscle, aiming at the restoration of dystrophin expression in 
myofibers, and have failed to improve cardiac function.4 Derivation of DMD 
patient–specific cardiomyocytes (CMs) and the correction of their genetic defect 
could provide a valuable cell source for in vitro modeling and for studying DMD-
related cardiac dysfunctions, in addition to potentially representing a significant 
advancement toward an effective therapy for DMD-associated 
cardiomyopathies. The efficient reprogramming technology pioneered by 
Yamanaka and colleagues5 opened the perspective of deriving large numbers of 
disease-specific human cells in vitro. Human induced pluripotent stem (hiPS) cells 
are recently emerging as an ideal cell source for the generation of clinically 
relevant cardiac disease models.6 Several recent studies demonstrate how hiPS 
cell–derived CMs can be used for modeling the pathological phenotype of 
inherited cardiac disorders, such as the LEOPARD syndrome,7 type 1 and 2 long 
QT syndrome, 8–10 catecholaminergic polymorphic ventricular tachycardia, 11 
arrhythmogenic right ventricular dysplasia/cardiomyopathy,12 and the dilated 
cardiomyopathy.13 However, to our knowledge, CMs from DMD patient–derived 
hiPS cells have never been obtained so far. Moreover, disease-specific hiPS cell–
derived cells could represent a platform for studying in vitro the pathological 
dystrophic phenotype and for testing and validating the therapeutic approaches 
and their efficiency in restoring the normal phenotype.14 In addition, it has been 
recently demonstrated that hiPS cell–derived CMs can efficiently integrate in 
injured hearts of a guinea pig,15 providing a proof of principle for the application 
of these cells in regenerative medicine aiming at the treatment of cardiac 
dysfunctions. In the perspective of a therapeutic application, the genetic defect 
of CMs derived from inherited disease–specific hiPS cells should be corrected 
before these cells are reengrafted in the patient. DMD is among the most 
difficult genetic diseases to treat, and the dystrophin gene is the largest gene 
described in the human genome. Promising results have been obtained in rodent 
models of Duchenne cardiomyopathy using adeno-associated viruses carrying 
minimized synthetic dystrophin genes (mini- and microdystrophin).16 These 
approaches do not allow the insertion of a complete functional version of the 
dystrophin gene. On the other hand, exon-skipping approaches,17 which redirect 
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the gene processing bypassing the mutation, can be applied only to defined 
ranges of patients, based on their specific mutations. Several studies suggest that 
utrophin may help in the preservation of heart function in young adult mdx mice 
and heterozygous mdx mice.18,19 However, similar to dystrophin, the large size 
of the utrophin gene also presents a significant challenge to gene delivery.16 
Other approaches for the treatment of Duchenne cardiomyopathy include the 
forced expression of sarcoendoplasmic reticulum calcium-ATPase via adeno-
associated virus gene transfer, aimed at restoring calcium homeostasis and 
improving cardiac contractility,20 without correction of the genetic defect. A 
highly promising gene delivery tool for the correction of the DMD gene is 
represented by human artificial chromosomes (HACs). HAC is an artificially 
created exogenous minichromosome having the ability to replicate and 
segregate autonomously in target human cells and to be stably maintained at 
episomal level, without integration into the host genome. In addition, HACs have 
the capacity to carry large genomic loci with all their regulatory elements.21 An 
HAC vector carrying, for the first time, the whole dystrophin genomic locus 
including the associated regulatory elements (DYSHAC) was developed by 
Hoshiya et al.22 Furthermore, Kazuki et al.23 have demonstrated the complete 
correction of hiPS cells derived from a DMD patient, using the DYS-HAC, 
pioneering an innovative and promising therapeutic approach for the treatment 
of DMD and DMD-associated cardiac diseases. The first preclinical proof of safety 
and efficacy of DYS-HAC– mediated therapy has been provided by Tedesco et 
al.24 In this study, the authors showed a significantly ameliorated phenotype in 
the mdx dystrophic mouse model after the transplantation of mdx 
mesoangioblasts genetically corrected with the DYS-HAC. In addition, the same 
group recently reported the differentiation in mesoangioblast- like 
stem/progenitor cells from DMD patient–derived hiPS cells, carrying the genetic 
correction with the DYS-HAC.25 
In this article, we aim to differentiate DMD patient–derived, genetically 
corrected hiPS cells into CMs with a mature phenotype and to assess the 
maintenance of the DYS-HAC during the differentiation of hiPS cells. In particular, 
we aim at investigating the correct activation, at HAC level, of the complex 
mechanisms regulating dystrophin expression, such as multiple promoter 
activities, which should be finely regulated in a development- and tissue-specific 
way. 
An ad hoc cardiac differentiation procedure, combining the delivery of cytokines 
with mechanical stimulation, by culturing cells on hydrogel with physiological 
stiffness, has been designed to allow full CM maturation. DYS-HAC–mediated 
dystrophin expression restoration has been assessed at different stages of the 
differentiation process. The dystrophic CMs established in this work could 
potentially represent a valuable cell source to be used for in vitro modeling of 
DMD-associated cardiomyopathies, and at the same time, the genetically 
corrected dystrophic CMs possess a promising therapeutic potential for the 
treatment of DMD. 
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Results 
 
Differentiation of hiPS cells toward the cardiac lineage 
To obtain DMD-specific CMs, their genetic correction, and a positive control of 
dystrophin expression, the hiPS following cell lines that differentiated toward the 
cardiac lineage were used: (i) hiPS cells derived from a DMD patient with 
deletion of exons 4–43 of the muscle isoform Dp427m (DMD hiPS cells); (ii) DMD 
patient–specific hiPS cells genetically corrected by an HAC carrying the full-length 
genomic dystrophin sequence (DYS-HAC hiPS cells); and (iii) hiPS cells derived 
from a healthy individual (healthy hiPS cells), carrying a normal genotype with a 
wild-type copy of the dystrophin gene. First, DMD, DYS-HAC, and healthy hiPS 
cell lines were cultured and expanded in their undifferentiated state for up to 10 
passages. During expansion, hiPS cell colonies maintained the expression of 
pluripotency markers such as Oct4, Sox2, c-Myc, Tra-1-60, and Tra-1-81, as 
evaluated by immunofluorescence (see Supplementary Figure S1a). In addition, 
DYS-HAC hiPS cells were monitored for the expression of the enhanced green 
fluorescent protein, a marker contained in the DYS-HAC (see Supplementary 
Figure S1b). The expanded colonies were then used for embryoid body (EB) 
generation. DMD, DYS-HAC, and healthy hiPS cell–derived EBs were 
differentiated toward the cardiac lineage through an ad hoc optimized 
procedure. Overall outline of this procedure is shown in Figure 1a. Remarkably, 
the enhanced green fluorescent protein gene, driven by a CAG promoter 
contained in the DYS-HAC,23 was expressed during all the stages of the 
differentiation procedure, in DYS-HAC hiPS cells (Figure 1b), in DYS-HAC hiPS 
cell–derived EBs (Figure 1c), and in cultured cells after EB adhesion (Figure 1d), 
indicating the stable maintenance of the DYS-HAC. During the first 16 days of the 
differentiation procedure, EBs were cultured in suspension and subjected to a 
staged protocol, adapted from the one developed by Kattman et al.,26 based on 
the addition of specific cytokines known to play a key role in cardiogenesis during 
embryonic development to the culture medium. This 16-day differentiation 
procedure resulted in a relevant percentage of spontaneously contracting EBs 
(see Supplementary Videos S1 and S2), ranging from a minimum of 14% for DMD 
hiPS cell–derived EBs to a maximum of 44% for healthy hiPS cell– derived EBs 
(Table 1). 
 
      Annex 4 
 
200 
 
 
Figure 1. Differentiation of hiPS cells. (a) Schematic representation of the differentiation 
procedure. (b) Undifferentiated colonies of DYS-HAC hiPS cells cultured on murine embryonic 
fibroblast feeder cells. (c) EBs generated from DYS-HAC hiPS cell colonies on day 4 of the 
differentiation procedure. (d) Cultured cells 2 days after EB adhesion. Epifluorescence images 
show the expression of EGFP in each condition, indicating the presence of the DYSHAC. BMP4, 
bone morphogenetic protein 4; DYS-HAC, human artificial chromosome carrying the whole 
dystrophin genomic sequence; EBs, embryoid bodies; EGFP, enhanced green fluorescent protein; 
hiPS cells, human induced pluripotent stem cells; VEGF, vascular endothelial growth factor; bFGF, 
basic fibroblast growth factor. 
 
Our recent data demonstrated that a proper cardiac differentiation requires cell–
substrate interactions to promote functional and structural maturation of hiPS 
cell–derived CMs.36 For this reason, contracting EBs were cultured in suspension 
up to day 20 and then seeded on hydrogel substrate with a physiological stiffness 
for additional 4 days. Following adhesion, a remarkable maturation of CMs was 
observed in terms of both cytoskeletal architecture and cardiac marker 
expression (Figure 2). CMs obtained on day 24 were characterized by a 
remarkable sarcomeric organization, as revealed by immunofluorescence of α-
actinin, cardiac troponin T (cTnT), and F-actin, and GAP junction formation, as 
revealed by immunofluorescence of connexin 43 (Figure 2a). The percentage of 
cTnT-positive CMs obtained on the overall population was ~10% (Table 1). The 
same percentage increased to 44 ± 2% when only contracting EBs were selected. 
Expression of sarcomeric cardiac-specific proteins, in particular cTnT and 
ventricular myosin light chain, in adhered CMs, was also confirmed by reverse 
transcription–polymerase chain reaction (RT-PCR) (Figure 2b). For DMD hiPS cell–
derived CMs, expression of ML2v, a marker of terminally differentiated 
ventricular CMs, was not observed before CM adhesion but was observed only 
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after adhesion. Mesoderm- and cardiac-specific transcription factors GATA4 and 
NKX2.5 were also expressed in all conditions tested, as revealed by RT-PCR 
(Figure 2b) and immunofluorescence (Figure 2a), respectively. CMs cultured in 
adhesion displayed both spontaneous and electrically induced calcium transients 
lasting less than 1 second, typical of calcium cycling during contraction (Figure 
2c), together with a diffuse intracellular distribution of cardiac-specific 
sarcoendoplasmic reticulum calcium-ATPase (Figure 2a), a key element of the 
calcium handling machinery needed for calcium reuptake after contraction. 
Taken together, these results show that functionally differentiated CMs were 
derived from DMD, DYS-HAC, and healthy hiPS cells. The observed differences in 
terms of percentage of spontaneously contracting EBs and cTnT-positive CMs on 
the overall population (Table 1) can be due to the intrinsic variability related to 
the use of different hiPS cell lines and the efficiency of the cardiogenic protocol 
itself. HAC-driven expression of dystrophin sequences originally deleted in the 
DMD patient We then focused on the genetically corrected CMs, testing the 
restoration of HAC-mediated dystrophin expression. DYS-HAC is the first vector 
carrying the whole dystrophin genomic locus, including all the associated 
regulatory elements.22 This potentially allows proper activation of the complex 
mechanism regulating dystrophin expression, for instance, the activities of seven 
different promoters driving transcription of tissue-specific isoforms and exon-
skipping and exon-scrambling events, which are finely regulated in both 
development- and tissue-specific manner.1 The possibility to restore dystrophin 
expression in a tissue-specific manner, following native regulation mechanisms, 
makes DYS-HAC a promising tool for the treatment of DMD also at cardiac 
muscle level. 
 
Figure 2. Characterization of hiPS cell–derived CMs. (a) Immunofluorescence of α-actinin; 
cardiac troponin T (cTnT) and F-actin; connexin 43 (Cnx43); sarcoendoplasmic reticulum calcium-
ATPase (SERCA2a); and GATA4 in adhered CMs on day 24 of the differentiation procedure. Nuclei 
are counterstained with DAPI. (b) RT-PCR shows the expression of NKX2.5, cTnT, and MLC2v in 
EBs obtained from DMD, healthy, and DYS-HAC hiPS cells cultured in suspension (on day 20) and 
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on the EB-derived adhered cells on day 24 of the differentiation procedure. (c) Typical calcium 
transients displayed by hiPS cell–derived CMs on day 24 of the differentiation procedure. The 
histogram reports quantitative evaluation of calcium reuptake rate by the half-life of calcium 
decay and the calcium release phase as the time to peak. Data are presented as SD. CMs, 
cardiomyocytes; DAPI, 4 ,6-diamidino-2-phenylindole; DMD, Duchenne muscular dystrophy; 
DYS-HAC, human artificial chromosome carrying the whole dystrophin genomic sequence; hiPS 
cells, human induced pluripotent stem cells; MLC2v, ventricular myosin light chain; RT-PCR, 
reverse transcription–polymerase chain reaction. 
 
First, dystrophin expression was analyzed on healthy, DMD, and genetically 
corrected DYS-HAC hiPS cells during the cardiac differentiation procedure, by RT-
PCR using specific primers designed to span exon–exon junctions localized inside 
the deleted genomic sequence of the DMD patient (from exon 4 to 43 of the 
muscle dystrophin isoform) (Figure 3a). mRNA from human heart and skeletal 
muscle was used as positive control. As expected, healthy hiPS cell–derived EBs 
displayed dystrophin expression both when cultured in suspension and after 
adhesion, whereas, as expected, in DMD hiPS cell–derived EBs, no dystrophin 
expression was observed in any condition (Figure 3b). In DYS-HAC hiPS cell–
derived EBs, dystrophin expression was restored both when cultured in 
suspension and after adhesion. A positive result was obtained for each of the five 
exon junctions checked, distributed on the whole deleted genomic region. HAC-
driven expression of multiple dystrophin isoforms In vivo, CMs are known to 
express the full-length muscle dystrophin isoform (Dp427m), together with other 
isoforms, such as the Dp260 (ref. 27) and Dp71, the smallest but multifunctional 
product of the DMD gene expressed in many tissues, including cardiac muscle. 
Dp71 has been shown to contribute to the proper clustering and anchoring of 
structural and signaling proteins to the plasma membrane and of nuclear 
envelope proteins to the inner nuclear membrane.28 
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Figure 3. HAC-driven expression of dystrophin sequences originally deleted in DMD patients. (a) 
The genomic organization of the dystrophin gene: the gray vertical bars represent the exons; the 
green arrows indicate the promoters driving the expression of the different dystrophin isoforms 
within the gene1,2; primer pairs used to amplify exon–exon junctions inside the deleted region 
are indicated by red arrowheads, and those used to amplify specific isoforms are indicated by 
blue arrowheads. Exon number is referred to exons composing the muscle dystrophin isoform 
Dp427m. (b) RT-PCR of specific dystrophin sequences localized inside the patient with deletion of 
exons (Ex) 4–43. Primers were constructed to spam five different exon–exon junctions (Ex. J.). 
cDNA from human heart and skeletal muscle was used as positive control. Analyses were 
performed at three different stages of the differentiation process: undifferentiated colonies, 
differentiated EBs cultured in suspension (day 20), and adhered cells (day 24), for each hiPS cell 
lines (DMD, healthy, and DYS-HAC hiPS cells). cDNA from human tissues was used as positive 
control. cDNA, complementary DNA; DMD, Duchenne muscular dystrophy; DYS-HAC, human 
artificial chromosome carrying the whole dystrophin genomic sequence; EBs, embryoid bodies; 
HAC, human artificial chromosome; hiPS cells, human induced pluripotent stem cells; RT-PCR, 
reverse transcription–polymerase chain reaction. 
 
The expression of different dystrophin isoforms such as Dp427m, Dp260, Dp140, 
and Dp71 was analyzed by RT-PCR during the cardiac differentiation procedure 
on healthy, DMD, and DYS-HAC hiPS cells (Figure 4a). mRNA from human tissues 
was used as positive control. As expected, healthy hiPS cell–derived EBs (both in 
suspension and after adhesion) displayed the expression of all the four different 
dystrophin isoforms. The expression of isoform Dp140 indicates the presence of 
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other cell types in addition to CMs, which are expected in this type of 
differentiation procedures.29 In DMD hiPS cell–derived EBs, the expression of 
the Dp260 isoform, the promoter of which stands within the large genomic 
deletion (exons 4–43), was not observed, whereas isoforms Dp140 and Dp71 
were still detectable as their promoters are downstream of the deleted area 
(intron 44 and intron 62, respectively). The amplicon relative to isoform Dp427m 
is still present, as the primers specific for this isoform are designed on the first 
transcribed exons (exons 1–3), upstream of the deletion, testifying a proper 
initiation of dystrophin transcription. On DYS-HAC hiPS cell–derived EBs (both in 
suspension and after adhesion), expression of all isoforms can be observed, 
notably with the restoration of Dp260 isoform transcript. To assess the efficiency 
of HAC-driven recovery of dystrophin mRNA levels, we performed RT-PCR 
experiments targeted at the isoforms expressed in the cardiac tissue (Figure 4b). 
A set of primers targeting exons 25–26 identifying all Dp427 isoforms was used in 
addition to the Dp427m-specific one to assess the relative expression of Dp427 
transcripts inside the deleted genomic region. Confirming the previous results of 
the RT-PCR, DMD hiPS cell–derived EBs did not display at all the expression of 
transcripts from inside the deleted genomic region, both in regard to Dp427 
isoforms, the transcription of which is truncated after exon 4, and in regard to 
Dp260 isoform, the transcription of which cannot be initiated. The expression of 
the truncated Dp427m isoform and the short Dp71 isoform was variable among 
the different experiments, not reaching statistical significance (n = 3). 
Differentiated healthy and DYS-HAC hiPS cell–derived CMs displayed similar 
amounts of all transcripts tested, highlighting the proper function of the HAC in 
driving and regulating the transcription of different dystrophin isoforms. 
 
 
Figure 4. HAC-driven expression of multiple dystrophin isoforms. (a) RT-PCR of dystrophin 
isoforms Dp427m, Dp260, Dp140, and Dp71 at three different stages of the differentiation 
process: undifferentiated colonies, differentiated EBs cultured in suspension (day 20), and 
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adhered cells (day 24), for each hiPS cell lines (DMD, healthy, and DYS-HAC hiPS cells). cDNA from 
human tissues was used as positive control. (b) Realtime PCR for dystrophin isoforms present in 
cardiac tissue. Muscle-specific Dp427m is double checked with Dp427m-specific primer set 
spanning exons 1–3 and an all Dp427 isoform-specific primer set spanning exons 25–26. Data are 
presented as mean ± SD. cDNA, complementary DNA; DYS-HAC, human artificial chromosome 
carrying the whole dystrophin genomic sequence; EBs, embryoid bodies; HAC, human artificial 
chromosome; hiPS cells, human induced pluripotent stem cells; RT-PCR, reverse transcription–
polymerase chain reaction; DMD, Duchenne muscular dystrophy. 
 
Taken together, these analyses on mRNA transcripts show that, during the 
cardiac differentiation protocol, dystrophin expression is correctly restored by 
the DYS-HAC and multiple dystrophin isoforms are expressed. 
HAC-mediated restoration of dystrophin protein expression and correct 
subcellular localization In vivo, in physiological conditions, dystrophin is a key 
structural protein creating a bridge across the sarcolemma, which provides a 
flexible connection between the basal lamina of the extracellular matrix and the 
inner cytoskeleton. For this important role, dystrophin should be correctly folded 
and localized under the plasma 
membrane of skeletal and cardiac muscle cells. For this reason, we verified the 
proper restoration of dystrophin expression at protein level and its subcellular 
localization by immunofluorescence and confocal microscopy. Analyses were 
performed 4 days after EB adhesion on substrate with a physiological stiffness 
of 15 kPa (Figure 5a). DYS-HAC hiPS cell–derived EBs displayed a clear dystrophin 
expression at membrane localization, drawing the boundaries of cTnT-positive 
CMs. A similar dystrophin staining was observed in healthy hiPS cell–derived EBs. 
On the other hand, as expected, in DMD hiPS cell–derived EBs, any dystrophin 
staining was observed. These results were confirmed by western blot analysis, in 
which full-length dystrophin was not observed in DMD hiPS cell– derived CMs, 
whereas its expression was perfectly restored in CMs corrected with the DYS-
HAC (Figure 5b). Although much less abundant, other dystrophin isoforms were 
also detectable in the DYS-HAC–corrected cells (see Supplementary Figure S2). 
These results demonstrate that the DYS-HAC restores the expression of 
dystrophin at protein level, which can correctly localize at membrane localization 
in genetically corrected, hiPS cell–derived CMs. 
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Figure 5. HAC-mediated restoration of dystrophin protein expression and correct subcellular 
localization. (a) Confocal microscopic analysis of dystrophin and cardiac troponin T expression on 
CMs obtained on day 24 of the differentiation procedure from DMD, healthy, and DYS-HAC hiPS 
cells. Nuclei are counterstained with DAPI. (b) Western blot analysis for dystrophin isoforms with 
a polyclonal antibody and for cardiac marker troponin T detected in two isoforms in the samples 
from human hiPS cell–derived cardiomyocytes. CMs, cardiomyocytes; DAPI, 4 ,6-diamidino-2-
phenylindole; DMD, Duchenne muscular dystrophy; DYS-HAC, human artificial chromosome 
carrying the whole dystrophin genomic sequence; HAC, human artificial chromosome; hiPS cells, 
human induced pluripotent stem cells. 
 
Discussion 
 
The derivation of genetically corrected, patient-specific hiPS cells has been 
recently shown to be a promising strategy for modeling genetic diseases. In 
particular, An et al.30 reported the derivation of hiPS cells from Huntington’s 
disease patients’ fibroblasts that were genetically corrected by an homologous 
recombination approach and differentiated into DARPP-32–positive neurons. 
Tedesco et al.25 reprogrammed fibroblasts and myoblasts from limb-girdle 
muscular dystrophy patients in hiPS cells and developed a protocol for the 
derivation of mesoangioblast-like cells that were genetically corrected in vitro 
with a lentiviral vector carrying the human α-sarcoglycan gene. The huge 
potential of hiPS cell technology has also been demonstrated in modeling human 
cardiovascular diseases. Some pioneering proof-of-concept studies on patients 
with inherited arrhythmogenic diseases, most notably different subtypes of long 
QT syndrome, reported the derivation of hiPS cell–derived cardiac cells to 
reproduce the clinical phenotype “in the petri dish.”14,31 In this work we 
derived, for the first time to our knowledge, human CMs (hCMs) from DMD 
patient–specific hiPS cells and genetically corrected hCMs from DYS-HAC–
containing hiPS cells. Different procedures for the cardiac differentiation of 
pluripotent stem cells have been reported in literature, mainly reproducing in 
vitro the processes of embryonic development through the stimulation of soluble 
cytokines, driving pluripotent stem cells toward early mesoderm specification 
until the derivation of cardiac progenitor cells.26,32,33 However, the major 
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drawback of their application, both in vitro and in vivo, is their immature 
phenotype. To study the restoration of dystrophin expression and its correct 
localization in cardiac cells, the derivation of hCMs characterized by a 
functionally and structurally mature phenotype is of paramount importance. We 
developed an ad hoc optimized differentiation procedure integrating a cytokine-
based EB differentiation with a subsequent step of adhesion-dependent 
maturation. Increasing evidence demonstrate that adhesion and substrate 
sensing are key requirements for the process of muscle cell functional 
differentiation. In our previous work, we have shown that the development of 
sarcomeric structures of human striated muscles is influenced by the substrate 
on which the cells are cultured.34 Furthermore, in our group, it has been 
recently demonstrated that adhesion on substrate with a physiological stiffness 
promotes functional maturation of hCMs, allowing a shortening of calcium 
transients.36 Using the procedure developed, we derived hCMs presenting 
expression of cardiac-specific markers, a defined sarcomeric organization, and 
calcium transients lasting less than 1 second. In these conditions, dystrophin has 
been observed to correctly localize at membrane level on both healthy and 
genetically corrected hCMs. Certain variability has been observed in the 
expression of cardiac muscle markers along the differentiation process, for the 
different hiPS cell lines. This could be explained since, as widely reported in 
literature, hiPS cell lines derived from different cells and different clones can 
have a different ability to differentiate toward the cardiac lineage. In addition, it 
has been recently demonstrated that in vitro cultured DMD skeletal muscle cells 
display a delay in the appearance of typical myogenic markers.35 Similarly, we 
observed a delay in the expression of the late cardiac differentiation marker 
ventricular myosin light chain in DMD-derived cardiac cells, compared with the 
healthy and genetically corrected (DYS-HAC) ones. Further analyses could be 
performed to specifically address this issue in cardiac muscle. hiPS cell–derived 
CMs represent a unique platform for testing in vitro the efficiency of the DYS-
HAC in restoring a proper dystrophin expression at cardiac level, in a patient-
specific manner. DYS-HAC is a potential tool for use in DMD gene correction, and 
its ability to properly restore dystrophin expression on differentiated human cells 
has been recently reported.25 However, its efficiency in restoring different 
isoforms’ expression on differentiated hCMs has not been extensively 
investigated so far. For the first time, we demonstrated that DYS-HAC (i) does not 
hinder and is stably maintained during cardiac differentiation of hiPS cells; (ii) 
allows a proper dystrophin expression restoration during the cardiac 
differentiation procedure of hiPS cells (in particular, the expression of specific 
sequences deleted in the patient was observed); (iii) drives the transcription of 
multiple dystrophin isoforms in CMs at similar expression levels compared with 
healthy hiPS cell–derived CMs, in particular, the full-length muscle isoform 
Dp427m and the cardiac isoform Dp260, which are not expressed in the DMD 
patient with deletion of exons 4–43; and (iv) allows the recovery of full-length 
dystrophin protein that localizes properly at the cell membrane. These results 
highlight DYS-HAC as a potential tool for use in gene correction of DMD patient 
cells. 
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Finally, the coupling of DMD CMs with specific technologies for testing cardiac 
functionality, such as measurement of force generation or performance under 
stressed condition, will provide a unique platform for studying in vitro the 
pathogenesis of DMD-associated cardiac disease and its correction. 
 
Methods 
 
hiPS cell culturing and cardiac differentiation 
hiPS cells, obtained as previously reported,23 were cultured on a feeder layer of 
mitomycin-C–inactivated murine embryonic fibroblasts. Composition of the 
culture medium was as follows: Dulbecco's modified Eagle medium/F12 (Life 
Technologies) containing 20% knockout serum (Life Technologies), 2 mmol/l of l-
glutamine (Life Technologies), 0.1 mmol/l of nonessential amino acids (Life 
Technologies), 0.1 mmol/l of 2-mercaptoethanol (Life Technologies), 50 units and 
50 mg/ml of penicillin and streptomycin (Life Technologies), and 4 ng/ml of basic 
fibroblast growth factor (Peprotech). To maintain the pluripotent state for a high 
number of passages and avoid chromosomal aberrations, the colonies were 
passed as described 
below—usually once a week. hiPS cells were washed with phosphate-buffered 
saline (PBS) and treated with 1 ml of CTK solution for 30 seconds. CTK solution 
was prepared as follows: 5 ml of 2.5% trypsin (Life Technologies), 5 ml of 1 
mg/ml collagenase IV (Sigma-Aldrich), 0.5 ml of 0.1 mol/l CaCl2 (Sigma-Aldrich), 
and 10 ml of knockout serum were all added to 30 ml of distilled water. The 
mechanical separation of colonies was performed with the use of a 
stereomicroscope to dissect the undifferentiated colonies into several pieces 
using a cutting pipette. These selected pieces were then replated for expansion 
onto dishes containing fresh murine embryonic fibroblast feeders or moved to 
ultralow adhesion plates to be cultured in suspension for EB generation. The 
obtained EBs were differentiated in suspension using a protocol adapted from 
Kattman et al.26 Briefly, for EB formation, the detached and separated colonies 
were maintained for 24 hours in basal medium (StemPRO-34; Life Technologies), 
2 mmol/l of l-glutamine (Life Technologies), 150 µg/ml of transferrin (Roche), 50 
µg/ml of ascorbic acid (Sigma-Aldrich), 0.4 mmol/l of monothioglycerol (Sigma-
Aldrich), 50 units and 50 mg/ml of penicillin and streptomycin (Life Technologies) 
supplemented with 10 ng/ml of human bone morphogenetic protein 4 (R&D). 
From day 1 to day 4, EBs were cultured in basal medium with 10 ng/ml of human 
bone morphogenetic protein 4, 5 ng/ml of human basic fibroblast growth factor 
(R&D), and 6 ng/ml of hActivin A (R&D). From day 4 to day 8, the EB culture 
medium consisted of basal medium and 10 ng/ml of human vascular endothelial 
growth factor (R&D) and 150 ng/ml of hDKK (R&D). Finally, from day 8 to day 14, 
the EB culture medium consisted of basal medium and 10 ng/ml of human 
vascular endothelial growth factor and 5 ng/ml of human basic fibroblast growth 
factor. Cultures were maintained in a 5% CO2, 5% O2, and 90% N2 environment 
for the first 16 days and then transferred to a 5% CO2 air environment. The 
obtained EBs were maintained in suspension using the last medium described 
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until day 20 and then seeded on hydrogel substrates with a physiological 
stiffness of 15 kPa (prepared as previously described)34,36,37, functionalized 
with 100 µg/ml of laminin (BD), and cultured in these conditions for additional 4 
days. 
Immunofluorescence 
A standard immunohistochemistry protocol was used. Briefly, cells were fixed 
with PBS containing 2% paraformaldehyde (Sigma-Aldrich) for 7 minutes, 
permeabilized with PBS containing 0.5% Triton X-100 (Sigma-Aldrich), and 
blocked in PBS containing 2% horse serum for 45 minutes, at room temperature. 
Primary antibodies were applied for 1 hour at 37 °C. Cells were washed in PBS 
(Life Technologies) and incubated with fluorescence-conjugated secondary 
antibodies against mouse, rabbit, or goat, depending on primary antibody used, 
for 45 minutes at 37 °C. Finally, nuclei were counterstained with 4 ,6-diamidino-
2-phenylindole (Sigma-Aldrich), and samples were mounted with Elvanol and 
viewed under Leica TCS SP5 fluorescence confocal microscope (Leica). Primary 
antibodies used were the following: mouse monoclonal 
anti-cTnT (Thermo Scientific; #MS-295-P; 1:100 dilution), mouse monoclonal 
anti-α-actinin (Sigma-Aldrich; #A7811; 1:100 dilution), rabbit polyclonal 
antidystrophin (Abcam; #ab15277; 1:200 dilution), mouse monoclonal anti-Cx43 
(Millipore; #MAB3067; 1:100 dilution), goat polyclonal anti-SERCA2a (Santa Cruz; 
#SC 8094; 1:200 dilution), and goat polyclonal anti-GATA4 (Santa Cruz; #SC 1237; 
1:200 dilution). Secondary antibodies used were the following: goat anti-mouse 
(Invitrogen; #A11005 and #A11001; 1:200 dilution), goat anti-rabbit (Invitrogen; 
#A11012 and A1108; 1:200 dilution), and donkey antigoat (Jackson ImmunoLab; 
#705-165-003; 1:300 dilution). All antibodies were diluted in 3% bovine serum 
albumin (Sigma-Aldrich). 
Calcium measurements 
Confocal calcium measurements were performed as previously reported in 
Martewicz et al.38 Briefly, CMs were loaded in serum-free 25 mmol/l HEPES 
Dulbecco's modified Eagle medium (Life Technologies) supplemented with 2,5 
mmol/l of fluorescent calcium dye Fluo-4 AM (Life Technologies) for 20 minutes 
at 37 °C in the presence of 2 mmol/l of Pluronic F-127 (Life Technologies) and 20 
mmol/l of sulfinpyrazone (Sigma-Aldrich), then incubated for additional 10 
minutes at 37 °C without Fluo-4 AM, and added with 0.2 mmol/l of di-8-ANEPPS 
(Life Technologies). Cell dynamics were obtained in recording solution: NaCl, 125 
mmol/l; KCl, 5 mmol/l; Na3PO4, 1 mmol/l; MgSO4, 1 mmol/l; HEPES, 20 mmol/l; 
CaCl2, 2 mmol/l; and glucose, 5.5 mmol/l, to pH 7.4 with NaOH. Line scans were 
acquired with a Leica TCS SP5 fluorescence confocal microscope using a 63× oil 
immersion objective, with 488-nm Ar laser line as an excitation source and 400-
Hz acquisition frequency. Line scans were then analyzed using ImageJ software 
(version number 1.46) to obtain calcium transient profile. For evaluating the 
calcium reuptake rate after contraction, the half-life of the calcium decay was 
considered. Half-life of the calcium decay was calculated by fitting a first-order 
exponential decay to the calcium reuptake phase of the calcium transient profile. 
For the calcium release phase, the time to peak value was calculated considering 
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the time from baseline to a minimum of the second derivative of the calcium 
transient. All numerical data were manipulated with Origin 8.1 software. 
Reverse transcription–polymerase chain reaction. 
Total RNA from hiPS cell colonies and differentiated EBs was purified with 
RNeasy Mini Kit (Qiagen), in accordance with the manufacturer’s instructions, or 
with TRIzol reagent (Invitrogen) and treated using a Turbo DNA-free kit (Applied 
Biosystems) to remove genomic DNA contamination. For the cardiac marker 
analyses, first strand complementary DNA (cDNA) synthesis was performed using 
an oligo- (dT)20 primer and the cDNA Reverse Transcription Kit (Applied 
Biosystems). PCR was performed with cDNA using AmpliTaq Gold (Applied 
Biosystems). Amplifications were performed with an annealing temperature of 
55 or 58 °C for 30–35 cycles. For the dystrophin isoform analyses, cDNA 
retrotranscription was carried out with High Capacity cDNA Reverse 
Transcription Kit (Invitrogen), followed by RT-PCR using Platinum Taq Polymerase 
(Invitrogen) with annealing temperature of 60 °C for 35 cycles. All the amplicons 
were resolved by electrophoresis on a 2% agarose gel, followed by staining with 
SYBR Safe Gel. Primer sequences are given in Table 2. 
Real-time PCR 
Real-time PCR on cDNA retrotranscribed with High Capacity cDNA Reverse 
Transcription Kit was carried out with Power SYBR Green PCR Master Mix 
(Applied Biosystems) in a 7000 System thermal cycler platform (Applied 
Biosystems). Annealing temperature for all primer sets was 60 °C (sequences 
reported in Table 2). Relative amount of transcripts was calculated with Pfaffl 
method relative to healthy hiPS cell–derived EB expression levels. Amplification 
efficiency for all primer sets was >1.9. 
Western blot analyses 
Detection of dystrophin (antibody 1:500; o/n + 4 °C; Abcam; #ab15277), cTnT 
(antibody 1:500; 60 minutes at room temperature; Thermoscientific #MS-295-P), 
and GAPDH (antibody 1:2,000; 60 minutes at room temperature; Abcam; 
#ab8245) was carried out after protein lysates were resolved in a NuPAGE 3–8% 
Tris-acetate polyacrylamide gel (Invitrogen) and transferred for 6 hours at 4°C on 
a polyvinylidene difluoride membrane (Invitrogen) with a BioRad cassette. 
Detection was performed with Novex ECL Kit (Invitrogen). Anti-rabbit 
(Invitrogen) and anti-mouse (BioRad) secondary horseradish peroxidase–
conjugated antibodies were used. 
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